var title_f13_4_13376="Pressures mitral regurgitation";
var content_f13_4_13376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pressure tracings in mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneously recorded pressures from the left atrium (LA) and left ventricle in a patient with mitral regurgitation. There is a tall \"V\" wave in the LA occurring during ventricular systole, reflecting a large regurgitant volume of blood ejected into the LA.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Kern MJ (Ed). Hemodynamic Rounds: Interpretation of Cardiac Pathophysiology from Pressure Waveform Analysis. Wiley-Liss, New York, 1993.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13376=[""].join("\n");
var outline_f13_4_13376=null;
var title_f13_4_13377="Los Angeles Prehospital Stroke Screen";
var content_f13_4_13377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F78128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F78128&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Los Angeles Prehospital Stroke Screen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 674px; background-image: url(data:image/gif;base64,R0lGODlhYQKiAtUAAP///wAAAGZmZiIiIpmZmYiIiN3d3URERDMzMxEREbu7u+7u7szMzHd3d1VVVaqqqkBAQICAgBAQECAgIKCgoMDAwPDw8ODg4NDQ0HBwcFBQUGBgYObm5rCwsPf39/n5+fj4+PX19TAwMPb29pCQkKamprW1tdnZ2fLy8vT09O/v7/r6+peXl+rq6ujo6Ozs7AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABhAqICAAb/wABgSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweNwMCMnotHrNbrvf8Lh8Ttea6/i8fs/v+/+AgU53goWGh4iJiouMX4SNkJGSk5SVlnZnl5qbnJ2en3GPoKOkpaano6Koq6ytrq90qrCztLW2t0yyuLu8vb6dur/Cw8TFfcHGycrLzF7IzdDR0tNEz9TX2Nm71trd3t+k3ODj5OWN4mEBBebs7e5T6AYJCksKZgED9EcEA1T87wADdhMnwIy+JPaGFEiA5N8UhwIjSmSGDkCAg0gSAjAQwMCBewQs3gMwICQDBGYaACCQAOVFkaI4flQHwJ4ZBAsACECQIACC/wZmDgw5mVJhpolIkyqq+FKJRgH9iLBcGZUkgQXzNs5jGXIn1SMcVRIIkJPIgHU7GWBFYIDjA6z05NErcFSp3bt+mGI8YtMnAwAFXAqBWLKvGQIO/0EkwtHAxo4GCppBK2DIgXVWDQcIibez5z166x1lQDMhYQL2yg5J3G/xkMaPDThgC+Cyzsq1MRcm+7m37zqhLQstonHIgwSOCwI4XrYk1soLHChgvTyB6tcdY/8EwODsbcu6ryaALh1w3d/o03cheO/MgeFEilsOKmSBS6s1XR4wQN1+zOyNKdATAt4JgJtt+Cmgn2N0qefgg1lUBKEU7VVo4YUYZqjhhhx26P/hhyCGKOKIAVSQDokopqjiiiy2qOISEk4o44y1xEjjjTieYmOOPPa4yY4+BinkOecNaeSRkwCJ5JJM4qFkk1BGycaTPRbgQBQL8CZlFD2BlABmSjyAQI9U8ugAmE4ct2UUpF3nRANX8lhmjgk8UESXCfylYFCk3bSmE4EV8YAQg350ZpcF0FUUjnPe2CYS2yXA2RAIoPnnEg60t0ADY3JKD2mODZHlX3IWuWWg8UlG0wAICEBqAKReykSdRWxXKXYOCJCTgD42SqMDKmGn0qgKFUTAo7IugewQAdiZlagCZGoAqqUmO8QAdq7GUHQMEbFASVNZq8RibS47VEfR9mr/apRZttddAC1dCdRk3JkRp7hGwFlEoNS6VJJ5NOXoK74E4ztwwQhfenDCDEe58BJjbRaGPXs1QWtGTYEhWagNdyyIOET5pcQA9CIh6ReuRaFmcfLtU5UVoHos88frFkGAAzkhAB8S3iGRJcdcpAwFsDVl0rIRQkvxwMszNw1azUgUgFsSPQ8wk1AzCaHoAH/xQxpU+mUa8D1cw9RRdlt33ZJBombHshCNLTATTu0BXLbXZlgHAFaTwnSAgXShRrLEHLm0E9vmOa34FhJGx0TVByzgFmwUA9BAa19eG7k9V451XboOBfjS5Sud7BVgw2kGd0cF9CM3f1FVTjpLuq3j/5pDO4WE1TqDthWASnShNWbiixdvhYQ4Px7etQTAVsBwo57GbFzZNdClUKGzDj2s1AGAAGdvx2aPgTk59HzbDEAU6K02R2XgEMVVSvkZSRtv/xPx0KY888w7v336VfmXRag3rXyg7iuxOd/euBeVfzBAb0WLz+ocswADMVAh/4PI7iAoFffhJn4FmN9qmHa/Eg4CavDLkxECVoSqcaYk86MHVBCInwHGhlN701l1ciI6Gbamgf1owNTC1xgBrAMrD2BO0XxIQ50EYGodHML79pa5sfjOMRoxHwpNWEJxKOoejmHhteglQBhmx25dCyBnXtIYA6CkJULxz9kYZIa7Af8RAM+KIPwmyA975fAOaWuiPYA2QikOcXAhESECG8TFRiLhYYUQkxoEsDNHWhINkKwFRyp2yU46YoueDOVnMinKUn6DlKZMJTZQqcpWRoOVroylMmApy1oOg5a2zCUvcHmIyunylyciUoaM0BcDuowKUwSmMnMBymMooS4aWUhDSOiEZC7zmkfgpTOeScwzNIZsf2kPbFgCr64QCB8G6EslsXlNba6Hm8Q5wwyJALqoBGgAjmFOWkiiEmuyk53u5MK6oHkPBPzFekFBYGO+aIbI4OZ9/vxnO5vJh4F2c18GPF/2pjU8ej60MhGVqDIDyjh4SrAIOLSPUJQoOpOMaYr/72vAOkUKTJLawaR7LIIb4aVDOTqvSyD9KHd6MlOa2tKmEcKpUZf6yXMolalQxYQwMRTVqjKOolbNajiwqtWuAoOrXg2rJZAq1rLCgaxmTesa0KrWto6BrYFoUP2+AJu0Xo6QWzDAAILVGbhSYUPdrJs/qBmGupaVNLH6AmI941d4KPVoDyEsGAwrhQhEgAQG+AAwc0UGzvYVrE567FG+WJnCmeFwL1FMP3rWOiOwKihiw8y8DKoTnvhkXkIxbcDIaTojSowIlt2ABCCQgl9eTAxq+qxTk0DQe4CJIwwIi3mE9xXFdEuAZtlcADpHFgXKtLZqaYnvHsAR3nVEAfjc/2HukrCCEUBABLqkLBhihpfGUki0xMmaAhSp2q8gUYktXCMBs4aP7+Smf2csCUPRBUUkuCAAJsilfOl6xjZcbZegBQ5+iZCAOF2Evz9c5HssVUM2duQAfDUkeBAcqjpRS8VMkEAEPGDLCXuBvnexbxQsGk9vNWslH3Yb/UKcvQqbRcAJVCEBgrpiq0C3dAuwh0sNrAQOQCACbnLlccOQ3PpmOBYbNkoAPrJfIReyv5ZpMP9sCBvJZG6KCDJjT561kNNSOQlWxnIuHXCvMHjWy8t9JBk2WYg8WyCXiw1DogHNCB6LgZKGaAEEIIACXXIKr1rQa4pz/OU5AJYWH4iABP/c+iAda8MDImCBZkmNHlNrIwQbMAEIWP0bV7/6BBrIQARoPcpOq8cDVtb1I11E7GIb+9jIvpCJVGlrbIAgAyWYNbOTTe1qW/vaw3ymr38DgiuPgNe+aTYb5gqJEkiAxuDujbhhpKEjhAwB+hAguRmxAA1AQAXpVve2z6pUecSJLvSQt2QhEexK55ux+36Do4eAQ3qeybkscQk95BaUnJREWobIc5aPMKjhmYuL7IPSup9aDSOguH015EptD+y9dVgtsYLQeBMQ+pcXF09sT1wgzJc0cuYq9eRRFHghK1QZ7BriBVfeuMk5tQ7OknaBLpGpGbIlmfT+iVb2YECXRZ7/cDcs3HId1cmVhP6VHwd4Kbu22AO+G/LlkOU467hcSP4GAM+2PUqPGtXlUKKrjRgO6j7hTJ0zlp6eC9rnOu2wUejBPuocACeAcXnfCsGREzShXGc7qEsYYiWGxwnFfXLun1D1eO/th2/fqgxi4Q6YfgQmJ991kOGz+dR3cyZiBaCOR24S8MkDwgMhEAEEVr0EVHWYITuhh76I1vIh1GneTMI5zoiFxwe0dnqdB8yYuuRH2Xe9DV9HRXAloIFvN4H5BRm77bxDK2K1aVD0UEBRmbRljbRpim1iPrBsXPjvT4nkpmBZmBUCT3Axg7IOioISDPAoyYUq85I5a8IR14Eq/4FyOZLTKtXnfG9BEx6xc+Hmf2vVbgcXCFtXd8FCNDuVc4/yKOSUc6UGgiMYg84AgzJYgxFCgzaYg3+FgzrYg/jDgz4YhNomhEQ4JUBYhEg4e0gYVkq4hF3VhE6YVVAYhVU1hVQIVVZ4hUuVhVpIU1zYhRL1hWAIUEc4hjIohma4TKYWUmTASGrghoLAhlHwL2IkBgrkbiRDMhUDhw1xGGoAWVUAfV0ESqpCYic1h74nh16giF/AiFTje2FgdDB2BZLYhkX1ZxBDWCezBoA4WKmEDrTlOQiBVZXoiFtgilyAiq4FiWBQimo2BZU4BndoBN/jBELzM2zQiZH1iVhlc/89VgTgVDqH8UVo8j4PFEJjVjKBdCsLkRPPtzaEp07W9UaXg057czXXIRP00hc4IY1RMVt/YTUJRYw+9hcOIBRt8nQU5xMTeA+VQY70ZFu0kTUuZWfrGDn48S/iOGZDEXVGkIK4cXFGJjYJMBzg+EVWJIxb0Q+CRQT0yDVPdI/lM2eT93TaGDCK0hOBxY7JlTmBQo/+pUMhEyx8qDgVETEemFNIkC4nQwAq4YoPlEi/A2RRNjpBdCUf8QBtonKn41FndjIHYEB7xXJtV15uBzQFghv/4F1CYTWS82OVWClY0V1hB12t9TpI8GSlSBsYKBUMwVkMgJOYcSv6GBJO6Rb/cKEVGPEeWmGWBwBzreMY38WU+NFDkYdm/5gdtNNklYJe+cRBOgUr0uU5lTMoI1MAo2IPY8J82kIV9gEdWSEXxGM8McISStcyCMWPjycAL5SIPMEZsLFQ/8McCQAngdI9PlldUaFA70N0gRkqMFSIBvYPBLZanVlDKOUADzBiRCN/96AA49N3+fWbuJmaSykYgDEemOGaZVlDu9EefdMU+lKJCHI+tVmX2oNyDtEXZeYYEEF0CwY0vmkQoZmdesQYslkpDWA9D2QngTESEfdBFcKKJslVhPeLCpFRw7FkCDB2iQhH2OEYook+eAQnD2QbqAljaMaalWF2YHFGdTIb/45hG1NEm5tWRmbpew9kRM+TFYpnQxVUEIn1oS/higphUKVxBgxASQOQJdlyZPnYmanBXPownb5XnVhzoTI5LTuDl69JQw6qfUpAot2ZQKlTFxJ6YFbCNXxmHaSxDqbhE+k1o5YkDvLHIHrDlvgJdjm0H7S1PiRGPgNQWgByXi8xT5liJwqIQK4Rews6HO/zeDmRKIGpNvahEt0Rd/vpekpWdLd5d85HFlmyLT82FgpgRFT0oi4KZIwXpldiHwVwHMkhBAcQEqkhp5EXo84pHuSxluh4MpXIKQugUsnZNX4qPi+RKP8AYD8KEZiaKFLGHWG3qIZangZwHH+hHLWCp//eQRpjMihXIqlO9BWzMarjsTflUZJOIw67hw/6oKUSJE5vpDPRUUf0gHtF8D56JQC2ikYKoTfSxKZM80Bj9qYq1qzwFphzFn8D0qtEhTt5I3n8g61FcI6W8W/0MR2D02cAQ2ZAJkYCcD3zkYwAw4Fz03uamiALolN/V5yi4hI65ETwIq/Okzf6+kd1MU5Vga5zAVRGoChk1q2SgRLE1K6YkTm7M7AfgUByuidjRkf3g4Z1wH8xiG02qyHLRiE3u7MlwlxlOAo0m4ZDIrNCq0tEW7RH9bNIy2tHu7Sx1LRO2wakISVQG7VcABSYIQ9jIk38whCSdAWDUiF8xq918EX/PYME60kJVWu1WoASnzeTRMCYlkO2VSC3fcB8QMGKgNpoSsu2h5AlAat9J0OWapoo99AAoQd5CGBbBxAng7JzF5MlCpAlUTcTVFdHmPYFx5UuT4dzD+CyhkgzfosLoNIsdQIrLvozqQsrRrC6SrktEFgEyDIoC8B6clcblWF3odsFy5J9xvF23dIdf2GYS9G3oysI66MOakK7y0sWvIJB96B13VIvFTRT18el2acvtYG4FbK7XPBitsEpeQMYcYJz8LIIa3u8VEA036UvFXgl/DI8/MA7nLczT4QcaHsvJ8d87PN8AwcGjDlIyTe3JrhmRKK+tbBlt0I0Z1LA6SJ2/7J6JXKLEqEbcrTSfqz7fi8hf2mALQwnMd4xvyQxlnDqvX+QvggMBctCLBfsLO45GTbBE+uwZdDauqxLvQzYLQ4Yr2jQLnwiZmsqNgu4sMWbwuPAEpmrb0b8DfJAn0q8xF2IwlBsP1I8xcVTxVZcn1lMhVi8xTPTxV7sMWAcxg0zxmScMGZ8xgWTxmpsMMbbxmQIx0HIxnIsK3Rcx39yx3i8JXq8xw7Ds4AcyII8yIRcyIZ8yIicyIq8yIzcyI78yJAcyZI8yZRcyX5sg318yUySyZqMJJzcyUbyyaAsJKI8yupiyvlWyqgsMG+8ytPmykzbyrBcSqo8yzJSy7YMIf+4nMvex8tttcu+3GqyHMzCELSvIA67GRQNAHs4F0JhK3qWUyEb2B6dMnX1spjuErbB0hNl0Tr2ssz50sy32r31cg/AYiEN8MxFIRhjVnPtgRk2MX9O2JX8JAYQMRZJYMx0MBax87PcQBrpxQBvyRHd4hFJ5BN7QzJ2AhR91i6JNS8t6qu/OzzPTA/c7ETDsZuJRdCvcQAHPSbfYnYooahmUBaDMr2U8mN0MTztohqqksRLSBpz0aL2XBX4nJVG1gdjcTK6OINNsNLtyK8dNx8hwdBF4NAoBS9PJNFuR9FKvX3OW2BKQBdCjdC18Vsj7WNactK0+GP2EBUtzWFKjRn/Q32Fd0UrvBUSLejETXDPqzMT69BmbLETeYhFiETAMm2CF2nCUTAWrRVNdZSSN3h57aGbdVeHQy0PejMv9zCqFaISWNsTKz3Rvzsb6sDNdCHPmWIpiZ0AEJTVbbPV0uw9P1YQwRLWQFYSUl3WVPgtx+qXO9SSmyYFbv0YYkEWRQR5+7RXKds7akIXKlEng6klWYDPZ5EQsvO/x7NFDMDYsLLZRqDO+BvNDW0GD60OdDEglO12DkAant1d/IhziQXdgtIe003aJC3aKE3a7qjVZfERiNkTnESFohiem8nWbW3TDGGrMgF5BmYgIDQqlZInuF2mMN3Xg3G6B6RzYBAj/xRM1dHNjiSDG0at1de9DhC73cAazSVtD92C1EQA4eWNExNOBKC9QOrd1dYHL6ES1hzhmmYYTWG3GjtBt1AQLl/B3z7RFDAlACBkggzRYbll4Ftw0+K44NTn00wgNRREMmpBMrrj0UMdMUW9XUdt3Um9Dn3i1E4dJ4OTEx8ROSAuKlB+jR/9r5xx4qjN1bXyYyjB0iVtHg10vqxNhRoRqyfhRjU341JglG5EpgIKGayjQj2esgkJ3NEc10SuBTcdMUukE8pdBf9cjWOWLbLhXOM8PAWBHM7dLD7sJ1j7wdgcvRvudloyeL/jJpc+GZkuRfASelaO4ib92OitFU/EUP/eDCY9QQB1HoXFMXi6IjbGZAV9NGY8ZOA/taJChV5+WC/xx7rdyuiZsLLe2uDDTMxcBMzY3mvbLlba3u2MBu5a9e3irhTkXu5Ice7oLhHqvu4C0e7uDhDwHu/uMO+g/GlnJYKhoO9NRe86AoBqEH7gB/CD7e+mIPBrRfBpgPBSFQVByQRYAZhcsK1iVjIGDyMKTwYMH/AZv9xRYD3/yw9bFgUKINg8gRuzePG50PFisPELz/I7CAWtc71JcCbaCzAayeG0RRys4nt8NkUpr/IAP8wuj0kwDw+gJCCwswSj8iiFqTUGOVMEcAClGeIvhfLmLPQYj3j8xvVdf3jW7gT/kjlXqOIdCpQQ1zmKhJJe/nSMWu/1KyQHRa/xR6+zTqA6mcvOQnH2lDrbSEP1JFkhTIMgbx/3cD/wh4/4YN/vN97PGFFXjSGsyrEQpkpMPZ8EcMau8631c9/yde8Inw8Flen4+7IztzKy3eJmllLySzBFjM3XF4/vCsfvs59tYb8GsVf4aHyEg7Pzuo8w9v77q3Ttwm8twV/803D8yP9KxL/8edz8zs/H0B/9f0z9SWv9taT82G8M2r/9xABLyioG7/KKzwT7eBCnQqGKaSX7Xkf77W/7jM8EhjF/hE/4K0n+WICJm2BN6g8EAOGQWAQoAodhIdAMFISERHNAADCd/wGAICAQFg6EbNNrNJ/RafWa3Xa/4XH5vKg92+l5AN7I18/9iAL/hprakNgOoIQU0wTKCIkQrCIrLbcgMS+HBBACFr6UrrQYAhSEGrzAigSmDK5EYTdnaWttb9EGhXRxd3N703h5/wzZENcaGaEIBgAYPLuQmpQcmhBAH7FEkV6HDKBVnU6FnskAFg6mQavEnAQMAl7hDeAZBgbQ1QEaqBiKqgNcw8SEUpQpCax0GhDw1SNNDvMlWQAv3RNn4OCNO5BJSAIFCBatuuIAwIMEoIiI5HTAgapYKoHFlDmT5p5fNX3dwVno5qxia6QxRFPRybJmLZ2RdHhlwCsEXjpZqf+nicgBJQYQAqjyzwsDkslAai34IACDeQDmwRMACmyBUq8aFGTqFOqkIgqaljzZie5DqF7awoNC1gBSr1tIniVi8gqCL1kanPP0aBwWJ1sO1FMJc2dnz5/bCOssenTPTT/bLEBA8kwyAI2YXUkgYNHSZIyXvm6wwFSdcQ1Ibk05e9EYL8JLPUAbbzk95nuyrE2w0V/VRbg5jspiYGlsh9+9GFdcpQBxIUgWNIg1xEHkqSINDFik4FGAyJwFKMm/eT1o///9Iw0nAQc07RLU2uDMuiFga8aZ/PCx7boEqDoiAfX6+C04uciBkDfliNgKq0XOSuu5AEBMqZVFlBECOyP/CnCMiKVi9EsTFIlQLAHlGPBQN4+K4C0LKFTKzUUt8LsqiZf6A9DJJ2UikCYppzTQEgTRoA2tsJAYh0EWG3zNCvQwnEu1v0IMgMPXlGAgK+EYHPOTAwQqAIoqFhggMiE+3CcexegExU4CHGBrzy+aOrPCIZCw4hnEJIMCPE0CvaKAqaRAR05QxHCQiNiiaEYkewogtDqrZJlRFC6YhNLVV3GhMkorZ5I1EizPkKIJ1roswrUwLYPCzSQAAEggIwvwNEdwhIDzsSagMKAiBE5hJwsltPnzOWmtUaAcoYgwFpvsZDOnlWmEmNQhbgNSAJ6DTgm2kDVd400By+xzhqjM/7S7LD8+p1uiSVgJLpgOW4FBOGFabx3GSfkMnsXINxRDI9OIMc4YY4VjZTgmjvPAFcqLNY5kYjcqPgPikllu+b8xYB4N5iw8m5lmWkR2Weedee7Z55+BliPnoIku2uijkU46YYeVbtrpp6GOOuihpa7a6quxznpKprXu2uuvwQ5bEK7FLtvss9H2meq02W7b7bdfJhvuuemu22491r5b77357jvvvgEPXHCz/x7c8MMRf7rwn3vLA9UnncXl5MS7tvmynSxf3KfMayn8Wy+N+NaiP0C9FXQ3Io/Dtdeuvaioc4gqNMfnUn/jWwSqe6wbTsilPGuQbQE+eI+JIRurQ//RSCCkgeMonZDG4aj9jdVXB0D5UIrdBoHdm2t2zTcIBQWBWEx6jnffwxYeZ+J7UT+Ov4Fbw94iVk5WK2hYgna5iqCgGYsB/CEFT1xoIXkhAl4CMIVqUWIrVahGOwKygGAtRVxaqUiTqMeic0BPCGFpjTgGcEFGOEEqSdDfGQpQhuSYL10IKKA8mCUW74mlGgyYFkrQ5zL3nYZ9HdMJzsjmwn5kKQAtWYQUZhjCBSCBJGKYiEUIA6peNaAZUrDCAQZQLeQt4HrzE04DD5C7Zt2JEg5JVl+UCI8UtYhBreOCEaMQEAEgTwjjOcAT14hEeETGiWZYAGvi84CUbQF3Won/DKqwYoUvKjKMTIEd93JYsh0eqIe3mKQb/qanFqaBOwIYgGO4+ACTrIMSvTFRN9jhIJHwhgGgEomRjrGHBSaREtx5nXAcchsKLdJXGqweWh7xySGkAgEJ4N54GGiFGF2mRCxkD0rCMsilOKRx8eOlcJDwCBxGkmWXrIQ3v1lJQJAtGbFMw/zAkAzhmFJb3diRK0XBSnimKxOx7M01KeGA7b2GjPTkp4t2mcxeLugM85OEBpHpvVJAARHNhOQ3dgczuUwzPBqSoQzhtID6iJGbGQPn88TZuZC+j2xnzN4ROPgNSpQHFPCgXSlPYaIAnmSUKD2FJwEwz0XxxgpiOAUC//j4JkoA1RkQ86AZE/WUi0Yug8ta6UnKCaQhGHSRJmmIFhx6wARwtI7OpCibnJEVolrxoloKZUe7OVIe/hBzan1D4Yz1il5NlQvdYhAk1hlTbcFLMob4XwBVuSqOtMMTp5BGMRVJCQVMwYXLgBYFrUHKGVZlSESRSF3bVa4EajBdTcCLQC+IVeakDF/mk2YZ1hXDwwo1VLtCa1rZWpOPgjS2B5JbHjLChkG+lrdumy3e3ErJ2l7ptnT4l26d2Vvloi1zxbWt5WrGOSAul7rVtW7nnHtd7W53u5rj7nfB21vvhpe85aXceM2bXvXyDb3rde97fZtd+M6XvmJrb33xm//fqt1Xv/3179H4+18BD3hnASbwgRFsMAPLYbdwiA0TZDLXOUC4M5NTw+SkxygOsqJ3dDAnxZKbi9NJGKVFUNDZmisz6KrYZthtg2WHwcWThMoIDQafsm5h4Qt3OA0LoUQymDEN54wBx2fQcZbIleE2HFkOH0ZZiO9wOjN8+MSEC244h1urK7PBuwJgTa4GsCMaF8HGbnBejnmMZDmE2UGNIMsiDjDjEruByWbA8PfeUGc4OLkNZc4QUPxQ5bL9NmRbvpWh1aA5PzugAPGDDmrgAQ2GOkEgulKT6/IVG00nABq/sQZXhxBCdD0agEHJDHN0lRWFBKAppv5UM77FET3/baURRA31fALBypOWQqNCzEtE7pjTgySkDPxgiKiJxbomlNA59lBWJxgr14Vc2qEUOSEWpmCECjrQtAE5obELiUAF0jAezMG2HQASMGCvQ4SVQzRwszyreD+vuEhBAyt5ndMiC6YkLIRYVgiwGyBhRQGarqKqHSOSMpkhhGjJCieUUoZ54OUVo+yEPzR5stgY5stjZAY6+rfGpfAZJFz8RI0ubsh/AgAkFNeLRlWRFwfg5Y5q/BSFTLQWVuzzKVwcTDubs8ecfqJXZDFxXpQaQo7ymzAKv2MX79nIiffG6CbFUFssiEd3z7t974a3GeTL5dtyIw010opRavxSW+qP/04CkFMWCGBwfdPYskUOdRm90IApEGsp8yhtJ/2pcVGZh353AkPIZ1QGPgPnAVYpQHuoQs3o/D2XGuTlMg1xSiN0J4t4AEm1RxsPkXxYlxedHSoJUHd7zrI5o9dCMlZhnKXiOWqEPpjXC811vN12I2qABrrO3D3rPUCfrwByJ2b+iVfPHVSxOQAdVZbPBiQrXvqRuOhldD4bFQFUPcLiNiEmQCjYeoznGYSbaAMGIH0VR0vIvj9Xt8iFlljzHP4CtTx/qdA7Rx6i34YfSi91dKTxkGf1Lsrv/m/lYm+NZm/rwK40dM+HHnC6DsGYNAx0FGMeamp2Zko1IoNUvsEfYv+Ei7zgjwquilCQxsojgLyALE4HYtxEARoAlMZnH0Rh6hzFMb5q4YbA+TYlRBZhIX4OzuSMz6znE3iDQiIPMOqkABrlIjTBpGauqiyQC4IuubwsUnxu6AygT/iB/5rDJPzBClMiqY5jTTDlJFYwp9bi0nzqAONBDLdAC2ZwAVRDCSrFThpQa2wPEHDv9iLwYORmZcwPdGCi5KBhdvhqsQJCPv6ICgwLfwxA7prPQerqeqjICMJMf74hgWpwWE7tFcrDXFCrK6ZgPR7sdYDQ/I5o2hrJ/M7AAUSBJfxJE9iFWjQLTYrFGuIDtKZBtMCQFfZuG6ZtpX4RDM+irjxB2yL/y/S8IYESaBwu0bG8jfWS0Rq0QDWs4SqmhfWUTHH+UGjCURwDcZykhtE0kfYSjL76kBwnsK3KUWjCzmUskH7UcR3hK8UwR7r2ccU2Bx8Bkg9dZR7VhiAD8iB1aCD50CARsiE9SiF/hyEdciIJRiLXCmsWjCI18kksUrgwsiM3MiQ/AySx7CNF8iR5hiQPLSJRsiVbRiVpyyRdciY3BiJlkiZxElZgkhgWMid90iadZCc3Rih/sijfByitJiONcikBkSN7kimhUraQcr+IMiqtsg6mUmqU8iq5Mh61jCW7Mix9IitrryrFEirN0h2vZivPMizT8ijBsi3lMvecMi7n//Iu4eAt8/Ip8bIvQ4MsoYYt/XIp9fKt+HIwEfMdg/IwE7Mxc6Iub9IxBxMDNKACbKICNAADAKQwoUQwJbMlJyAAQnM0F9MuP7MvKWAMKKA0I/M08dICJMAJJMACWHMtOdM1AzIDnCADINM2cXMwL8AJLqA3k/I2fxMfISAAIKAzGfM45bIDAqADmNM0nVMul3M6W7M6tVMCfXM7vZM7i/M7xVOkqHM8zfPruvM81RM9w/MW/CzK1CD4JCbNeuaX1vPRWixANpMfT4NsImKfPggShe+tpIz77G4TmEw+N0EbzoOvHIez6mgAJE7S6ohCJVN9NHN4XmYcx2bJZGQ1hv9iEWRxQDGpQJdPctJMQS1hBsXoespDD+yzmMrAAUiiFPyBRp2hLC60hyyAAiZAAyxpMzm0EMgmC/ehw5KhEc7ir7bEHI5gIcYtJZog2+Ru7vyEITqxC1BhiFKNQ6BNKL4lMrKAMayHSBwjTLc0IDCu3aZKR4egFAqBo5wAgAjphZp0s7StJcpAqhqBTyHULxXmAjIgNgPAMjVUP70yL/1TRoMtQFktWuJhipoBkRBiCw2qEPuN+RzkwWROASiVAN5iHwjA5TawheiCi2LKI0CFlZDAMdoDVR3uXkQBQ9Ko/Y5k2rygdAaAASGOkDDukETBg9zPFp9jjhRjjnY03jr/IDmdYALAs2aGdBdKClsI0QjKyRQQkE/KopqSrxAMMQGr1Pk0iFu5iDr6pQm4h/OCYtlKByQaQO/c5AHWVU3qbg8N4hXiVVcZUO/Qhf00QoMeIC/WpVgb4FihD1BphVmba2EZNmY2NFHfimykSkVdowqydYNKQUMMUGBgMVwndVwt6gpWxOzsrAxiBD1OdCQAiEZPAmUZhI54iVGUkJ/gFGPLsPqWUJbY6Fnm1HrGISykSlgT01aWNQucNTCjFTraoAbBisRWTgzMIlJ7A6dQxU0IgKeGDnSsag7nzqrQQVQ6tWoRInx04wkfZUZIQjUKgATPYeY2sBQcgyzSdjba//ZetooN7fUcridjy1Q2imAGJcP6/EmpSMXIZrRGdRRHbTRZFdMIBJVQDdVp2rEOyOZ25GrDiCIrlnSIsrQMCGvDlJFCQOWCHCSuOhfT9mkUtXRGhvE8JFEb7aCLrucIJHEO8TRmGWXa5sNBvWGAavCr7IHVqjXxKvSEsvRPETYCe/RHkRZiMck49YAH7/O8QipDJTdpPZMWpq2Qphd99NG++NO2ujcqoZdtsnd8B6x80+Z80fe/1Je53rd9zSt+CYd+5Te87Bd877co8zd9+nd/tet/v4Z9Abi+BNhrCLiA5+uAK4eBFVi8yCuBH9i9HLg8J3gjKzg7LxiDIziDN/84hzy4PT9YJEOYKkf4JEtYK1P4hA1nhQPThVk4cGBYcmc4htmrg21YI2tYaSQ4h7sLh33YIXc4aXo4iK1riJGmiI2YupAYwJp4idvmiYtGiaEYgvFXiqsYxYA4i9cRi6fGi7k4fbY4jA8MjBnHjMnYAb+LitMYhMe4jd33jaPGE5BXOw4WDvih4+B4fa64z6BBj4vg95pAoxJIFFkNJQ5iCZpgT4wN1LYUkNmAjs/gXSIhj9egGurYZSy5L9G4Z/6m9+KjjiVZEpKgFBoHgowxgSZi7xzZTyB5DUbZCMji/fJgk6vGlu+yk1OSbBpH0GLZ/KARTKBRFJggzLyMlf3/hI5w+RETiBKCTCJY7gnyxFaFpAkYwIY+rd9mw1b1TR/4YXxYjQGYQBRcAZP1JZstmQlACSCKiAiqGZqfuSwWQgS7oBQSoBp2BJ+VoxocYCEOIGCTDZtZ7QHw5QEm45PMGQkONCd1ucDIRkJRYaEFOfsYtKtMAV1HAaigxZqT+W/beQgk2RNEidWGzjHoOB04iywoxOTMIgFoakyHgCyqKCD8JOEkwqUXQAxIApNZGitOIp1puhruuI0EwJ5xiB8iY56NWgzUkFiEWivyZSEUIE/wwZ5duYMobZbnMJNpsqF15m+Cl9VomZQh9H9QYpyjmUgiKAHwgaPPwJZdCi66/4ALShBdByjZFiOBhs5BPIEAVHrztFRIDMCSrfqBqmGfn6BTsDrg2lmdbff5tokpnMABXOpCHIXVWjVHKeSv/9qcQzqxYYYBNjmW5xmnyVeOL3mofxmloJE1pq1nHVtb3dQM4Bqj+aE+6joefq8eY1qvFTua/VqvWSGw0dWSkWCzk4CthQCTf7uvgVpG1IMKpPQaLPkB+PXS0sHHNFubuduzLYKOf3uYPjqWi3l10RK100DvLvd0VlsIpWFUMdql7oWmZdsfkNqjO+6zR3qmTdo+vrkI/rqncfqvAZykxcAxLPmNmmWRl1uap6ClT0Kx/7sHSVq88fCjF7ynpHu7Of9br717/BzcIqRFgpItll1qtpnSq3WIbA6rOpxWkD+BC2SECyQUr9OBNuh7g3T0vonA2JzgAZj54Z452CRZCPNaCQW6kAjcQL0ZGqH5SqvDnJPcH/JhAKqhv6dBjLLUExyALFQRqhfBqjucQj48rc/ZtbLUoEenwZnnJ1X8Jd88bd4lsmViIXjVKONckvL8bHB5JmSaK/fcowJ9j5MYvQmdHQ390PMx0RWdghm90dVr0COGjSFdcCRdwS690j350TU9gjm908Er0ytS1EH9JT+91H+4jxHywTNmtc+mfMbaaEj9VSi9a7x8T6aAziuB1WvCx1ntsmfWCFa7z5FmydH/QKqvutBVnbe8vDdyvRZ4nSbu+7h1PZDX/JGfxtj9aJCTHcBO3XBUmqaffcr9xCo+YQrqyk70p9nz5Qhb+RZ43BWsehdbO5r1KYIKumm03TJI4vfyXda/fXDklo5zXcB/OgtMTpCa4AHmnU+0O9pn4r4PfLv5QQks2RMiQ5KJ/WiMnQmggKc5euOBZtYHkuRrQm7tOdebW01s+cGFhAFePj2GxN1xwtdlxKr7+qol+alFvmiM/bV35eW7HeCX/bXk9ko/YeUZ+8tc3ppfPh363SIgXiaQ+r23O+cv3iJ4HsOV5ucvrU13nOunOOAF5+ihGgkf3KdlnunLIuatmY6n/xkKpj4m7psLjMmq6XoXo/7j8wWtncbYv1lQdoOj/d7bix6tzN7LQYHcW77tnd6ay+cepB7Fqb7dPQF39Po/tXTn8yXN9X0M7mPvdlXoPZ/oQ93ktcvVGZrsG9OUT4gwWR/Vlwv1g5L2Zb8iY//2ecv240b314v3AwT4fb82uavWh/9thH8kk//4QWP5ZYb5y8v59xH6Pf3wqT+Ac//6qdf6I+Fx0pEOUOXISBYNKGzU/dH881OFz1+Lud8M8KXN2eAb2eDIhLbAktYj+4Byd+Xd7R8IAMKhMEAsBpIOxrHpfEKj0im1WrRis9ott+s9JquFw3c4IJQFAigjsCjD4//G5zxud9abeUBAAVg4JBjcEX7tER32/QUOFjo+XkFKTlJWhVGNER0kBaABECQEJCioAShwIrydHTUkDTCAIog2DAQMDJaWLmwGHLwBNKyZ1oYqGAQwDJwNfCbIJtDaDhZwCoOK+rUGIDDxFdgdDoVXao3zgfkJ5QpQEyjUdgo5JKUCCCDUIjSSW5knpttbo6bduySeqNlici/fPn6EzDmMKLHLpSkIkwAEZUpRgQKliAz4tmpIm0ENCIBCc2CAnwENAsI88A0Agpmj/iT4tqDPMQFvCDBLCWBly5dDjjE45adjJmBkvIGDAnGi1KqIMjK7h2ZBTgAPAhgocIumQH3/ZKlK8acHqz0EW7t+NaAUWFazCIShLTM1L9++fPYKaRpYVhjBMA0I4CTSkxCuBwQwARr46TqYnJKsecBsozhjYIVIlgygaSkFvPoYPm3LkVq/U1p3HiL546khNWUKeZAA5qfNrsVZvSo7q7DaQmo23cngo+jf5ZxD71tRiuA232obLuXALO6RRDzmFE1aIHk+D444mGmcj+dGoTePB5DAQREFqY1Cgh0dTPD6QypzdtwYM+nGWwEI7Keff+qUFyBNHT2l3EcH7ocFYBViCM6FgumGixFzdVQKAi8lsxgRBDjwxgEnwUdZeaUcUE9HOzWy03kE8PRZbzuO5qKNn/QB/2JHCUQmTAAzwaEghgoqAoggvHH1DY5h3bLAXfbQZyWSzinZJCNQdjXlXAJklWVNGVJxIZprcjFdFKklsUlgSYxSWij4mEgSYfqI5yJMpRjACwL2PQUaPcgc415QLTI4Wpwc0elHYqLMdGRUdLB5DqaIcHJANx8NY5A89LwhQCi9VNhlp5/iVVA8jiZkz6mFZopHrbfKoWamCJzXhG6/4KqprWwqCQeoqfZ3x7HB8sess1m4+SwUkybAWLCXYRttqtle5siy0XHbrbd4SRtJuefSoSu667LbrruZqvtuhtrKW6+99+IbUbz5/kYvv/8CHLDAUew7MFX+GpywwguvW/8ww+Qg/LDEE1MMncMVPxIxxhtz3HHGHkt3Mcgjk1yysCY7pDHKK7PsscgtW/gyzDPTbK/MNRN8M84788yszj1zCrTQQ9tMtIZ2UGP0X+H+LAnTKlvxbRUH0ErJ001LTQXVyCqtl5oKEBYAZF3rkeyS/VHoFTJCJNCrFFmDm2zaX3XTNhVwP9u00FC3YRQDB1hL9snNrqlfG2+08s3hd5M7b7KLJw7A4lPg7azeQEP9WBNIKROaM9gIsfXMxSaYrN0IHEAfhQwQ9tIppMLEQFdEzCMKGUC1oUZZDOVn9umpj4bgLnG+wckrsc8+BEKh9JZ7Lvhs0xBal/cMtd1H9PT/U1A30RJ61SuTHvemQzjQwE4K7FY+V34YcJMZ36ghe+BimXT77M8PcuXH45Nvfh/pvwQ3DyKCAOgTv2odYS5facZM8HcW6QjOC9Y7zzEMkijQLEoIF8RZ+CwmN14hiEhtex0nCIAYxbQFgUcQYCaaA6DmFEJJB3pACGV3HmytoQGzSmHgeiSE2riwQTCcXgQpciHNicOEOnqPECZXsw5y6XFie4kDErOAUwALANsZBG5MhbomsPB2vgFQ2lhjttxR0Yrm+Q5LfOjF7zUFiGNsUBnzQj2eQe0UwtiJEhXVDHU8RXQwg2K/fBeA81BDeAlYAyDARqKQBGQBA2hcA4T3/8UgYukPZ9rfsI4QCkRuI3QyKkAlNUkGNUiycR2yhxEwWUBNbomIRdwC1EwRNshs0HP0aIQgW0ZI1yhpHm/o2w8JcwC53AmSgJokEaxED/q4coe94x/53CC5ABglUPQwxjO+uMzGTQoBu4lmnIA5S1rqbYg7+6Vf2HmHTTqhcnIwWyUa8L3/NA6C54RWOn1TvafBC6CVqGAvsngEeSZJoOSABzemlU++3HGdEd0nRStKTYtKZaIY3ShFNUqzWnI0pCKl50j/UtKTovQ1KQ3aSlvaUo+ODqYunanJZOpLm9I0px3DKfh4qtOfTsynNRUqUIuaMKKSDKRGXeroZqpUpv9CFWVIHdlTo7owS2Gslz5z6lSHyrSAfvUoSWiEIuR1NeyNdUFX5epP3QnR/hxjkWp1l4LiaiSAKKyrLtNrUkkqvk4C4BjUGIQiXNXD2iXglOzoxCoGwIt7SqSuR/pMYeFxWDqJ0Xm7i96t+MqxqlbUrXaEax9e2Ycoqa0h9HNKWzzRWDK0r4eRTdYxSEGf08JFR4EZiz0Z2Kh75O+hZ3MpaDvqVw/yr7a1DVId4DmUmWQCVI31BEInIVnPKGU9zg0jj/5kDX8Wjq06Fa0sAVtbe2xCAdrdEneli4aRlE+fgA2sIgSQ3vVqArpixKeBEFQrz26suPsk78FIyz6MoHb/SkQopZUUa4b3Ks59o6XmeSuogATrFhiW3O9vzRRLNAEYYwI+J4Enop/zOsoPhj2CM7dhQLw09lQfNjFty0oNFVuWxXuC5hxlVc7OijenJZ7tRbvg3CN4p53H1cKRCSjc8BI3xDtdciGLjAWC+gIKSZZv2b6AZYM62XJBpulZiaVQgZWZqmO2KpufuOY2w5llUqbYiONsZ4PNOah5vjOf/7rSOvc50Pfa88MALehD0/XNiF70URXN6EcDjNAMMzSkKw3kKFs60/+S9FU5zQV15u3M8xJ1mhRXiyc/YT3TI3WpJXfqLKgayi/VVXrtsEFjfZddQ9ZXsi6zhChUkb7S/4tCrGl8UV934wnBBsCWie1p4GC6CscYka0z/AXmgFdau05Zr/3gpGHbBg23nkKxiTxf9iziSU9wixCaDYVyD3fWVhhDgeibjDN8Dhq1GMuCXfE3TrwDRWC5BgIXIo3AEiYnJATc52z8bMJ1WdYRV+s62nGGi1xGAdo43nfoNIfapUI5WiTD4QzOb0OYrazetTgBLuLya7xKeR6fU0JE7gCSu8Hk4Haao51wJrtlrxkqaaNLiFASYPSx3Z4axiB+dQ8mFF10Z2JOwf2btGtR2ZzUVPls2M3s94r7M0c/CREUaITVXqkmXHEDhZ7ObPxIMOVs0Uq7wV53tqGBAHA3+/9GssEMtYdiAW1vaNG5He0pLO6VuWQUbxqT2LFtcCQYB8tHSlHWLua6u2K2sp8hjm4MNn66wsbJY5I9mR8aQYAFaoADHkC1AsS38qjuh9yHE3q7f12UApjfU7ATIWSw3vUyib0wqnspeVNBG3RawOJP33jlmaoAkT+If/lrmXRgHvSa3yrnkTtflQMo96u4NXi2FMfUE2g3smPHGG4i+yTV/rcwxr13CHAP+iiv92f/PQPWDyH3F9/sxVDPIRljnEHz+dDzoYiK+E86jMQpoAHr8IaIPNI39BaPiMfDIULWKdnWeduXuFfunc8npMhQwJ1uKMTZVYn+BN5O7MYECmD/mtTet91e7g2QATRUHaEgK/WdPWxGC4pCozxfJWggmgEG+gCLPSFgfOjJLrFSH3hHAZxKg5RCMtgCJMlOL4hGBnLfuXHN962KEIofdSXBgTghAR3KqGzDL9xc6ODf++lFyoVhDY4EjhxJ7bQRGm7DHCAEx7XhULxhAPLa4T1L++DVu2wbPyTi5nlhgBEgmtghNuFLmoEYq/ELJbrMI2raJpZLEQYMpXFiKFYZ8oliKZ6LJ0YaKpriKkIbKbLiK/6XJsLiLGqdK9LiLXYeSoEiLvLiPBFiLwLjhNliMBLjIA5jMSKj1chiMi4UGhgfFczFEMgRmoQfHEQj6o1egf1i/5SFVeGIGrYcYu494xZM40OQGjg2QTU6Qm2MmzH+mSqiGQdymeepnBOswjhqQTneQZeEY5jhI6wZQTsa3jH+mTy+lQdKIyqogjOuAcxZC+eERDXQFy98wwUtTysxAySNRrZBS/whQaxUhkMW4DxEYj04VjlZ5Mwlin2h3s4N4Da+lEEK48QtDaq8jziuAQLpHREEnVgxgGClVqLwnefcXdwdW6cQ0IvBhE7CHbMtHUiIBGxVi1AqwgIlClIMIc/BZEF2XxQhpAZNiqXc4xrEyO6hVSOYBsBNX6Kc345wxQP8CsodG17pUDlVRln20EicUBnaoBqwpf6N3oqMIMQsY/9ILSIRdhv5cIeJMMf98aSOzEd9bFDb/CU29okAGeW5qZxYLIWDNSYC4N+DycNi2mD5VCZnXBD6XCBhbmVKHaYyfiVNVCBO4iAT1NEF/QiOeEZkJADzgcUOJgaPVJBL0t5cDgGDeRN51GbwFOBxzCYWjkKiAGdA6kgtyNY0EaTnhZZMlhdNqhz6bAMkjSUguAJebRBCpFdcgc4FhRNGDgESyaVmAgQOikJyRhIeHuIDJpNIyNjotWc2ioVKHd87yiBHvaZ1cSccCOQUoFh80qRDuNsUaCTB7KMswmPDJKixNeIkLOjbQNZzdKUkRGgUgAKYPWhmEqiAbhQmLokl5gv/i2LogLomYFwoM0bQz9TooNGojfYijlooj/Kij7bmBgLpLQppdhJpkc7ikaZoWigpLTLpjBbok75ilOrijlJplVbokLZilpqilZ6UyuSol+LRliKpOFxNmqrpmrJpm7rpm8JpnMrpnNJpndrpneJpnurpnoJpSe2iKI7pUgWqWQ2qYZKphRRmMBYqUC1qu/xpKDbqeCUqMEaqkE1qjx5qcZ5pMlYqmV3qLGIABVjAOVgABWBApjYBBmhABZxDBWjAqV4plUqABGxAAGzArKKqE0xAAOxqrzZpkUYAtkRArjYBBWALBfwqkF4AtlwAsR6BBUgAJ0jAqEopldZqEmyA/7M2QQZwQgZsKjFWACewqrYSwbImQbMma5H6KrkeAQQEAARwKTIaK7KyKxF0QAB0QLwWowVMALXW6xDAq74WI7r+a1t1asEiLK48asIyrFQdbMNC7LZE7MTO0sJS7MXqGcYyI4xKDMcmFFXAWyfOmBV06M58kRcsi6X8YxRcZeHFQcl+4Yl2bIamyYZcxshiQcjiCqhNgTrBrBSQJ6UYymYYR1l1jzpUX3fhCH3pSI5gRLGdwu1ky2J1y0U0lOP1JjY+gViY6BM0W9ZIzc8+wQW1gel5mbVJnHYGFc2+xoY8xdV5gc7eCs9Kgc+irRUggFmgj5SIAhoUbTpI0nWsjf/tGQp9yRW6nVex3YM1OV8C5t9oDsf1hKwKVcHXClfY3i2D6siyKWjmxpvMFhrbpoXbBgb+GQ8TsA5m/MFjvcFFNgHIqcJjNUHqSmKMHAcZnEbe5Vs0nFw6Qg93lFBN5h7tvkQsYITwihVFfuTxiOQQfAWwaASOBOjfOi9YUNuJ+MbSChZlHZiKHcIowJNgGEYCNkd6sJ7Wzi7jGm9Zwa7LEZA4cdZYworYDAXAEa+9KcNFrMEG1dtx0kcb+EF8ERwa6K9/6oPOrS7xDM8a0q4waJWZgu6kiW7OiMFlNOUrBRsD0IcA1QTfsVFwOaVvug1OsM8oSFIDVFIWRS8CEcX/202LXZBL9PrGGaxPYI2CUNzD9tFX8TKuOtAHU35H0ibK0oYE9ZJPAmRbc2hvad1W9zpIbuxGGYkvtviQlewRMiwOvClx1W0kCH8tDOPkY/7kZ9SwIfakBiGKjhyd80axJI7QWMQlGo8xYtSD20XdTCAHM+yCAWQw/j2wjCapiE1wRonBUxgAJNUlqkghO3wkZrRlfkGxDSYZCYmK7KibGYZBn4hhOuYaJrtn3VFyJ2xhBp3l6CUy7t7F/AjxwLVS28xBPR7DCGvfHylXHyhC4u5BfGGl447vRRRK2kCSFmfvZkiG6u2G5YKe/KYlRqQmtiSdKZxGe6BxQyhHTRAJ/9thi1xE8zHEyC+8Hw7pkU+MxiLh7EMMslmdMx6QLoNwZgIux0r8yOM+8XNF8khMcg9rUAIQyTUJLo8wYTwJw4FYB2c0xxlgEfaCnt0OAlu2UVPYH2gSwfPKxjjNwUnO1eedyAvuyHnZ1y0XVh7sxM02bi+fEr+FDaoIM+EWc/rZYJgxp/xGJns0cxZNpulK8zVJT/nsxnyQQR3Jh01PW1l9sywvgBqszTsPQNdCsNrObIgaUSE3UUggJ+76rRt082gUwHQeAf1YsSRbC1cwkgNcmEvQwgKsUnBqMkzsRCy9kpactRHEMQ3LVSONsldk7WMuNFhM9XL6dN4Owt4Cif+hvPIh1iMaV+SVVNjx4jJCa5/4Vk1TdPMGUeUTTE5dc3XafVhbn8l4HhKQXFiTzLVY42Zn6yb/arTMvUTkQKDkpAJp50hY7PP7XXWI6ETbAM5GqMiHxqFT41k664HNcsJL0Kcz9DQKadM2SEoaogfs2HPggE2cBIp/fdFjfXJ8xMVBSRN1a1IYrMJz94IB1HWL4bWwDTfqBG0eDkHQzs7Shs4rZxxGYy/x0Fc63BhBqRe2YOYITnHVFkreGkYHUzERrDcxbwbsAglWqYM0yS961tfTGpMBnOej3DTnksRHd4MUqi6DS7MULocgHvegAIUSzO9M/LEvbqgE8zY6Ucz/+GZlVHGts5TtpLmojHdjDD0sFjhAD61sS50srhxyU4auwGqskX7qkK/ijYeakfMoklsOkys55hT5k0NqlEv5Jjr5tVx5lbuZkGt5KWZ5Z315l5vMBcDqHGAAwfppmIs5yVjAu86ru/prmq85Ll4rJ2Rrtc45qGILrMZqntOiuyZBwOK5n7+isSYBvQ46obNitEoAlyv6owXrsH7ro1fasqJ5n1M6K47rpGd6pzeMmnu6n1tsqJN6O4F6qYv5qLdLKPRfEKI6ltd4xXis12ABNYTmAvMKFGBcAYS02d7B68zYv/WCrzsBq7fBab/OebRBJyhfEpyH68WJ+XTBPBhF/yu8xDO0riR+xQtuAhlgu6MYBbTbwkxY50ZAireLQrYD+RS0Qmi+5/Eex2UcU2DhYQMwgbgLJlrMQzl7wb7TBIJLwbE7wrajKFMH+YkbwoUsewCE5iYQAFfctROE9Bv0+iNIEl82QS0oQBtwZBMYu6v/RyjNAxm0u9Ed3N8QexVQuxBY+78rsrYHYSLF+8u7zsH5eyusAUJ8wyZ8gzGBuxaU/GOqbryfRyuQQS2cByAUAMcPAsrniyzweyUQPEX4tqNWPUtVMP5VkIrEXBNMvHygQm9AN9hPSkfwZdAyPBjlLcCj3gvKwgh/RXCzDRaDvOOJjSiYRNrLXD1IPGJtRf8StHw1VbskPkMnUMNLbPtXJHW8h0LL1e6rQPwVrYbsFsO/N/7hb3W2NGXQy1woaPTbq80riILpJVLXCrul0BAnpC6ZIEiIf7fk8MIAFP02bMI+73tI1yX+XeRpqwMntJ4oJMYD7HvtJMECCLvs/zvrC3zcA/4RHPs8tA30Jz3xL70Ff72mRvBapXg56IqtN5Gr+/sTfH3FR62jkMEnVdADCPzKO4EU0ueHWdi/z9jFo8HH8/78Dv5lGL+vyTIQIAIFgPCxCCQDDUAT4Fg2G1FhITCwMh+BRCKgcFavWYCX4Rx8ywFDYjBIKK5NMTbqxOfzU0c+TfijC3gAEIhKSzr/IGJQCnAgxEuDBJAbMAhTQpA7ALA6WHhbYEwAmEIoDeCEKkAaXPBS2BpY2CLFO7gD2FJ6WC0aAgCdHf1NQiB2Ag0gwBtdIOBa8ATABUuL5WpqXdDrdgrwBgAPJy83P0dPV/8OH19HT1K36gNA9vXeDk46M2wkNWvFIGC/Aw24OZHDrEonJX0IeHkzCM+CKUqImEGWR8gAJ3zyMKi4z4mBJJemCAioBwoTVEyEMIDiRUsjAZhgcoliBo0aXKsM4ar566bMdx4RZpvCqViSoBQRAQPZ6MzOAAKInMSzsFAjLtC4Ru1j5dSqlF4eYK01saSTtE18LfQqVSsxio2IOCGW/7YWSa4F2r5r4k6PYMCFDR9+RxiPYsSLGYeb14QvN1zM8CXhltJQUCcA96VsgGtOR67A8Hm55KTnr4sBGGTEYxQVvW5aAfA1WTVlHkMsp7h0/SrJzDhJLL8UHqWyti7crMCKezy4l1xNrHBlSZr2Vq6XjIQztJ01HgMNhFTFiunuZjzQOMZ2xHDskLKD0GZLtrbJ37fA3Gs0jZjVbKsnG724wA2PvwB7TJzGHoQwwsDakTCPeNKJrInK2kiAm+/UCuAgWHTh4oxe1hDoM5Ga+K8207zBJTtBWEmjtdfw2yM+KXS0ToBLlJlqxl+OWFHBAE4BUiiGokjrOe9cW5KJSv8uWakJObLhiw1BzrhORnRkW8OyGods5gBIcCmgAB+DSSNIPDabUr39StTFAeGIMOATj8R6gj6RzILmlOfyiJEtHH1BMxgv8PxkrmyqUOauJvIy8FEdH5HDlnzSabDBCj8F1UIKQ73QHEYaIWQB0RCA5EPr7FryFALOA8az4Pah9QA3s3oRvjH0eACiMTHCET7aQkriAZAQMTOPBaDoSh8o9QDEGOmmEoI4DY9c4CVBWHpAtAQkBSANpdJ4T8lfvDwH2SFwtIIjV4MJLQks6mmA2UmkTcJOAGZVggHbAE5iEdHi2/PIPln5U6KKNnK2H0f4AyZYzBg4uA9HSbE4InL/KeU4mwUkPuAS0QzCTJ1OQ2W5ZVG98RSxUl2muWabb8Y5Z51rDm9nn8lZ+WehzQka1JmHRjpppZdm2mfqHDmoaZ1L40pqpaluhOWjrea6a6+/Bjtssccmu5uty0Y7bbXXZrttt5s++22556a7brvvVjtuvPfmu2+//wY8sZgDJ7xwww9H/Gu9E2e8cccfh/zBxSOnvHLLL0d8csw357xzz9HW/HPRRye9dJxDNz111VdnHZ7BW4c9dtlLR31222/HvfHac+e9d9/t3v134YcnPuzgi0c+eeV9Pn5555+HPsLmo6e+euuBfv167bfnfnruvwefeO/DJ79828c3P331/01Hf33338e8ffjnp59x+evHP3+/79e/f//l5t//BDhAsgWQgAdEoNQMaA6vWGZpvTKHFUyVBs6wDBBdE0BNMighOYBBDwdQijpIkprDQLAbA3BgOSC4wXXIYQsphIcHPzXCcuSrAB0qR7dGEyoUxi97UgghEMmRJTAkAIZy0IMVJJUxFlGnh6pqSNTS0UMIOaCCgKFiOS4IKhoaZoMs5FoXH5RFPZDxHFQEozoUIQDxnEMN6jCjN8ToDRQ6gFxOIEgn0qWOLcpRS+WCoYTmWMDs8SWEhiwHScCABBJaSTEDQMApNIQnLDDCgw2oiQOUogAENBIdcTQMAgK5DlBSa/+PgvxjYb54xaYN8jClBCQpLZPGdHCyDYmR4SdHqQdXNmMWs/CGAJSCScD0sRtdhGVjemm8H3YiiM5MJE+UgAckNiMBJJmKIpqQwWBJsQh3zNGRDJBBKwCCANehj2g+gc03XPBK3MIDOhWgAEQwAxCMqOBDjINONVllGfQ0zr840i1OCGw4eXiIEBKQrytcwqDKUUIu2+OFOLwTAdxYpR8IAAUD6NOIwVBnPc7DhBGycVJs+CIC0HUJA5xnXORJRcFedYUzPFSDKhUnIPlpUW6QMVhNeGkBToFCfgoAp5YglBJ26QSPKqClTLFSGkb0UC/pcxn8vGdVALqM22jJqAb/gGIqvBlMTrxTUiQRzV2uM4AzZK0bB6NnSEV60IQmQaJZFQBVqRFRKvawjstIwHkkyrxmFuCZho0mGAZZzY70wQEs0SYDjKjDDHowUAJgVwGQ6gAFGFVMzKCiNr9JEpQI1A93fOJLt9DRl+bhowRgAhpFqSgirBYQ3arJKxQbh4ky4wADsIZBeNsGp6ZSDx3sBLnuldFI6IoSSO0mCG9z0eHGYYSMMEkfUnqGATBBut+EKROgsQDk5usJNYFJITpZhJr4NZD3IiMSGCCHscQWtLM8RrnY1URyIDdN0m0DAV5BBCQoQLe34W1n7GnfJhJYtWwo6UWpcRcEgLMbwtzm/xVJIt4QlZcjxuTlHwewTldUVwEPYYZREfrSAxMXmZ8tl3NRrN6k7Q6x8XxmiBVrXEoQJgGEeMi2DmqlDOYCkwi45i3IBUb3BoYmXbzgOC2i0R6HoQAg1hACBADjQgSFsRVOqJe5ksIt3riyY14mNEciMSIwFw2WQWdJ3tjjRhCAhhV+BSGYu8E3ilYyWhrhjeV7Q6tkmEUcafJt2BzLrBSgAQ1IgGQJkWgW0lKo04RMEN/YAM664wvvDKhqtMzlLX65AGiVsDhocg4MdzkPNAy0UuSLZZimpq8EAPUytgjiUqNZxDCm4q5PSVh5HDbHr1bDYgWzi4hOOBxb0EOFlf/8Js4kWiIj+eMFHbBePzehh6am9b+M2gc0itnKgUKqHMZ6aOso5cxSTPON3cLtNmvwilQUqoVkqO5aC3SLe65Jn8kFazYIGkoMEOYsWJjvRG/bZEQwYwEcwFYHOACHlA5KGhlBBMZ2Q97iuGSnvzHPEIWDAONmdK+tTBIhePDa6Wg1LQluAIMzINx/tvVn+c3U9/D6PTvHubeBbRlh17iwxj6KRBXZVU92HIwb7PZGs8kJ0SogwdbZbGerrZC7HEDCaYKyvJjAgHtFghkD/hcbsNxSLp1C2q6mbdo7ypFtL+AVueVse95jZpQkAO8GfuMWculfoY59ufamco+ZITD/anCipXcPBmdp+IrWArwIhh84oNmAXAFw5ADMULdJuwVxrtMB84zGi8K2QI8evr3SFQzWJQzRXzX8t6CT5So0DOz3yMuQ7Z1w+122iHZoGCDQkabG1+/43Te5W8OaNwDnOdJNKeAwPx68NeSfdeKen3L4vN9+gU3/r48Gu/tGR0eWgKF+js+5q3ZVtj9kGN2PHaxknaBOa/EArU4y2Z4FyxNjKK7UcCcvUCnUsoytsqdhexZ7AQOv6CeEqCfTSj7yOo/747l2MzROSgTZsyvzyoPrqCgDPDy4ezMnuCGoeqpUoIQLNL4/MoSDsDyyu4KyCzoaWisumTIBoI5z+b8h/7C6I4GvQGKx1uohCHy9pIqpchBBpzqPoPCKlmvBDkwGaAGutBuCPlJApsM/BgjAI5Eo5tumRDDBG9SSHAyG82AvPegHeoIxDkyFuWM3vUMIF+QOkjuS8iO680OaBUogt7CwtCGuxqAl/7k62mmmP0yHJGObuNivdyhE/SG71fFDRbTES6SZSsTETeRECNHETgTFUFSZROSjYYObQEydZBI8nEkmmUHFpZGgC/I5oUEuBnlFnEmzTFwECvoZ1IlENoRCUwybXJzDdyBGmGOld7i5M1oqULiLQHC2EPMkBkqXVlyHYzQlnKElWfQ+YYQca+TCobGiofHFZATGYiybY/9cxiHiMS8yx1J8paXSLDRwg0k6pnbUompcKsDARoTyRlDZxg/rRs4Bx35smdkSmtB5J1UwBilayLraNGPYFSVgK/JTKDAwqjRYL3K6Kns5g7riLbzqoYPxrYjSK8eQM7LjiIc5A5LcK7uCpESAFuGjqBQ7quhTgiACSYz0J1ybwKzZQvLjAieEKtRTiezorpHEkyd8yS8Iq0/oMYnKmhEjQ6H8qDfBqfVCp5qAqx7SK7SSKbf6sycULDrjlofIjKuclCd8SIGkQKYKrKEEqUTwJo+ys+5CsFOLKdNgyS4rJy2xS4u0q7lkQb+SK4AaEZSsyInaJ4vgSJ8MKBr6qpP/9JVjCDKgYoa+pEoW1Ch56sXsWTik0jLegMKPUrEbC41gcgjeMq+vWkPPispS+DDWnM1nJDNSmDwTo8OuKi3U1EncFLFPkAOH6DDo6hCj4i4mKMSHAIPWnC20s633gM7Nqz3Dcjw9DIcswoLb0iYAM6IuEi1pq8UM9DYSewB6ugTqw6P1Gk1s88JfazHrioLxWrsoUCIaiwSIIwIQG8f0YiFufMsmak7PozByQU9d6BBGeIDRJInaKrhh4gTYHKED7aYZUzEAGyrQMk+0E78LE4/XYjD1OrsHe8Fxuqj4zCXfLANm+CkVHbEFIIl9iSVwbJlytEcEJc05vKCD2aHq/yPDLSqpYIS7mgNStdNH4JsmGso1MnsP8GwEjri0eHixwNgxmuuOJFzOJkUpc6ODK/s5d6iwj9s0clsq7dRPbRrTLuKKd+yjW4sz4/pPjlAAuHqxJZ25+ryEaoqyRcu3t0NBv1sPIQXQ3RyhNY2n7kg7SXoxHuUIFgq07ig690s0FGIs9yuFHiSUURM6Q6uyLkU1bljSW3jSUqA67xrVW6MyGtUa0AwK0fopatNRz3tEzQIDxNoiRhiZoMi3hZM117jVEGlTAti4KlPSkuuGIk2NgmgGYECiKQU5pss3WHW1LD2pXHWkc/tSKxPTkDPKxCuX/QwsIkjTP3o5cghWof+L1gvT1VNIAHr4gjo1VjOUQ2TL03HQNnqjLetrhoSzVtMaVPLE1XKNJ0kyEgnroh9TVmkNNIKN1Wc9wVur1BS9wo9jEZQrt2v11CNRA6AjFC9RJC1J2BPs1kT7zC9RCs0Cq/bsCKUouhv6yAoyjzTkhMvEMNGTNhaSPvLbppnVx9jbCn1YJPDLO7bAoS5yWXHz2dnrUCpKNupcvFNIwtRcsZ2FO+JjA+qzWpysVeusB+yUoDx4LDR4RmCQLskSsD5TvthUEOuDWK5ivDfpg9FDAiBzyjdCIe2TPOhTT2yrV3ZDgNPbClb6vB6jCJZ1S16zBQzzOucwULc9BQVFgD7/wCbykwbkOzm4m1DHpcAddbwMZbS7lQjdiw0kQYAg+r0+DVTm2E8IK7hIw9sUtdxWTYCTjd3PhSGSJbZzkCwW5D9v2t3P48N+0L/p4oLSFcqc4sGqBCM0tKr1Old1Goc2hEMM1IbzECPhJQLoHcMvYNoqxT+oSsLfZUzk5Ywt1CFwCMomXMGg6KGvjSdb+FZHWsqibMMv1AS1TQY1RNUUrArewNQlqYY7/DYXnLnz7Tc9lVMSvAs5mEZ+6tpUAFDENQaWWhWJ4l8fwcs20EuK8iDsxdwzpI6aKLoV5IRJ/UFvGQmFMt4qdEAsjMCoikwQni87fJMkaC1omAQPRlWz/+vWqSHFmwGxX/SGdeQbIr4ZZ/QaIVaaVvMag6SZvR2eT0SMIH7HY/3HvjHimwmWwVoaJUaapfsaJw4V4d3H3JFiUUTjNLaQH1bjNnZjomHjN5bjOXaysRnPcxDDuvE6Oubjkj0Hit0rGWIiVJDIuZKpa8RHq/Fic3AlJO7jR74Z1KFYlssObTIALEDZ23AAZmgtQGbkRJaaRY6madQjSDblTMweijWsV43GDJLa6wuHpwQkjmIDuPpK13iDDdrKwfBIgcKnp5QiiPSg3l3IiVIohkIqvYIrZ5mWU3bmCpHkZ5K2H7NHs5WsAcig1AiPQiOUzo2xMxih3Nyt4iqtNP+aXA8lv64r0N6isUwezeX8qN8KLhRdJrV85ntujGheVoyih4PJDjWBAkgYp85jWIfdVKYr1jrrog2a02aLDUztI0Mlzx29i5+iVjU7M4VOZFXF546GmVQOImTBoW7bg2fqUCrlYYTWEo5d6JpoV5RGwYnl2W+Q0Ykm0P0ghYvmO5ZOZHv26J/mFJBO6VjqtgzihpY6NYS8ISnCUEYbIfF73Zae27TLpZglqLdc3OTazQtCWdwi1WzE6L77uw51X/kC6rMOanR4U31NzaijldySmPsljwt0aq+yq+ktUUO7jgBO4eKdacmo4K1+j959YJ3cO+ebwji8Q/edR7R2bBVrimPqceTHpmxerp89ruzMdgzN5mz9OePOBm3e+ezQJu3ZGe3SRm3WOe3UZm1EbO3X1p7Vhu3Z9iHatm3nke3b1m3diezd9m3Rye3fFm7ACe7hNu69Ke7jVm66Se7ldu62CQAIeO7pJh0ICAIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kidwell CS, Starkman S, Eckstein M, et al. Identifying stroke in the field. Prospective validation of the Los Angeles prehospital stroke screen (LAPSS). Stroke 2000; 31:71. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13377=[""].join("\n");
var outline_f13_4_13377=null;
var title_f13_4_13378="Legionella on BCYE";
var content_f13_4_13378=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Legionella on BCYE",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Parallel cultures of Legionella on blood (left) and buffered charcoal-yeast extract (BCYE) agar medium (right). Legionella only rarely grows on blood agar; it is best isolated on BCYE.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13378=[""].join("\n");
var outline_f13_4_13378=null;
var title_f13_4_13379="Swan neck deformity";
var content_f13_4_13379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55390&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Swan neck deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 556px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Posterior view of normal dorsal extensor expansion. The extensor expansion near the proximal interphalangeal joint splits into three parts; a central part, which is inserted into the base of the middle phalanx, and two lateral parts, which converge to be inserted into the base of the distal phalanx. B) Mallet or baseball finger. The insertion of the extensor expansion into the base of the distal phalanx ruptured; sometimes a flake of bone on the base of the phalanx is pulled off. C) Boutonniere deformity. The insertion of the extensor expansion into the base of the middle phalanx is ruptured. The arrows indicate the direction of the pull of the muscles and the deformity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Snell, MD, PhD, Clinical Anatomy, 7th ed. Lippincott, Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams and Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13379=[""].join("\n");
var outline_f13_4_13379=null;
var title_f13_4_13380="Scapular strength T PI";
var content_f13_4_13380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scapular strengthening exercise - \"T\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 345px; height: 487px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Using the same body position, squeeze your shoulder blades down and backward towards the spine while moving the arms to form a \"T.\"",
"    <br/>",
"    (B) Raise the arms straight out to each side, parallel to the floor. This can be done with the thumbs up or down. Hold for a second or two, then return the arms to the starting position; repeat 10 to 15 times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13380=[""].join("\n");
var outline_f13_4_13380=null;
var title_f13_4_13381="Stage III sarcoidosis PA";
var content_f13_4_13381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sarcoidosis, stage 3",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows coarse reticular and reticulonodular opacities involving both lungs diffusely. The lung volumes are preserved. Enlarged central pulmonary arteries suggest pulmonary arterial hypertension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13381=[""].join("\n");
var outline_f13_4_13381=null;
var title_f13_4_13382="Metacarpal neck fractures";
var content_f13_4_13382=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metacarpal neck fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13382/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13382/contributors\">",
"     Josh Bloom, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13382/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13382/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13382/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13382/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/4/13382/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metacarpal fractures are common injuries that account for 30 to 40 percent of all hand fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13382/abstract/1\">",
"     1",
"    </a>",
"    ]. Metacarpal neck fractures are the most common and are usually due to direct trauma. They most often involve the fifth and to a lesser degree, the fourth metacarpal neck. Fractures of the fifth metacarpal neck (\"boxer's fractures\") account for approximately 10 percent of all hand fractures.",
"   </p>",
"   <p>",
"    This topic will review issues related to metacarpal neck fractures. A general overview of metacarpal fractures is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=see_link\">",
"     \"Overview of metacarpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Finger anatomy is discussed in greater detail separately; items of particular relevance to metacarpal neck fractures are described here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=see_link\">",
"     \"Finger and thumb anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metacarpals are often described using the numbers one through five. The first metacarpal refers to that associated with the thumb, the second to that associated with the index finger, and so on through the fifth metacarpal.",
"   </p>",
"   <p>",
"    The heads of the metacarpals are bulbous and \"cam\" shaped, thereby permitting adduction, abduction, flexion, extension and passive rotation of the fingers. The collateral ligaments join the metacarpal to the proximal phalanx and are taut in flexion, while having some laxity in extension (",
"    <a class=\"graphic graphic_figure graphicRef65855 \" href=\"UTD.htm?0/25/415\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    These characteristics have important implications for therapy. During splinting or casting, the metacarpophalangeal (MCP) joints should be immobilized in flexion to prevent shortening of the collateral ligaments and subsequent loss of motion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual mechanism of injury with metacarpal neck fractures involves direct trauma to a clenched fist, such as punching a wall or solid object. The \"roundhouse\" punching motion common in street fights (but rare in professional or high level amateur boxing) generally transmits significant force to the fifth metacarpal, resulting in fracture. Experienced boxers rarely sustain this type of fracture, and the term \"boxer's fracture\" is therefore a misnomer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In metacarpal neck fractures, the dorsum of the hand is swollen and bony tenderness is found over the fractured metacarpal. Significant tenderness or ecchymosis on the palmar (volar) bony surfaces is highly suggestive of fracture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fracture angulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metacarpal neck fractures almost universally result in dorsal angulation of the apex of the fracture due to the pull of the interosseous muscles. As a result, the metacarpophalangeal (MCP) joint is often depressed, causing loss of the usual knuckle contour. Angulation is determined using a lateral radiograph. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Radiographic findings'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    No clear consensus is established in the medical literature regarding acceptable degrees of angulation. However, it is clear that the second and third metacarpals tolerate significantly less angulation than the fourth and fifth metacarpals due to their fixed proximal position at the carpometacarpal (CMC) joints.",
"   </p>",
"   <p>",
"    Historically, a simple \"10, 20, 30, 40 rule\" was used to determine acceptable angulation. The second metacarpal neck tolerates 10 degrees of angulation, the third 20 degrees, the fourth 30 degrees, and the fifth metacarpal up to 40 degrees of angulation without adversely affecting functional outcome. However, some researchers believe the threshold for fifth metacarpal fractures should also be 30 degrees. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Indications for surgical referral'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rotational alignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rotational alignment should be assessed with the MCP joint in flexion. The rotational alignment of the metacarpals can be assessed in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With a semi-clenched fist (flexion to 90 degrees at the MCP and proximal interphalangeal (PIP) joints), normal alignment will show convergence of the digits, but not necessarily to a single point (",
"      <a class=\"graphic graphic_picture graphicRef73269 graphicRef71612 \" href=\"UTD.htm?4/2/4134\">",
"       picture 1A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      With the MCP joint flexed 90 degrees and the PIP and DIP joints in full extension, the plane of the fingernails should be aligned, and can be compared with the contralateral side (",
"      <a class=\"graphic graphic_picture graphicRef52326 \" href=\"UTD.htm?14/14/14575\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Extensor apparatus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The function of the extensor apparatus should be evaluated in patients with metacarpal neck fractures. In a severely angulated fracture, efforts to extend the finger may result in hyperextension at the MCP joint with flexion at the PIP joint (so-called \"pseudo-clawing\") (",
"    <a class=\"graphic graphic_figure graphicRef81613 \" href=\"UTD.htm?38/23/39295\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Skin integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special attention must be paid to skin integrity near the metacarpal head since this site is particularly prone to injury caused by a tooth during an altercation (sometimes called a \"fight bite\"). Any evidence of laceration or skin breakdown requires aggressive decontamination to avoid potentially disastrous intraarticular infections. Prophylactic antibiotics appear to be beneficial with hand bites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link&amp;anchor=H4#H4\">",
"     \"Soft tissue infections due to human bites\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three views of the hand (anteroposterior (AP), lateral, and oblique) adequately display metacarpal neck fractures (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60355 graphicRef53210 \" href=\"UTD.htm?31/14/31969\">",
"     image 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66007 \" href=\"UTD.htm?10/54/11119\">",
"     image 2",
"    </a>",
"    ). Measurements of angulation should be performed on the",
"    <strong>",
"     lateral",
"    </strong>",
"    view using the shaft of the metacarpal and a line through the mid-point of the fracture fragment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13382/abstract/2\">",
"     2",
"    </a>",
"    ]. Use of an oblique view results in an exaggerated measurement of angulation.",
"   </p>",
"   <p>",
"    The head-to-neck angle of the metacarpals is normally 15 degrees, and angulation references are based upon this baseline. Angulation is almost universally apex dorsal in metacarpal neck fractures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate surgical consultation is needed for open metacarpal neck fractures (laceration extends to bone) and injuries associated with major neurovascular impairment. Such injuries are uncommon. Complex metacarpal neck fractures not amenable to conservative management, such as severely comminuted fractures and fractures with any rotational component, should be referred to a hand surgeon. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Rotational alignment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In comparison, limited angulation alone is functionally well tolerated in many metacarpal neck fractures. The traditional \"10, 20, 30, 40 rule\" can be used to determine the tolerability of fracture angulation, with the exception of the fifth metacarpal. Cadaveric studies looking at the effect of different degrees of fracture angulation upon biomechanics suggest that any fracture angle greater than 30 degrees impairs motor function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13382/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Therefore, we suggest that 30 degrees be used as the threshold for acceptable fracture angulation for both fourth and fifth metacarpal neck fractures.",
"   </p>",
"   <p>",
"    Remember that the normal metacarpal head-to-neck angle is 15 degrees. Thus, fracture angulation is equal to the measured angle on the lateral radiograph minus 15 degrees.",
"   </p>",
"   <p>",
"    Fractures angulated beyond acceptable levels are managed with closed reduction and immobilization or operative fixation to restore more normal alignment. Hand surgery referral should be obtained for such injuries if the primary care clinician is inexperienced in metacarpal fracture management. Referral is also necessary when adequate fracture reduction cannot be maintained.",
"   </p>",
"   <p>",
"    Hand surgery consultation should be obtained for individuals whose occupations or hobbies require a great deal of fine motor movement or gripping of the hand (eg, musicians, craftsman, seamstresses). In addition, some patients may prefer less angulation for cosmetic reasons. Hand surgery referral is prudent in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion describes the initial therapeutic approach in patients who do not require immediate fracture reduction or surgical referral as described in the previous section. Initial therapy typically consists of a splint, since swelling often prevents optimal casting. Splinting is used in the initial immobilization of, and sometimes is the definitive treatment for, metacarpal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13382/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. A detailed description of the techniques for applying splints is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"     \"Patient information: Cast and splint care (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ulnar gutter splint is used to immobilize fractures of the fourth and fifth metacarpal necks (",
"    <a class=\"graphic graphic_picture graphicRef65376 \" href=\"UTD.htm?28/12/28879\">",
"     picture 3",
"    </a>",
"    ). The appropriate position for initial immobilization is 70 to 90 degrees of flexion at the metacarpophalangeal (MCP) joint, slight flexion at the proximal interphalangeal (PIP) and distal interphalangeal (DIP) joints, and mild wrist extension. A similar splint applied to the radial side of the hand with an opening to accommodate the thumb is used for fractures of the second and third metacarpal necks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ice, elevation, and analgesia are indicated during the first 48 to 72 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Closed reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute reduction is indicated if there is pseudo-clawing as evidenced by hyperextension at the MCP joint and flexion at the PIP joint with attempted extension of the finger. Reduction is also needed for significantly angulated fourth or fifth metacarpal fractures. Acceptable degrees of angulation amenable to splinting without reduction are described in greater detail above. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Indications for surgical referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are several methods for reducing a metacarpal neck fracture; the following is our preferred approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, effective anesthesia is quickly obtained with a hematoma block. The placement of a hematoma block for metacarpal fractures is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20565?source=see_link&amp;anchor=H13#H13\">",
"     \"Metacarpal shaft fractures\", section on 'Anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;When adequate anesthesia is confirmed, fracture reduction is undertaken using the 90-90 method. Initially, flex the MCP, PIP, and DIP all to 90 degrees. Pressure is then directed axially through the flexed PIP joint creating a dorsal force on the distal fracture fragment. Simultaneously, a volar force is applied over the fracture site until it is felt that anatomic reduction is achieved. The fracture is then immobilized with a Burkhalter-type splint (",
"    <a class=\"graphic graphic_picture graphicRef77846 \" href=\"UTD.htm?7/0/7183\">",
"     picture 4",
"    </a>",
"    ) or an ulnar gutter splint (",
"    <a class=\"graphic graphic_picture graphicRef65376 \" href=\"UTD.htm?28/12/28879\">",
"     picture 3",
"    </a>",
"    ). Post-reduction radiographs are imperative to ensure adequate reduction and alignment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     General follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with significantly angulated second (&gt;10 degrees) or third (&gt;20 degrees) metacarpal neck fractures should be seen again within three to five days, while fourth and fifth metacarpal fractures should be seen within one week. Repeat films are indicated to look for evidence of worsened angulation, loss of reduction, or malrotation. Follow-up films should be obtained at two-week intervals from that point forward until healing is documented.",
"   </p>",
"   <p>",
"    The definitive treatment for metacarpal neck fractures differs from other fractures in that a splint (non-circumferential immobilization) can be used for the entire duration of immobilization. For other metacarpal fractures (eg, head, shaft, or base), a splint is used for the first few days to permit swelling to diminish. A short arm cast is then applied and used for the remaining period of immobilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=see_link\">",
"     \"Overview of metacarpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In minimally displaced fourth and fifth metacarpal neck fractures and nondisplaced second and third metacarpal neck fractures, simple immobilization for three to four weeks in a gutter or Burkhalter-type splint provides definitive treatment (",
"    <a class=\"graphic graphic_picture graphicRef77846 \" href=\"UTD.htm?7/0/7183\">",
"     picture 4",
"    </a>",
"    ). The splint should be worn continuously, and it is crucial to maintain at least 70 degrees of flexion at the MCP joints to avoid stiffening of the MCP collateral ligaments.",
"   </p>",
"   <p>",
"    The usual healing time for metacarpal neck fractures is four to six weeks, which does not appear to be shortened with surgical intervention. There should be evidence of radiographic healing, (ie, callus formation around the fracture site) by four weeks (",
"    <a class=\"graphic graphic_picture graphicRef73161 \" href=\"UTD.htm?36/29/37342\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Following immobilization, there is often stiffness at the MCP and PIP joints. This is typically alleviated within a few weeks by performing passive and active range of motion exercises with these joints. These can be performed at home. If the patient is unable to regain adequate range of motion after two to three weeks using a home program, formal referral to occupational therapy may be necessary.",
"   </p>",
"   <p>",
"    When fractures heal completely, approximately 50 percent of the initial deformity correction is typically maintained. Despite adequate reduction, residual cosmetic deformity may persist (loss of dorsal knuckle contour), but function is generally not impaired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fifth metacarpal neck fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, many fifth metacarpal neck fractures are managed with an off-the-shelf Galveston splint or a custom orthosis; the latter is typically molded from low-temperature thermoplastic. These devices allow the use of other fingers and movement at the fifth PIP and DIP joints, while maintaining fracture position. This is particularly helpful in students (due to frequent writing) and the elderly. Functional bracing of metacarpal neck fractures is often helpful for patients at high risk of developing joint stiffness (eg, the elderly).",
"   </p>",
"   <p>",
"    Many occupational therapists receive specific training in constructing and fitting custom orthoses to allow greater hand and finger mobility (and often comfort) than a plaster splint or cast, while maintaining fracture position.",
"   </p>",
"   <p>",
"    No approach to the management of fifth metacarpal neck fractures has been shown to be superior to rigid splint immobilization. The following alternatives have been evaluated in small randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gutter plaster immobilization was compared with a pressure bandage and immediate mobilization in 40 patients with non-rotated fifth metacarpal neck fractures angulated up to 70 degrees (mean 39 degrees) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13382/abstract/7\">",
"       7",
"      </a>",
"      ]. No significant differences were noted in outcome variables at six or 12 weeks.",
"     </li>",
"     <li>",
"      Functional taping allowing more hand and finger motion was compared with plaster immobilization in 50 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13382/abstract/8\">",
"       8",
"      </a>",
"      ]. Earlier functional recovery and greater mobility were noted in taped patients but long-term results were similar in the two groups.",
"     </li>",
"     <li>",
"      Molded bracing was compared with",
"      <span class=\"nowrap\">",
"       taping/strapping",
"      </span>",
"      in 73 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13382/abstract/9\">",
"       9",
"      </a>",
"      ]. Molded bracing was associated with less pain and an earlier return to work.",
"     </li>",
"     <li>",
"      Closed",
"      <span class=\"nowrap\">",
"       reduction/splinting",
"      </span>",
"      was compared with functional treatment in 29 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13382/abstract/10\">",
"       10",
"      </a>",
"      ]. Functional treatment was associated with a slightly earlier return of grip strength and mobility but comparable results at three months.",
"     </li>",
"     <li>",
"      No difference in fracture alignment, joint motion, or strength was noted in a study of 81 patients immobilized in one of two types of short arm casts (SAC) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13382/abstract/11\">",
"       11",
"      </a>",
"      ]. One SAC included a volar outrigger while the other was extended to include the PIP joint.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RETURN TO WORK OR SPORT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return to work should be expected when the patient's metacarpal joint is pain-free, non-tender, and has functional range of motion. Risk of reinjury remains high for four to six weeks after completion of immobilization. Thus, return to contact sports prior to this time requires orthotic protection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the fifth to sixth grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/6/5219?source=see_link\">",
"       \"Patient information: Boxer&rsquo;s fracture (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metacarpal (MC) neck fractures are common. They usually result from a direct blow to the hand or from striking an object with a clenched fist. fifth metacarpal (MC of little finger) neck fractures are most common. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Angulation occurs in an apex dorsal direction due to the pull of interosseous muscles.",
"     </li>",
"     <li>",
"      Second (MC of index finger) and third metacarpal (MC of middle finger) neck fractures cannot tolerate significant angulation due to their lack of motion at the CMC joint. Angulation &gt;10 degrees at the second metacarpal and &gt;20 degrees at the third metacarpal warrant reduction or referral. Angulation is determined using a lateral radiograph and must account for the normal metacarpal head-to-neck angle of 15 degrees. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Indications for surgical referral'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fourth and fifth metacarpal neck fractures tolerate greater angulation due to increased mobility at the CMC joint. Most of these fractures result in good functional results even with significant degrees of angulation. Our preferred method for reducing these fractures is described in the text. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Closed reduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudo-clawing (MCP joint hyperextension and PIP flexion with attempted extension of the finger) mandates reduction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Extensor apparatus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lacerations at the site of trauma (\"fight bites\") are common and predispose to infection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Skin integrity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional bracing with custom or off-the shelf orthoses are effective and commonly used in the management of metacarpal neck fractures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13141939\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Kevin E Burroughs, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/1\">",
"      Ashkenaze DM, Ruby LK. Metacarpal fractures and dislocations. Orthop Clin North Am 1992; 23:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/2\">",
"      Lamraski G, Monsaert A, De Maeseneer M, Haentjens P. Reliability and validity of plain radiographs to assess angulation of small finger metacarpal neck fractures: human cadaveric study. J Orthop Res 2006; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/3\">",
"      Birndorf MS, Daley R, Greenwald DP. Metacarpal fracture angulation decreases flexor mechanical efficiency in human hands. Plast Reconstr Surg 1997; 99:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/4\">",
"      Ali A, Hamman J, Mass DP. The biomechanical effects of angulated boxer's fractures. J Hand Surg Am 1999; 24:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/5\">",
"      Low CK, Wong HC, Low YP, Wong HP. A cadaver study of the effects of dorsal angulation and shortening of the metacarpal shaft on the extension and flexion force ratios of the index and little fingers. J Hand Surg Br 1995; 20:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/6\">",
"      Burkhalter WE. Closed treatment of hand fractures. J Hand Surg Am 1989; 14:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/7\">",
"      Statius Muller MG, Poolman RW, van Hoogstraten MJ, Steller EP. Immediate mobilization gives good results in boxer's fractures with volar angulation up to 70 degrees: a prospective randomized trial comparing immediate mobilization with cast immobilization. Arch Orthop Trauma Surg 2003; 123:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/8\">",
"      Braakman M, Oderwald EE, Haentjens MH. Functional taping of fractures of the 5th metacarpal results in a quicker recovery. Injury 1998; 29:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/9\">",
"      Harding IJ, Parry D, Barrington RL. The use of a moulded metacarpal brace versus neighbour strapping for fractures of the little finger metacarpal neck. J Hand Surg Br 2001; 26:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/10\">",
"      Kuokkanen HO, Mulari-Ker&auml;nen SK, Niskanen RO, et al. Treatment of subcapital fractures of the fifth metacarpal bone: a prospective randomised comparison between functional treatment and reposition and splinting. Scand J Plast Reconstr Surg Hand Surg 1999; 33:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13382/abstract/11\">",
"      Hofmeister EP, Kim J, Shin AY. Comparison of 2 methods of immobilization of fifth metacarpal neck fractures: a prospective randomized study. J Hand Surg Am 2008; 33:1362.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 187 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-9D3D6B0F7E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13382=[""].join("\n");
var outline_f13_4_13382=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fracture angulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rotational alignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Extensor apparatus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Skin integrity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Closed reduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      General follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fifth metacarpal neck fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RETURN TO WORK OR SPORT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13141939\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/187\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/187|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/56/21391\" title=\"diagnostic image 1A\">",
"      Metacarpal neck fx angulated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/44/27342\" title=\"diagnostic image 1B\">",
"      Metacarpal neck fx lateral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/54/11119\" title=\"diagnostic image 2\">",
"      Metacarpal neck fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/187|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/25/415\" title=\"figure 1\">",
"      MCP collateral ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/23/39295\" title=\"figure 2\">",
"      Pseudoclaw metacarpal fx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/187|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40528\" title=\"picture 1A\">",
"      Examination metacarpal malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/20/39232\" title=\"picture 1B\">",
"      Metacarpal fracture with malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/14/14575\" title=\"picture 2\">",
"      Examination metacarpal malrotation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/12/28879\" title=\"picture 3\">",
"      Ulnar gutter splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/0/7183\" title=\"picture 4\">",
"      Burkhalter splint for metacarpal fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/29/37342\" title=\"picture 5\">",
"      Metacarpal neck fx healing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/41/42645?source=related_link\">",
"      Finger and thumb anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20565?source=related_link\">",
"      Metacarpal shaft fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=related_link\">",
"      Overview of metacarpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/6/5219?source=related_link\">",
"      Patient information: Boxer&rsquo;s fracture (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=related_link\">",
"      Soft tissue infections due to human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_4_13383="Epi MPEC hemostasis NBVV";
var content_f13_4_13383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56986&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Combination therapy for a nonbleeding visible vessel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 563px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Upper endoscopy showing a deformed gastric antrum with three circumferential ulcers (arrowheads) near the pylorus (panels A-C). One of the ulcers contains a nonbleeding visible vessel (arrow), which was treated by a combination of epinephrine injection and multipolar electrocoagulation (panels D-E). Panel F shows the coagulated vessel after treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dennis M Jensen, MD, and Gustavo A Machicado, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13383=[""].join("\n");
var outline_f13_4_13383=null;
var title_f13_4_13384="Non-antiretroviral interventions to reduce perinatal HIV transmission in the developing world";
var content_f13_4_13384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Non-antiretroviral interventions to reduce perinatal HIV transmission in the developing world",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13384/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13384/contributors\">",
"     Lynne M Mofenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13384/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13384/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13384/contributors\">",
"     Mary E Paul, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13384/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13384/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/4/13384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of December 2010, approximately 3.4 million children were living with human immunodeficiency virus (HIV) infection globally; 250,000 children died secondary to HIV-associated disease during 2010 alone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/1\">",
"     1",
"    </a>",
"    ]. Most of these children live in the developing world, where an estimated 390,000 infants with HIV infection were born during 2010.",
"   </p>",
"   <p>",
"    The major mode of acquisition of HIV in children worldwide is through mother-to-child transmission. Prior to the development of effective specific interventions to reduce this risk, the estimated rates of perinatal transmission ranged from 15 to 25 percent in the United States and Europe and 25 to 40 percent in African populations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=see_link\">",
"     \"The global human immunodeficiency virus pandemic\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of interventions to prevent perinatal HIV transmission that do not involve antiretroviral drugs have been evaluated in the developing world. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Treatment/prophylaxis",
"      </span>",
"      of malaria and sexually transmitted diseases",
"     </li>",
"     <li>",
"      Nutritional supplementation",
"     </li>",
"     <li>",
"      Vaginal virucidal cleansing",
"     </li>",
"     <li>",
"      Prophylaxis of chorioamnionitis",
"     </li>",
"     <li>",
"      Passive",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      active immunoprophylaxis",
"     </li>",
"     <li>",
"      Prevention of breast milk transmission",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Non-antiretroviral interventions to prevent perinatal HIV transmission will be reviewed here.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    prophylaxis, the results of other clinical trials of antiretroviral prophylaxis of perinatal HIV transmission, and the care of the HIV-infected pregnant woman to prevent perinatal transmission are discussed separately. Risk factors for and prevention of HIV transmission through breastfeeding are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"     \"Prevention of HIV transmission during breastfeeding in resource-limited settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT/PROPHYLAXIS OF MALARIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection with malaria increases HIV RNA levels in plasma, placenta, and peripheral blood mononuclear cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Since elevated HIV RNA levels at delivery have been correlated with an increased risk of HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/6\">",
"     6",
"    </a>",
"    ], studies have been conducted to determine whether coinfection with malaria increases the risk of perinatal HIV transmission.",
"   </p>",
"   <p>",
"    The following conflicting findings have been described in different series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placental malaria was associated with increased risk of MTCT of HIV infection after adjustment for viral load in several studies [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/7-11\">",
"       7-11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, in a study in Kenya, although there was a higher prevalence of placental malaria in HIV-1-infected women, there was no association between placental malaria infection and in utero or intrapartum transmission of HIV-1 from mother to child [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/12\">",
"       12",
"      </a>",
"      ]. &nbsp;Similarly, in a study in Malawi, Tanzania and Zambia, placental malaria was not associated with infant HIV infection status at birth [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a separate study in Kenya, low density placental malaria was associated with a reduced risk of HIV transmission, while high density placental malaria (&gt;10,000",
"      <span class=\"nowrap\">",
"       parasites/mL)",
"      </span>",
"      was associated with a significant increase in perinatal HIV transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If malaria does increase the risk of HIV perinatal transmission, it may act via the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased HIV RNA levels [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Disruption of placental integrity [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increases in Th-1-type cytokine secretion by the placenta, which may favor HIV replication [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Enhanced expression of CC chemokine receptor 5 on placental macrophages, thereby increasing the number of target cells for HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malaria infection is associated with preterm delivery and low birth weight, both of which are risk factors for HIV transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study of malaria prevention in Mozambique, the use of two-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/37/34389?source=see_link\">",
"     sulfadoxine-pyrimethamine",
"    </a>",
"    prophylaxis against malaria was not associated with maternal HIV viral load nor the risk of mother-to-child transmission of HIV among 207 HIV-infected women who received single-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    during labor [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/10\">",
"     10",
"    </a>",
"    ].Of note, this study was conducted prior to the availability of current antiretroviral regimens for prevention of mother-to-child HIV transmission in developing countries; no studies have evaluated the association between placental malaria and HIV transmission in the context of maternal combination antiretroviral treatment during pregnancy. Given the availability of effective antiretroviral prophylaxis to reduce transmission in these settings, it is likely that the impact of placental malaria on the risk of mother-to-child transmission may be limited, particularly in women with undetectable viral load. However, this question will need to be addressed through careful cohort studies. The complex interactions between HIV and malaria infection on pregnancy outcomes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=see_link\">",
"     \"Overview of malaria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT/PROPHYLAXIS OF SEXUALLY TRANSMITTED DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested that sexually transmitted diseases (eg, gonorrhea, herpes simplex virus) may facilitate both heterosexual and perinatal HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As a result, it has been hypothesized that treatment of sexually transmitted infections might provide an effective intervention to decrease both sexual and perinatal HIV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized, controlled, community-based trial of mass sexually transmitted disease treatment was conducted in Rakai, Uganda to address this hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/19\">",
"     19",
"    </a>",
"    ]. All adults, including pregnant women, in communities randomized to the treatment regimen received single doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    (in pregnant women),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , and benzathine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    , to provide protection against gonorrhea, chlamydia, chancroid, syphilis, and trichomoniasis and short-term control of bacterial vaginosis.",
"   </p>",
"   <p>",
"    Antibiotic therapy was associated with substantial reductions in overall maternal and infant morbidity and in the rate of sexually transmitted diseases compared to control populations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/21\">",
"     21",
"    </a>",
"    ]. However, there were no decreases documented for sexually or perinatally-transmitted HIV infection. For example, the cumulative overall population-based incidence of HIV was 1.5 per 100 patient years in both study arms. An accompanying editorial raised the question of whether the absence of effect resulted from the relatively high rate of HIV infection in the population at the time of study initiation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     NUTRITIONAL SUPPLEMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of nutritional supplementation has been evaluated for vitamin A, micronutrients, and multivitamins. Studies evaluating the relationship between maternal vitamin A concentrations and the risk of perinatal HIV transmission have produced conflicting results. Some studies have shown that low serum retinol concentrations are associated with an increased risk of perinatal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], while other reports have shown no such relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized, placebo-controlled perinatal trials have been conducted to determine whether administration of vitamin A",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other micronutrients to HIV-infected pregnant women would lower perinatal HIV transmission. Vitamin A supplementation did not reduce in utero, intrapartum, or early breast milk transmission of HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/27-31\">",
"     27-31",
"    </a>",
"    ] nor did it affect maternal morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/32\">",
"     32",
"    </a>",
"    ]. In one trial, vitamin A supplementation started at approximately 20 weeks' gestation and continued throughout lactation actually increased HIV transmission during lactation (relative risk 1.38), while multivitamins had no overall effect but significantly reduced breastfeeding transmission among mothers with low baseline CD4 counts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/29\">",
"     29",
"    </a>",
"    ]. However, this increase in postnatal transmission with vitamin A supplementation has not been observed in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/27,30\">",
"     27,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although vitamin supplementation may not reduce HIV transmission, provision of supplementation to all pregnant women in developing countries, regardless of HIV status, could have an overall benefit to maternal, fetal, and childhood health in these countries, where vitamin deficiencies are common [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect on fetal health and maternal lymphocyte counts was addressed in a randomized controlled trial of 1075 pregnant women who, at 12 to 27 weeks of gestation, were assigned to placebo, vitamin A alone, multivitamins excluding vitamin A, or multivitamins including vitamin A; one-third were vitamin A deficient at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/33\">",
"     33",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multivitamin supplementation, but not vitamin A supplementation alone, was associated with significant improvement in non-HIV related pregnancy outcomes including fetal death (5.9 versus 9.6 percent in the multivitamin versus placebo groups, respectively), low birthweight (8.8 versus 15.8 percent), severe preterm birth at &lt;34 weeks (6.2 versus 10.2 percent), and small for gestational age infants (10 versus 17.6 percent)",
"     </li>",
"     <li>",
"      Multivitamin use, but not vitamin A, resulted in significant elevations in maternal CD4, CD8, and CD3 counts during pregnancy and immediately postpartum [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/33\">",
"       33",
"      </a>",
"      ]. Additionally, multivitamin supplementation modestly decreased long term risk of HIV disease progression in the mothers [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, in the United States and other industrialized countries, where prenatal vitamin supplementation is routinely provided and vitamin deficiency is uncommon, additional supplementation is not recommended and could be harmful. As an example, large doses of vitamin A (&gt;10,000",
"    <span class=\"nowrap\">",
"     IU/day)",
"    </span>",
"    in pregnancy can be teratogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     VAGINAL VIRUCIDAL CLEANSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a microbicide (0.25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ) to cleanse the birth canal before vaginal delivery reduces the risk of neonatal group B streptococcal sepsis and appears to be safe for the mother and infant [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A perinatal clinical trial in Malawi evaluated vaginal swabbing with 0.25 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    every four hours during labor combined with infant cleansing immediately after birth. The treatment was well-tolerated, but no overall reduction in HIV transmission was observed (27 versus 28 percent transmission in the treatment and control arms, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/40\">",
"     40",
"    </a>",
"    ]. However, in the subgroup of women with membranes ruptured more than four hours prior to delivery, transmission was significantly lower in the chlorhexidine group (25 versus 39 percent in the chlorhexidine versus control groups, p = 0.02).",
"   </p>",
"   <p>",
"    In a study of vaginal lavage with 0.2 (increased to 0.4 percent later in the study)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    during labor in Kenya, there was no evidence of a difference in intrapartum HIV transmission between lavage and non-lavage groups (15.9 versus 17.2 percent, respectively), similar to the data on overall transmission rates in the Malawi study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of vaginal disinfection with 1 percent benzalkonium chloride vaginal suppositories was conducted in West Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/42\">",
"     42",
"    </a>",
"    ]. Women self-administered a daily vaginal suppository or placebo from week 36 of pregnancy and a single intrapartum dose, and the neonatal was bathed in 1 percent benzalkonium chloride solution; no difference in perinatal transmission was observed between treatment and placebo groups (21.2 versus 21.6 percent, respectively).",
"   </p>",
"   <p>",
"    In the Malawi study, non-HIV-related maternal and infant outcomes were significantly improved in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    group. In the neonates, hospital admissions due to sepsis were reduced by 57 percent and mortality from sepsis by 67 percent; in the mothers, hospitalizations due to sepsis were reduced by 63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/43\">",
"     43",
"    </a>",
"    ]. The duration of hospitalization was also decreased in the treatment group.",
"   </p>",
"   <p>",
"    While use of vaginal virucides does not appear to reduce perinatal HIV transmission, vaginal virucidal cleansing, like vitamin supplementation, is inexpensive, easily administered, does not require HIV testing for implementation, and is of potential overall benefit to infected and uninfected women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS OF CHORIOAMNIONITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histologic chorioamnionitis appears to be associated with perinatal HIV transmission in some, although not all, studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/44-48\">",
"     44-48",
"    </a>",
"    ]. Chorioamnionitis is associated with significant inflammation and activation of immune cells in the placenta, which could lead to breaks in the placental barrier, allowing passage of virus or infected lymphocytes from the mother to the fetus. However, data from a controlled clinical trial in Malawi and Zambia in which empiric therapy for chorioamnionitis with a short course of antibiotics was given to infected pregnant at 20 to 24 weeks gestation and again during delivery found that such therapy did not reduce perinatal HIV transmission or infant morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HIV HYPERIMMUNE GLOBULIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of antiretroviral prophylaxis to prevent MTCT has disadvantages, including the potential development of resistance and inherent toxicities. As a result, other medical approaches have been evaluated, including passive immunization with HIV hyperimmune globulin (HIVIG) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/50\">",
"     50",
"    </a>",
"    ]. Such an approach begun at birth has been successful for the prevention of perinatal hepatitis B transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, transmission, and prevention of hepatitis B virus infection\", section on 'Perinatal transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A clinical trial, PACTG 185, examined whether HIVIG combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    prophylaxis would prevent in utero and intrapartum transmission in HIV-infected women who did not breastfeed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. While there was an indication that HIVIG may have had an effect in reducing intrapartum transmission in women with CD4 counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    in the treatment and control groups there was no measurable difference in transmission (4 percent with HIVIG versus 6 percent with standard immune globulin without HIV antibody).",
"   </p>",
"   <p>",
"    A separate trial evaluated the addition of HIVIG (given in the late trimester and to the infant) to single-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    prophylaxis (given intrapartum and to the infant) among 492 pregnant women in Uganda [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/53\">",
"     53",
"    </a>",
"    ]. HIVIG appeared safe among both mothers and infants; however, there was no difference in rates of HIV infection in the infants at six months compared with nevirapine prophylaxis alone.",
"   </p>",
"   <p>",
"    Additional studies will evaluate the safety and pharmacokinetics of monoclonal anti-HIV antibodies in pregnant women and newborns. Ideally, a product targeted against specific conserved HIV epitopes with cross-clade neutralization capacity would be desired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10154463\">",
"    <span class=\"h1\">",
"     HIV VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and immunogenicity of HIV vaccine candidates are also being evaluated in newborns of HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Several studies of a recombinant canarypox HIV vaccine (ALVAC) in infants born to HIV-infected mothers have revealed no safety concerns and demonstrated induction of HIV-specific immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13384/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Once a promising candidate vaccine is identified, a phase III trial that would potentially combine anti-HIV monoclonal antibodies with HIV vaccine in neonates to prevent breastmilk transmission is planned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION OF BREAST MILK TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research on breast milk transmission is particularly critical since there are now effective short-course antiretroviral prophylaxis regimens that can decrease in utero and intrapartum HIV transmission.",
"   </p>",
"   <p>",
"    In many resource-limited settings, replacement infant feeding is not safe, affordable, sustainable or culturally acceptable, and breastfeeding is the norm even among HIV-infected women. Issues related to breastfeeding transmission and prevention of such transmission are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=see_link\">",
"     \"Prevention of HIV transmission during breastfeeding in resource-limited settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=see_link\">",
"       \"Patient information: HIV and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10154410\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antiretroviral prophylaxis is the cornerstone of preventing mother-to-child transmission of HIV. A number of non-antiretroviral interventions to prevent perinatal HIV transmission have been evaluated in the developing world, but none has been shown to effectively reduce transmission. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Coinfection with malaria is associated with increased HIV levels in maternal plasma and the placenta, but studies are conflicting on whether it increases the risk of transmission to the infant. No randomized trials have evaluated malaria prophylaxis as a strategy to prevent perinatal transmission. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment/prophylaxis of malaria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Interventions that do not appear to decrease perinatal HIV transmission but offer other benefits to maternal and infant health include treatment of maternal sexually transmitted diseases (eg, gonorrhea, chlamydia, syphilis), multivitamin supplementation, and vaginal virucidal cleansing. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment/prophylaxis of sexually transmitted diseases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Nutritional supplementation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Vaginal virucidal cleansing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Passive immunization with HIV hyperimmune globulin is safe, but studies to date have not demonstrated efficacy. HIV vaccination appears safe and immunogenic in infants, but there have been no efficacy trials. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'HIV hyperimmune globulin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10154463\">",
"       'HIV vaccines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization/UNAIDS. Global HIV/AIDS response: epidemic update and health sector progress toward Universal Access, progress report 2011. UNAIDS, Geneva, Switzerland, 2011. file://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf (Accessed on July 19, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/2\">",
"      Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/3\">",
"      Mwapasa V, Rogerson SJ, Molyneux ME, et al. The effect of Plasmodium falciparum malaria on peripheral and placental HIV-1 RNA concentrations in pregnant Malawian women. AIDS 2004; 18:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/4\">",
"      Slutsker L, Marston BJ. HIV and malaria: interactions and implications. Curr Opin Infect Dis 2007; 20:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/5\">",
"      ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 2004; 71:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/6\">",
"      Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 2002; 29:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/7\">",
"      Brahmbhatt H, Kigozi G, Wabwire-Mangen F, et al. The effects of placental malaria on mother-to-child HIV transmission in Rakai, Uganda. AIDS 2003; 17:2539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/8\">",
"      Brahmbhatt H, Sullivan D, Kigozi G, et al. Association of HIV and malaria with mother-to-child transmission, birth outcomes, and child mortality. J Acquir Immune Defic Syndr 2008; 47:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/9\">",
"      Bulterys PL, Chao A, Dalai SC, et al. Placental malaria and mother-to-child transmission of human immunodeficiency virus-1 in rural Rwanda. Am J Trop Med Hyg 2011; 85:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/10\">",
"      Naniche D, Lahuerta M, Bardaji A, et al. Mother-to-child transmission of HIV-1: association with malaria prevention, anaemia and placental malaria. HIV Med 2008; 9:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/11\">",
"      Msamanga GI, Taha TE, Young AM, et al. Placental malaria and mother-to-child transmission of human immunodeficiency virus-1. Am J Trop Med Hyg 2009; 80:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/12\">",
"      Inion I, Mwanyumba F, Gaillard P, et al. Placental malaria and perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 188:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/13\">",
"      Ayisi JG, van Eijk AM, Newman RD, et al. Maternal malaria and perinatal HIV transmission, western Kenya. Emerg Infect Dis 2004; 10:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/14\">",
"      Fievet N, Moussa M, Tami G, et al. Plasmodium falciparum induces a Th1/Th2 disequilibrium, favoring the Th1-type pathway, in the human placenta. J Infect Dis 2001; 183:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/15\">",
"      Tkachuk AN, Moormann AM, Poore JA, et al. Malaria enhances expression of CC chemokine receptor 5 on placental macrophages. J Infect Dis 2001; 183:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/16\">",
"      Menendez C, Ordi J, Ismail MR, et al. The impact of placental malaria on gestational age and birth weight. J Infect Dis 2000; 181:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/17\">",
"      Ayisi JG, van Eijk AM, ter Kuile FO, et al. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. AIDS 2003; 17:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/18\">",
"      Cowan FM, Humphrey JH, Ntozini R, et al. Maternal Herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. AIDS 2008; 22:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/19\">",
"      Wawer MJ, Gray RH, Sewankambo NK, et al. A randomized, community trial of intensive sexually transmitted disease control for AIDS prevention, Rakai, Uganda. AIDS 1998; 12:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/20\">",
"      Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 1998; 351 Suppl 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/21\">",
"      Wawer MJ, Sewankambo NK, Serwadda D, et al. Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 1999; 353:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/22\">",
"      Hitchcock P, Fransen L. Preventing HIV infection: lessons from Mwanza and Rakai. Lancet 1999; 353:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/23\">",
"      Semba RD, Miotti PG, Chiphangwi JD, et al. Maternal vitamin A deficiency and mother-to-child transmission of HIV-1. Lancet 1994; 343:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/24\">",
"      Greenberg BL, Semba RD, Vink PE, et al. Vitamin A deficiency and maternal-infant transmissions of HIV in two metropolitan areas in the United States. AIDS 1997; 11:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/25\">",
"      Castetbon K, Manigart O, Bonard D, et al. Maternal vitamin A status and mother-to-child transmission of HIV in West Africa. DITRAME Study Group. AIDS 2000; 14:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/26\">",
"      Burger H, Kovacs A, Weiser B, et al. Maternal serum vitamin A levels are not associated with mother-to-child transmission of HIV-1 in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/27\">",
"      Coutsoudis A, Pillay K, Spooner E, et al. Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. South African Vitamin A Study Group. AIDS 1999; 13:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/28\">",
"      Fawzi WW, Msamanga G, Hunter D, et al. Randomized trial of vitamin supplements in relation to vertical transmission of HIV-1 in Tanzania. J Acquir Immune Defic Syndr 2000; 23:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/29\">",
"      Fawzi WW, Msamanga GI, Hunter D, et al. Randomized trial of vitamin supplements in relation to transmission of HIV-1 through breastfeeding and early child mortality. AIDS 2002; 16:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/30\">",
"      Iliff PJ, Piwoz EG, Tavengwa NV, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS 2005; 19:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/31\">",
"      Kumwenda N, Miotti PG, Taha TE, et al. Antenatal vitamin A supplementation increases birth weight and decreases anemia among infants born to human immunodeficiency virus-infected women in Malawi. Clin Infect Dis 2002; 35:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/32\">",
"      Kennedy CM, Coutsoudis A, Kuhn L, et al. Randomized controlled trial assessing the effect of vitamin A supplementation on maternal morbidity during pregnancy and postpartum among HIV-infected women. J Acquir Immune Defic Syndr 2000; 24:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/33\">",
"      Fawzi WW, Msamanga GI, Spiegelman D, et al. Randomised trial of effects of vitamin supplements on pregnancy outcomes and T cell counts in HIV-1-infected women in Tanzania. Lancet 1998; 351:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/34\">",
"      Villamor E, Saathoff E, Bosch RJ, et al. Vitamin supplementation of HIV-infected women improves postnatal child growth. Am J Clin Nutr 2005; 81:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/35\">",
"      Fawzi WW, Msamanga GI, Wei R, et al. Effect of providing vitamin supplements to human immunodeficiency virus-infected, lactating mothers on the child's morbidity and CD4+ cell counts. Clin Infect Dis 2003; 36:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/36\">",
"      Siegfried N, Irlam JH, Visser ME, Rollins NN. Micronutrient supplementation in pregnant women with HIV infection. Cochrane Database Syst Rev 2012; 3:CD009755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/37\">",
"      Fawzi WW, Msamanga GI, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/38\">",
"      Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995; 333:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/39\">",
"      Rouse DJ, Hauth JC, Andrews WW, et al. Chlorhexidine vaginal irrigation for the prevention of peripartal infection: a placebo-controlled randomized clinical trial. Am J Obstet Gynecol 1997; 176:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/40\">",
"      Biggar RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996; 347:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/41\">",
"      Gaillard P, Mwanyumba F, Verhofstede C, et al. Vaginal lavage with chlorhexidine during labour to reduce mother-to-child HIV transmission: clinical trial in Mombasa, Kenya. AIDS 2001; 15:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/42\">",
"      Dabis F, Msellati P, Meda N, et al. Vaginal disinfection with benzalkonium chloride and vertical transmission of HIV-1 in West Africa: DIATRAME ANRS 049b trial. AIDS 2001; 15(Supplement 1):S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/43\">",
"      Taha TE, Biggar RJ, Broadhead RL, et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. BMJ 1997; 315:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/44\">",
"      St Louis ME, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. JAMA 1993; 269:2853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/45\">",
"      Temmerman M, Nyong'o AO, Bwayo J, et al. Risk factors for mother-to-child transmission of human immunodeficiency virus-1 infection. Am J Obstet Gynecol 1995; 172:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/46\">",
"      Ladner J, Leroy V, Hoffman P, et al. Chorioamnionitis and pregnancy outcome in HIV-infected African women. Pregnancy and HIV Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/47\">",
"      Nair P, Alger L, Hines S, et al. Maternal and neonatal characteristics associated with HIV infection in infants of seropositive women. J Acquir Immune Defic Syndr 1993; 6:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/48\">",
"      Schwartz DA, Sungkarat S, Shaffer N, et al. Placental abnormalities associated with human immunodeficiency virus type 1 infection and perinatal transmission in Bangkok, Thailand. J Infect Dis 2000; 182:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/49\">",
"      Taha TE, Brown ER, Hoffman IF, et al. A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS 2006; 20:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/50\">",
"      Safrit JT, Ruprecht R, Ferrantelli F, et al. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2004; 35:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/51\">",
"      Lambert JS, Mofenson LM, Fletcher CV, et al. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group. J Infect Dis 1997; 175:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/52\">",
"      Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185. J Infect Dis 1999; 179:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/53\">",
"      Onyango-Makumbi C, Omer SB, Mubiru M, et al. Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 2011; 58:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/54\">",
"      Borkowsky W, Wara D, Fenton T, et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. J Infect Dis 2000; 181:890.",
"     </a>",
"    </li>",
"    <li>",
"     McFarland E, Johnson D, Muresan P, et al. Safety and Cell-mediated Immune Responses to a Prime Boost Immunization with ALVAC HIV Vaccine and AIDSVAX B/B in Newborns of HIV-infected Mothers. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2005 (abstract 48).",
"    </li>",
"    <li>",
"     Tomaras G, McFarland E, Johnson D, et al. Anti-HIV Antibodies Elicited by the Prime Boost Vaccination, vCP1452+AIDSVAX B/B, in Newborns of HIV-infected Mothers. 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2005 (abstract 779).",
"    </li>",
"    <li>",
"     Jones N, Sebikari D, Ssewanyana I, et al, and HPTN027 Protocol Team. Safety and Immunogenicity of ALVAC-HIV vCP1521 in Infants Born to HIV-1-infected Women in Uganda (HPTN 027). 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 2008 (abstract 501).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/58\">",
"      McFarland EJ, Johnson DC, Muresan P, et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 2006; 20:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13384/abstract/59\">",
"      Johnson DC, McFarland EJ, Muresan P, et al. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. J Infect Dis 2005; 192:2129.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3767 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-F3B3B15694-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13384=[""].join("\n");
var outline_f13_4_13384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10154410\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT/PROPHYLAXIS OF MALARIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT/PROPHYLAXIS OF SEXUALLY TRANSMITTED DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NUTRITIONAL SUPPLEMENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VAGINAL VIRUCIDAL CLEANSING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PROPHYLAXIS OF CHORIOAMNIONITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HIV HYPERIMMUNE GLOBULIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10154463\">",
"      HIV VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION OF BREAST MILK TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10154410\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/33/16921?source=related_link\">",
"      Overview of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/29/7635?source=related_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/23/29050?source=related_link\">",
"      Prevention of HIV transmission during breastfeeding in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/2/21546?source=related_link\">",
"      The global human immunodeficiency virus pandemic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_4_13385="Erythroderma";
var content_f13_4_13385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Erythroderma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13385/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13385/contributors\">",
"     Mark DP Davis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13385/contributors\">",
"     Erik Stratman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13385/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/4/13385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12240271\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythroderma (literally, &ldquo;red skin&rdquo;), also sometimes called exfoliative dermatitis, is a severe and potentially life-threatening condition that presents with diffuse erythema and scaling involving all or most of the skin surface area (&ge;90 percent, in the most common definition). Erythroderma is the clinical presentation of a wide range of cutaneous and systemic diseases (including psoriasis and atopic dermatitis), drug hypersensitivity reactions, and more rarely S&eacute;zary syndrome, a leukemic subtype of cutaneous T cell lymphoma.",
"   </p>",
"   <p>",
"    This topic will discuss the clinical manifestations, diagnosis, and treatment of erythroderma. S&eacute;zary syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link\">",
"     \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12240278\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythroderma is a rare condition. The annual incidence has been estimated to be approximately 1 per 100,000 in the adult population [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/1\">",
"     1",
"    </a>",
"    ]. In a retrospective study, erythroderma accounted for 13 in 100,000 patients presenting with skin diseases in China [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/2\">",
"     2",
"    </a>",
"    ]. Erythroderma can occur at any age and in both sexes, but is more frequent in older adults (mean age 42 to 61 years) and in males [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Erythroderma is exceedingly rare in children; its prevalence is estimated to be approximately 0.1 percent in pediatric dermatology clinic populations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12240285\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5244727\">",
"    <span class=\"h2\">",
"     Cutaneous and systemic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide range of cutaneous or systemic diseases can evolve to or cause erythroderma (",
"    <a class=\"graphic graphic_table graphicRef87714 \" href=\"UTD.htm?30/28/31180\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Exacerbation of a preexisting inflammatory dermatosis",
"      </strong>",
"      &ndash; The most common cause of erythroderma is the exacerbation of a preexisting inflammatory dermatosis, most often psoriasis or atopic dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/3-6\">",
"       3-6",
"      </a>",
"      ]. In patients with psoriasis, triggers of erythroderma include the abrupt discontinuation of systemic corticosteroids or other immunosuppressant therapy, systemic illnesses, phototherapy burns, medications (eg, lithium, antimalarials), or HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Hypersensitivity drug reaction",
"      </strong>",
"      &ndash; A hypersensitivity drug reaction is the second most frequent cause of erythroderma (approximately 20 percent of cases). A wide variety of drugs have been reported to be associated with erythroderma, including penicillins, sulfonamides, carbamazepine, phenytoin, and allopurinol (",
"      <a class=\"graphic graphic_table graphicRef88412 \" href=\"UTD.htm?40/24/41355\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/4,10\">",
"       4,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Uncommon causes",
"      </strong>",
"      &ndash; Uncommon causes of erythroderma include cutaneous T cell lymphoma and other hematologic and systemic malignancies, immunobullous diseases, connective tissue diseases, and infections (",
"      <a class=\"graphic graphic_table graphicRef87714 \" href=\"UTD.htm?30/28/31180\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3350288\">",
"    <span class=\"h2\">",
"     Erythroderma of unknown origin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 30 percent of cases of erythroderma, no underlying cause is identified and erythroderma is classified as idiopathic (sometimes called &ldquo;red man syndrome&rdquo;, which is also used to describe an infusion reaction to vancomycin) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12240306\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of erythroderma is incompletely understood. A complex interaction of cytokines (eg, interleukin-1, -2 and -8 and tumor necrosis factor), chemokines, and intercellular adhesion molecules is believed to play a role in the massive recruitment of inflammatory cells to the skin and elevated epidermal turnover. The increased mitotic rate and decreased transit time of epidermal cells through the skin layers results in exfoliation, with significant loss of proteins, amino acids, and nucleic acids through the skin.",
"   </p>",
"   <p>",
"    Increased circulating levels of adhesion molecules (intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin) have been demonstrated in patients with erythroderma secondary to psoriasis or eczema and in patients with S&eacute;zary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunohistochemical studies demonstrate a predominantly Th1 cytokine profile in the dermal infiltrates of patients with erythroderma associated with inflammatory dermatoses and a Th2 profile in the dermal infiltrates of patients with S&eacute;zary syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/15\">",
"     15",
"    </a>",
"    ]. These findings suggest that different pathophysiologic mechanisms may lead to the relatively uniform clinical presentation of erythroderma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12240313\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8845926\">",
"    <span class=\"h2\">",
"     Onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythroderma may develop acutely over hours or days or evolve gradually over weeks to months. The onset is usually abrupt in drug hypersensitivity reactions. A morbilliform or urticarial eruption may first appear anywhere on the skin, then erythematous patches increase in size and coalesce into a generalized bright red erythema with occasional islands of sparing (",
"    <a class=\"graphic graphic_picture graphicRef87792 graphicRef72342 \" href=\"UTD.htm?8/30/8681\">",
"     picture 1A-B",
"    </a>",
"    ). Organ involvement (eg, hepatitis, nephritis, pneumonia) may occur in DRESS (drug reaction with eosinophilia and systemic symptoms). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24360?source=see_link\">",
"     \"Exanthematous (morbilliform) drug eruption\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link\">",
"     \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erythroderma from underlying cutaneous or systemic diseases usually develops more gradually. Erythematous patches may occur anywhere on the skin, enlarge and coalesce over hours to days to weeks to involve nearly the entire skin surface. Initially, the erythematous patches may have the characteristics of the underlying disease, but the specific features of the underlying diseases are often lost after erythroderma has fully developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2942806\">",
"    <span class=\"h2\">",
"     Cutaneous symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 90 percent of the skin is red and warm to the touch (",
"    <a class=\"graphic graphic_picture graphicRef72342 \" href=\"UTD.htm?11/30/11745\">",
"     picture 1B",
"    </a>",
"    ). Most patients complain of severe skin pain or itching. In light-skinned patients, the color of the skin varies from bright pink (characteristic of a drug reaction) to a dusky red (characteristic of chronic erythroderma from many causes). In patients with darker skin tones, these features may be more subtle or missing.",
"   </p>",
"   <p>",
"    Linear crusted erosions and secondary lichenification may result from rubbing and scratching. On palpation, the skin may feel leathery and indurated. Scaling is a common feature, particularly in erythroderma that has been present for more than a week. Scales can be large, small, or bran-like, and are particularly abundant in patients with underlying psoriasis.",
"   </p>",
"   <p>",
"    Palmoplantar keratoderma (hyperkeratosis of the palms and soles) is most often associated with pityriasis rubra pilaris (",
"    <a class=\"graphic graphic_picture graphicRef87793 \" href=\"UTD.htm?42/22/43366\">",
"     picture 2A",
"    </a>",
"    ), but also may occur in patients with S&eacute;zary syndrome (",
"    <a class=\"graphic graphic_picture graphicRef83371 \" href=\"UTD.htm?11/32/11783\">",
"     picture 3",
"    </a>",
"    ). Nail pitting is characteristic of psoriasis (",
"    <a class=\"graphic graphic_picture graphicRef70962 \" href=\"UTD.htm?15/7/15474\">",
"     picture 4",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p>",
"    Moist, crusted lesions on the face and upper trunk often precede the development of erythroderma in patients with pemphigus foliaceous (",
"    <a class=\"graphic graphic_picture graphicRef87796 graphicRef87795 \" href=\"UTD.htm?38/27/39354\">",
"     picture 5A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link&amp;anchor=H181679733#H181679733\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\", section on 'Pemphigus foliaceus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hair and nail changes (eg, telogen effluvium, scaling of the scalp, paronychia, nail dystrophy, and onychomadesis [nail shedding]) may be present. Involvement of the eyelids manifests with blepharitis, epiphora (excessive tearing), and ectropion (eyelid eversion). These features may be particularly prominent in patients with chronic erythroderma secondary to S&eacute;zary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link&amp;anchor=H449462700#H449462700\">",
"     \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\", section on 'Skin lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2942857\">",
"    <span class=\"h2\">",
"     Extracutaneous findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with erythroderma often appear uncomfortable, shiver, and complain of feeling cold. Constitutional symptoms (eg, malaise, fatigue, fever, or hypothermia) and signs of high output cardiac failure (eg, peripheral edema, tachycardia) also may be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=see_link&amp;anchor=H2#H2\">",
"     \"High-output heart failure\", section on 'Physical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphadenopathy and hepatomegaly or splenomegaly may be observed in chronic erythroderma. Lymph node biopsy often shows only the features of dermatopathic lymphadenopathy (a benign reactive lymph node enlargement), but may be diagnostic of lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Lymph node and tissue biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5244680\">",
"    <span class=\"h1\">",
"     LABORATORY ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonspecific laboratory abnormalities may occur in patients with erythroderma due to various causes, including leukocytosis, anemia, and elevated erythrocyte sedimentation rate. Eosinophilia may be found in patients with DRESS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link&amp;anchor=H872951#H872951\">",
"     \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\", section on 'Laboratory abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atypical lymphocytes with cerebriform nuclei (S&eacute;zary cells) are often observed in erythroderma regardless of cause. Counts of S&eacute;zary cells greater than 20 percent of the circulating peripheral blood lymphocytes are found in S&eacute;zary syndrome, a leukemic variant of cutaneous T-cell lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link&amp;anchor=H63648001#H63648001\">",
"     \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\", section on 'Peripheral blood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8113942\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythroderma is relatively well-tolerated by many patients. However, patients at the extremes of age and patients with comorbidities may experience complications. (See",
"    <a class=\"local\" href=\"#H56307720\">",
"     'Hemodynamic and metabolic disturbances'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H56307727\">",
"     'Infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5244713\">",
"    <span class=\"h2\">",
"     Evolution of skin findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the cause, the erythema may become generalized in hours to days, weeks, or months. Exfoliation typically begins two to six days after the onset of erythema, starts in flexural areas, and rapidly extends to the entire body surface. Scaling is particularly pronounced in patients with underlying psoriasis. Over weeks to months, hair and nail changes may occur. (See",
"    <a class=\"local\" href=\"#H2942806\">",
"     'Cutaneous symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The duration of erythroderma is highly variable. Erythroderma due to drug reactions usually resolves in two to six weeks after stopping the culprit drug. In patients with drug reaction with eosinophilia and systemic symptoms (DRESS), resolution of erythroderma may require many weeks to months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link&amp;anchor=H27761113#H27761113\">",
"     \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\", section on 'Clinical course'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erythroderma due to underlying cutaneous or systemic diseases may persist for weeks, months, or years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56307720\">",
"    <span class=\"h2\">",
"     Hemodynamic and metabolic disturbances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Profound disturbances in fluid and electrolyte regulation, thermoregulation, and metabolic balance occur with erythroderma. Increased skin perfusion leads to fluid loss by transpiration, and consequent electrolyte imbalance. Heat loss, hypothermia, and compensatory hypermetabolism associated with hyperthermia may occur. The shunting of the blood through the skin due to peripheral vasodilation may result in high-output cardiac failure, especially in older or compromised patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=see_link&amp;anchor=H15#H15\">",
"     \"High-output heart failure\", section on 'Dermatologic disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Exfoliation of the skin results in significant protein loss that may exceed 9",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    body surface per day, particularly in patients with erythrodermic psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/16\">",
"     16",
"    </a>",
"    ]. The protein loss causes negative nitrogen balance, hypoalbuminemia, edema, and muscle wasting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56307727\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation, fissuring, and excoriation increase the susceptibility of the erythrodermic skin to bacterial colonization. Sepsis from",
"    <em>",
"     S. aureus",
"    </em>",
"    , including methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    , has been reported in erythrodermic patients and is of particular concern in those who are HIV positive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Widespread superinfection with herpes simplex virus (Kaposi varicelliform eruption) also has been reported in erythrodermic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H31627071#H31627071\">",
"     \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Eczema herpeticum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12240350\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of erythroderma is straightforward; it is made clinically in a patient presenting with diffuse and generalized erythema and scaling involving 90 percent or more of the body surface area (",
"    <a class=\"graphic graphic_picture graphicRef87792 graphicRef72342 \" href=\"UTD.htm?8/30/8681\">",
"     picture 1A-B",
"    </a>",
"    ). Determining the cause of erythroderma is more difficult and requires meticulous clinical assessment and clinicopathologic correlation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5244967\">",
"    <span class=\"h1\">",
"     DETERMINATION OF UNDERLYING CAUSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying cause of erythroderma is often difficult to determine and may remain elusive. In approximately one third of patients, the cause cannot be determined and erythroderma is classified as idiopathic. However, ongoing evaluation of patients with idiopathic erythroderma is important, since the underlying cause may become apparent over time [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Late-onset atopic eczema, intake of drugs overlooked by the patient, and pre-lymphomatous eruptions have been reported in older patients with a protracted diagnosis of &ldquo;idiopathic&rdquo; erythroderma. &nbsp;",
"   </p>",
"   <p>",
"    The evaluation of the erythrodermic patient to determine the underlying cause involves a detailed history, physical examination, skin biopsies, and laboratory tests. Specific tests are performed based upon the suspected cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85504020\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed history is of key importance in establishing the cause of erythroderma.",
"   </p>",
"   <p>",
"    Important elements of history are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of inflammatory skin disease (eg, psoriasis, atopic dermatitis)",
"     </li>",
"     <li>",
"      Family history of inflammatory skin diseases",
"     </li>",
"     <li>",
"      Medication history, including over the counter medications and supplements",
"     </li>",
"     <li>",
"      Preexisting systemic diseases or neoplasia",
"     </li>",
"     <li>",
"      Onset of symptoms and course of erythroderma",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85504067\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination should include a complete examination of the skin, nails, and mucosae for any sign of underlying skin disease. Lymph node and organ enlargement should be assessed.",
"   </p>",
"   <p>",
"    Clinical signs that are nonspecific but may be helpful in suggesting the cause of erythroderma include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Color of erythema",
"      </strong>",
"      &ndash; In light-skinned patients, the color of the erythema may be helpful in ascertaining the diagnosis. Salmon",
"      <span class=\"nowrap\">",
"       pink/orange",
"      </span>",
"      color with islands of sparing is typical of pityriasis rubra pilaris (",
"      <a class=\"graphic graphic_picture graphicRef87792 \" href=\"UTD.htm?34/44/35526\">",
"       picture 1A",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/23\">",
"       23",
"      </a>",
"      ]. A deeper red color associated with exfoliation is associated with psoriasis or cutaneous T-cell lymphoma (",
"      <a class=\"graphic graphic_picture graphicRef72342 \" href=\"UTD.htm?11/30/11745\">",
"       picture 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Scaling",
"      </strong>",
"      &ndash; Severe scaling may indicate psoriasis. Crusted scales are seen in pemphigus foliaceus, whereas exfoliation of large skin sheets is seen in drug reactions.",
"     </li>",
"     <li>",
"      <strong>",
"       Bullae",
"      </strong>",
"      &ndash; The presence of bullae and the involvement of the mucous membranes may indicate immunobullous disease (eg, pemphigus, bullous pemphigoid). Moist, crusted lesions on the face and upper trunk often precede the development of erythroderma in patients with pemphigus foliaceous (",
"      <a class=\"graphic graphic_picture graphicRef87796 graphicRef87795 \" href=\"UTD.htm?38/27/39354\">",
"       picture 5A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link&amp;anchor=H181679733#H181679733\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\", section on 'Pemphigus foliaceus'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Keratoderma",
"      </strong>",
"      &ndash; Waxy keratoderma of palms and soles with an orange hue is characteristic of pityriasis rubra pilaris (",
"      <a class=\"graphic graphic_picture graphicRef87793 graphicRef87825 \" href=\"UTD.htm?13/35/13882\">",
"       picture 2A-B",
"      </a>",
"      ), but may also be observed in S&eacute;zary syndrome (",
"      <a class=\"graphic graphic_picture graphicRef83371 \" href=\"UTD.htm?11/32/11783\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Nail abnormalities",
"      </strong>",
"      &ndash; Nail thickening, subungual hyperkeratosis, and splinter hemorrhages are found in psoriasis and pityriasis rubra pilaris (",
"      <a class=\"graphic graphic_picture graphicRef87823 \" href=\"UTD.htm?15/51/16181\">",
"       picture 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/2,24,25\">",
"       2,24,25",
"      </a>",
"      ]. The presence of nail pitting is a clue to the diagnosis of erythrodermic psoriasis (",
"      <a class=\"graphic graphic_picture graphicRef70962 \" href=\"UTD.htm?15/7/15474\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Hair abnormalities",
"      </strong>",
"      &ndash; Diffuse alopecia is common in erythroderma from all causes but may be particularly prominent in S&eacute;zary syndrome (",
"      <a class=\"graphic graphic_picture graphicRef83374 \" href=\"UTD.htm?9/9/9375\">",
"       picture 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10165654\">",
"    <span class=\"h2\">",
"     Skin biopsy and histopathologic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple skin biopsies may be necessary to identify the cause of erythroderma. Skin samples are usually obtained by punch biopsy of multiple involved sites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H12#H12\">",
"     \"Skin biopsy techniques\", section on 'Punch biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The histopathology of erythroderma may reflect the underlying etiology. However, histology is more often unrevealing or nonspecific Hyperkeratosis, acanthosis, spongiosis, and perivascular inflammatory infiltrate are frequent findings in erythroderma. The relative prominence of these features may vary with the stage of the disease and the severity of inflammation (",
"    <a class=\"graphic graphic_table graphicRef87724 \" href=\"UTD.htm?15/62/16366\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. More specific histopathologic changes may become apparent later in the course of the disease. Therefore, repeated skin biopsies may be needed to establish the diagnosis.",
"   </p>",
"   <p>",
"    As an example, in the initial phase of S&eacute;zary syndrome histology may show a nonspecific perivascular lymphocytic infiltrate without atypical lymphocytes and an overlying hyperplastic and parakeratotic epidermis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/27\">",
"     27",
"    </a>",
"    ]. At a later stage, the infiltrate may become increasingly pleomorphic and acquire specific diagnostic features, such as atypical cerebriform mononuclear cells and Pautrier microabscesses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link&amp;anchor=H1060012#H1060012\">",
"     \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\", section on 'Light microscopic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunohistochemistry and T cell receptor gene rearrangement studies should be performed if atypical lymphocytes are identified in the inflammatory infiltrate by routine histologic examination. The demonstration of an immunophenotype of T cells lacking mature T cell antigens (CD3",
"    <sup>",
"     +",
"    </sup>",
"    , CD4",
"    <sup>",
"     +",
"    </sup>",
"    , CD7",
"    <sup>",
"     -",
"    </sup>",
"    ) and the clonality of the T cell receptor gene rearrangement support the diagnosis of S&eacute;zary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link&amp;anchor=H1060895#H1060895\">",
"     \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\", section on 'Immunophenotyping confirming T cell origin (CD3+, CD4+)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link&amp;anchor=H1060880#H1060880\">",
"     \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\", section on 'Clonality of the T cell receptor (TCR) gene rearrangement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A predominance of CD8+ lymphocytes in the dermal infiltrate suggests chronic actinic dermatitis (actinic reticuloid). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=see_link&amp;anchor=H12594781#H12594781\">",
"     \"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment\", section on 'Chronic actinic dermatitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Direct immunofluorescence should be performed if an immunobullous disease is suspected based upon the presence of intraepidermal bullae or subepidermal bullae or an urticarial appearance of the erythroderma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link&amp;anchor=H176631240#H176631240\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\", section on 'Direct immunofluorescence'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290533#H53290533\">",
"     \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Direct immunofluorescence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In approximately 30 percent of cases, the histologic features of erythroderma remain nonspecific throughout its course and a precise diagnosis of the underlying condition cannot be made.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12240357\">",
"    <span class=\"h2\">",
"     Laboratory and imaging tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing is based upon the patient's medical history, clinical presentation, and suspected cause of erythroderma. The initial laboratory evaluation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood cell count and differential. Leukocytosis is common in all types of erythroderma. Eosinophilia",
"      <span class=\"nowrap\">",
"       &gt;700/microL",
"      </span>",
"      may be found in drug reaction with eosinophilia and systemic symptoms (DRESS). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link&amp;anchor=H872951#H872951\">",
"       \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\", section on 'Laboratory abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Routine biochemistry tests including electrolytes, glucose, serum albumin, LDH, liver and kidney function tests.",
"     </li>",
"     <li>",
"      Examination of a peripheral blood smear for the presence of S&eacute;zary cells (atypical lymphocytes with cerebriform nuclei). Counts of S&eacute;zary cells &gt;20 percent of examined lymphocytes suggest S&eacute;zary syndrome; counts &lt;10 percent can be found in erythrodermas of different etiologies and are considered nonspecific. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link&amp;anchor=H63648001#H63648001\">",
"       \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\", section on 'Peripheral blood'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bacterial cultures and assessment of antimicrobial susceptibilities, fungal cultures, and swabs for polymerase chain reaction tests for herpes simplex virus and varicella zoster virus should be performed if superinfection of skin lesions is suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=see_link&amp;anchor=H29#H29\">",
"       \"Clinical manifestations and diagnosis of herpes simplex virus type 1 infection\", section on 'Polymerase chain reaction'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis of varicella-zoster virus infection\", section on 'Polymerase chain reaction'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific tests that may be helpful in determining the underlying cause of erythroderma include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Peripheral blood flow cytometry and T cell clonality",
"      </strong>",
"      &ndash; Immunophenotyping and T cell receptor gene rearrangement studies should be performed to confirm or to rule out the diagnosis of S&eacute;zary syndrome. Findings that support the diagnosis of S&eacute;zary syndrome include: absolute S&eacute;zary cell count",
"      <span class=\"nowrap\">",
"       &ge;1000/microL;",
"      </span>",
"      CD4:CD8 ratio greater than 10; aberrant expression of pan-T-cell markers including CD2, CD3, CD4; deficient expression of CD26 and CD7 (CD4",
"      <sup>",
"       +",
"      </sup>",
"      CD26",
"      <sup>",
"       -",
"      </sup>",
"      &ge;30 percent and CD4",
"      <sup>",
"       +",
"      </sup>",
"      CD7",
"      <sup>",
"       -",
"      </sup>",
"      &ge;40 percent); and evidence of a circulating T cell clone [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=see_link&amp;anchor=H63648001#H63648001\">",
"       \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\", section on 'Peripheral blood'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Studies for immunobullous and autoimmune disease",
"      </strong>",
"      &ndash; Direct immunofluorescence studies of skin biopsy specimens are essential for the diagnosis of immunobullous disease. Biopsies should be taken in perilesional skin (erythematous areas close to bullae or erosions). The detection of circulating autoantibodies anti-desmoglein 1 and 3 or anti-bullous pemphigoid antigens BP180 or BP230 confirms the diagnosis of pemphigus or bullous pemphigoid, respectively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link&amp;anchor=H176631249#H176631249\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\", section on 'Serology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=see_link&amp;anchor=H53290547#H53290547\">",
"       \"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Antigen-specific serological testing'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The presence of antinuclear antibodies (ANA) and antibodies against extractable nuclear antigens (ENA) suggests the diagnosis of lupus erythematosus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H7#H7\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Subacute cutaneous lupus erythematosus'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Myositis-specific antibodies (eg, Jo-1 and other anti-synthetases, anti-Mi2, SRP,",
"      <span class=\"nowrap\">",
"       PM/Scl)",
"      </span>",
"      in addition to ANA and increased serum levels of muscle enzymes can confirm a clinical suspicion of dermatomyositis (",
"      <a class=\"graphic graphic_picture graphicRef77822 \" href=\"UTD.htm?13/41/13969\">",
"       picture 8",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Skin scrapings",
"      </strong>",
"      &ndash; Scrapings of burrows for mites should be performed and examined under a microscope in patients with suspected crusted scabies. KOH preparations may be useful to identify hyphae and arthrospores if a generalized dermatophyte infection is suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=see_link&amp;anchor=H11#H11\">",
"       \"Scabies\", section on 'Skin scraping'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H25#H25\">",
"       \"Dermatophyte (tinea) infections\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Imaging studies",
"      </strong>",
"      &ndash; In patients in whom erythroderma is suspected to be the manifestation of occult malignancy, radiologic workup may include chest radiograph, computed tomography (CT) or magnetic resonance imaging (MRI) (or, alternatively, positron emission",
"      <span class=\"nowrap\">",
"       tomography/computed",
"      </span>",
"      tomography",
"      <span class=\"nowrap\">",
"       [PET/CT])",
"      </span>",
"      of the abdomen and pelvis, colonoscopy, mammography in women, or ultrasonography of the prostate in men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12240380\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H579960\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute or symptomatic erythroderma and patients who are in any way unstable (particularly patients who are hemodynamically unstable) may require hospitalization for initial evaluation and treatment. Regardless of the specific etiology, the initial management involves:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Replacement of fluid and electrolytes",
"     </li>",
"     <li>",
"      Monitoring of the hemodynamic status",
"     </li>",
"     <li>",
"      Monitoring of body temperature",
"     </li>",
"     <li>",
"      Nutritional support",
"     </li>",
"     <li>",
"      Symptomatic treatment of skin inflammation and pruritus",
"     </li>",
"     <li>",
"      Treatment of cutaneous superinfections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should be placed in a warm and humid environment to prevent hypothermia. Symptomatic relief of skin pain and itching may include intensive skin care with emollients and wet dressings.",
"   </p>",
"   <p>",
"    For the symptomatic treatment of skin inflammation and pruritus, we also suggest low to mid-potency topical corticosteroids. We generally use low-potency topical corticosteroids (groups six and seven (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 4",
"    </a>",
"    )) for the face and body folds and mid-potency corticosteroids (groups four and five) for other body areas two to three times per day until improvement.",
"   </p>",
"   <p>",
"    Oral antihistamines may be helpful in reducing itching in some patients. We prefer first generation antihistamines for their sedating effect (eg, diphenhydramine [25 to 50 mg orally every four to six hours for adults and children &ge;12 years] or hydroxyzine&nbsp;[25 mg orally three to four times per day for adults and children &ge;6 years]). &nbsp;",
"   </p>",
"   <p>",
"    Cutaneous infection from",
"    <em>",
"     S. aureus",
"    </em>",
"    , including methicillin-resistant",
"    <em>",
"     S. aureus",
"    </em>",
"    , is common and requires prompt institution of systemic antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link&amp;anchor=H703176#H703176\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\", section on 'Antibiotic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cutaneous infection with herpes simplex virus requires treatment with antiviral medications such as acyclovir, valacyclovir, or famciclovir. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\", section on 'Oral antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12240401\">",
"    <span class=\"h2\">",
"     Treatment of underlying conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the underlying etiology of erythroderma has been determined, appropriate treatment of the underlying condition should be added to the initial management measures. (See",
"    <a class=\"local\" href=\"#H579960\">",
"     'Initial management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If a drug hypersensitivity reaction is suspected, all medications that are not essential should be withdrawn. For these patients, a short course of",
"    <span class=\"nowrap\">",
"     moderate/high",
"    </span>",
"    dose systemic corticosteroids (eg, prednisone 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) may be beneficial. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24360?source=see_link&amp;anchor=H14870405#H14870405\">",
"     \"Exanthematous (morbilliform) drug eruption\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=see_link&amp;anchor=H97599699#H97599699\">",
"     \"Drug reaction with eosinophilia and systemic symptoms (DRESS)\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with erythrodermic psoriasis require systemic therapies including methotrexate, cyclosporin, acitretin, or biologics (eg, infliximab, etanercept) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of psoriasis\", section on 'Erythrodermic psoriasis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with erythrodermic atopic dermatitis may benefit from systemic corticosteroids or other immunosuppressants such as cyclosporine, methotrexate, or azathioprine, although most patients respond to intensive topical treatments alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of severe refractory atopic dermatitis (eczema)\", section on 'Systemic immunosuppressants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with S&eacute;zary syndrome may require systemic and skin-directed therapies that target the circulating S&eacute;zary cells and control the skin manifestations. These treatments, which include extracorporeal photochemotherapy, systemic retinoids, and interferon, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=see_link\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with pityriasis rubra pilaris, treatment options include systemic retinoids, methotrexate, TNF-alpha inhibitors, cyclosporine, and azathioprine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43497?source=see_link&amp;anchor=H427352231#H427352231\">",
"     \"Pityriasis rubra pilaris\", section on 'Systemic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3350265\">",
"    <span class=\"h2\">",
"     Management of patients with idiopathic erythroderma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific treatments for idiopathic erythroderma. Most patients respond to skin care measures (eg, wet dressings) and symptomatic treatment of skin inflammation with low to mid-potency topical corticosteroids and oral antihistamines. (See",
"    <a class=\"local\" href=\"#H579960\">",
"     'Initial management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients who fail to respond to topical treatments are often empirically treated with systemic corticosteroids or other immunosuppressants (eg, methotrexate, cyclosporine). However, evidence for efficacy of systemic corticosteroids or other immunosuppressant therapy for patients with erythroderma is scant and limited to small case series and their use in the absence of a precise diagnosis remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/2,4,12,33\">",
"     2,4,12,33",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H579960\">",
"     'Initial management'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    For patients with idiopathic erythroderma that does not respond to topical therapy, we suggest systemic corticosteroids rather than methotrexate or cyclosporine because they have a more rapid onset of action (usually within days rather than weeks). We generally use prednisone 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 7 to 10 days up to a maximum dose of 60 mg per day; prednisone is then slowly tapered over several weeks to minimize the chances of rebound. &nbsp;",
"   </p>",
"   <p>",
"    A frequent problem with this regimen is that patients have a great difficulty in weaning from prednisone because of the high chance of rebound after the interruption of treatment. Patients should be monitored for potential adverse effects from systemic corticosteroids (in particular, fluid retention, hypertension, hyperglycemia, increased risk of infection). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cyclosporine (4 to 5 mg",
"    <span class=\"nowrap\">",
"     /kg/day)",
"    </span>",
"    or methotrexate (10 to 20 mg weekly) may be alternative therapies for patients for whom systemic corticosteroids are contraindicated. However, these agents have a slower onset of action and a less predictable antiinflammatory effect than systemic corticosteroids. Cyclosporine or methotrexate may be continued until the erythroderma is under control and then gradually weaned to the lowest dose that satisfactorily controls the skin inflammation. It is generally recommended that cyclosporine be used for less than one year to avoid renal damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55421654\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important that patients with idiopathic erythroderma be reevaluated periodically (eg, every six months). Over time, repeated skin biopsies and other laboratory or imaging studies may reveal the underlying cause of erythroderma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H375012\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapses of erythroderma may be prevented by controlling the underlying cause and avoiding triggers. Known triggers of erythroderma in patients with psoriasis or atopic dermatitis include the abrupt discontinuation of corticosteroids or other immunosuppressants; topical application of irritants; medications (eg, lithium salts and antimalarials in patients with psoriasis); and phototherapy burns. Patients with a history of erythrodermic drug eruption must avoid reexposure to the culprit drug. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12240415\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythroderma is a serious disorder associated with both increased morbidity and mortality. Its prognosis varies depending upon the underlying condition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythroderma secondary to psoriasis or atopic dermatitis usually improves within several weeks to several months after starting appropriate treatment. However, chronic or recurrent erythroderma is not uncommon in these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Erythroderma due to drug reactions usually resolves in two to six weeks after stopping the culprit drug.",
"     </li>",
"     <li>",
"      Erythroderma in S&eacute;zary syndrome and paraneoplastic erythroderma are often refractory to therapy and have a poor prognosis.",
"     </li>",
"     <li>",
"      Most patients with idiopathic erythroderma have a favorable prognosis. However, they require clinical monitoring because the underlying diagnosis may become apparent over months to years (see",
"      <a class=\"local\" href=\"#H55421654\">",
"       'Monitoring'",
"      </a>",
"      above). In some of these patients, erythroderma may represent a pre-lymphomatous condition. In a study of 28 patients with idiopathic erythroderma observed over a mean period of 33 months, 15 improved, 10 went into remission, and 2 patients developed a cutaneous T cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/11\">",
"       11",
"      </a>",
"      ]. In another study, 4 of 38 patients with erythroderma of unknown etiology followed-up for a median of 30 months developed mycosis fungoides [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mortality rate for erythroderma ranges from 4 to 64 percent, with higher rates reported in older case series. Advanced age and comorbidities are associated with unfavorable prognosis. Mean survival rates for erythrodermic mycosis fungoides and S&eacute;zary syndrome range from 1.5 to 10.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13385/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12240422\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythroderma (exfoliative dermatitis) is a severe and potentially life-threatening condition that presents with diffuse erythema and scaling involving &ge;90 percent of the skin surface area. (See",
"      <a class=\"local\" href=\"#H12240271\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common causes of erythroderma include exacerbation of a preexisting inflammatory dermatosis, hypersensitivity reactions to drugs, and cutaneous T cell lymphomas. Less common causes of erythroderma are summarized in the table (",
"      <a class=\"graphic graphic_table graphicRef87714 \" href=\"UTD.htm?30/28/31180\">",
"       table 1",
"      </a>",
"      ). In approximately one third of patients, the cause of erythroderma remains undetermined (idiopathic erythroderma); this group requires repeated reassessment as the underlying diagnosis may become apparent over months to years. (See",
"      <a class=\"local\" href=\"#H12240285\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erythroderma may develop acutely over hours or days or evolve gradually over weeks to months. Patients typically present with erythematous patches that increase in size and coalesce into a generalized bright red erythema with occasional islands of sparing (",
"      <a class=\"graphic graphic_picture graphicRef87792 graphicRef72342 \" href=\"UTD.htm?8/30/8681\">",
"       picture 1A-B",
"      </a>",
"      ). The skin feels warm to the touch and dry. Patients appear uncomfortable, shiver, and complain of feeling cold. Scaling begins two to six days after the onset of erythema and may become prominent. Extracutaneous symptoms include fever or hypothermia, peripheral edema, and tachycardia. (See",
"      <a class=\"local\" href=\"#H12240313\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5244713\">",
"       'Evolution of skin findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erythroderma is relatively well-tolerated by many patients. However, patients at the extremes of age and patients with comorbidities may experience complications, including high-output heart failure, fluid and electrolytic imbalance, heat loss, hypothermia, compensatory hypermetabolism, protein loss and negative nitrogen balance, hypoalbuminemia, edema, and muscle wasting, and secondary skin infection. (See",
"      <a class=\"local\" href=\"#H8113942\">",
"       'Clinical course and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Determining the cause of erythroderma is often difficult and involves a detailed history, physical examination, skin biopsy, and laboratory studies. In some cases histology reveals the underlying etiology (",
"      <a class=\"graphic graphic_table graphicRef87724 \" href=\"UTD.htm?15/62/16366\">",
"       table 3",
"      </a>",
"      ), but it is more often nonspecific and repeated skin biopsies may be necessary. (See",
"      <a class=\"local\" href=\"#H12240350\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are hemodynamically unstable or those with severe symptoms may require hospitalization. Regardless of the specific etiology, the initial management involves:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Replacement of fluid and electrolytes",
"     </li>",
"     <li>",
"      Monitoring of the hemodynamic status",
"     </li>",
"     <li>",
"      Monitoring of body temperature",
"     </li>",
"     <li>",
"      Nutritional support",
"     </li>",
"     <li>",
"      Symptomatic treatment of skin inflammation and pruritus",
"     </li>",
"     <li>",
"      Treatment of edema",
"     </li>",
"     <li>",
"      Treatment of cutaneous superinfections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the symptomatic treatment of skin inflammation and pruritus, we suggest topical corticosteroids and oral antihistamines (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). We generally use low-potency to mid-potency topical corticosteroids (groups four to seven (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"UTD.htm?38/56/39809\">",
"     table 4",
"    </a>",
"    )) two to three times per day until improvement. (See",
"    <a class=\"local\" href=\"#H579960\">",
"     'Initial management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After the underlying etiology of erythroderma has been determined, appropriate treatment of the underlying condition must be initiated promptly. (See",
"      <a class=\"local\" href=\"#H12240401\">",
"       'Treatment of underlying conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with idiopathic erythroderma that does not respond to topical therapy, we suggest systemic corticosteroids rather than methotrexate or cyclosporine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We generally use prednisone 0.5 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 7 to 10 days. Prednisone is then slowly tapered over several weeks to avoid rebound. (See",
"      <a class=\"local\" href=\"#H3350265\">",
"       'Management of patients with idiopathic erythroderma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with idiopathic erythroderma should be closely monitored with clinical, histologic, laboratory, or imaging evaluation, since an underlying etiology may become apparent over time. (See",
"      <a class=\"local\" href=\"#H55421654\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/1\">",
"      Sigurdsson V, Steegmans PH, van Vloten WA. The incidence of erythroderma: a survey among all dermatologists in The Netherlands. J Am Acad Dermatol 2001; 45:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/2\">",
"      Li J, Zheng HY. Erythroderma: a clinical and prognostic study. Dermatology 2012; 225:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/3\">",
"      Pal S, Haroon TS. Erythroderma: a clinico-etiologic study of 90 cases. Int J Dermatol 1998; 37:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/4\">",
"      Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: a clinical study of 97 cases. BMC Dermatol 2005; 5:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/5\">",
"      Rym BM, Mourad M, Bechir Z, et al. Erythroderma in adults: a report of 80 cases. Int J Dermatol 2005; 44:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/6\">",
"      Sigurdsson V, Toonstra J, Hezemans-Boer M, van Vloten WA. Erythroderma. A clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Acad Dermatol 1996; 35:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/7\">",
"      Sarkar R, Garg VK. Erythroderma in children. Indian J Dermatol Venereol Leprol 2010; 76:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/8\">",
"      Sarkar R, Basu S, Sharma RC. Neonatal and infantile erythrodermas. Arch Dermatol 2001; 137:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/9\">",
"      Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythroderma: diagnosing and treating the \"red man\". Clin Dermatol 2005; 23:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/10\">",
"      Sheen YS, Chu CY, Wang SH, Tsai TF. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. J Dermatolog Treat 2009; 20:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/11\">",
"      Sigurdsson V, Toonstra J, van Vloten WA. Idiopathic erythroderma: a follow-up study of 28 patients. Dermatology 1997; 194:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/12\">",
"      Thestrup-Pedersen K, Halkier-S&oslash;rensen L, S&oslash;gaard H, Zachariae H. The red man syndrome. Exfoliative dermatitis of unknown etiology: a description and follow-up of 38 patients. J Am Acad Dermatol 1988; 18:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/13\">",
"      Groves RW, Kapahi P, Barker JN, et al. Detection of circulating adhesion molecules in erythrodermic skin disease. J Am Acad Dermatol 1995; 32:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/14\">",
"      Sigurdsson V, de Vries IJ, Toonstra J, et al. Expression of VCAM-1, ICAM-1, E-selectin, and P-selectin on endothelium in situ in patients with erythroderma, mycosis fungoides and atopic dermatitis. J Cutan Pathol 2000; 27:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/15\">",
"      Sigurdsson V, Toonstra J, Bihari IC, et al. Interleukin 4 and interferon-gamma expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immuno-histochemical study. J Cutan Pathol 2000; 27:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/16\">",
"      Kanthraj GR, Srinivas CR, Devi PU, et al. Quantitative estimation and recommendations for supplementation of protein lost through scaling in exfoliative dermatitis. Int J Dermatol 1999; 38:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/17\">",
"      Green MS, Prystowsky JH, Cohen SR, et al. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996; 34:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/18\">",
"      Jaffe D, May LP, Sanchez M, Moy J. Staphylococcal sepsis in HIV antibody seropositive psoriasis patients. J Am Acad Dermatol 1991; 24:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/19\">",
"      Bakri FG, Al-Hommos NA, Shehabi A, et al. Persistent bacteraemia due to methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in a patient with erythrodermic psoriasis. Scand J Infect Dis 2007; 39:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/20\">",
"      Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and S&eacute;zary syndrome. Br J Dermatol 2008; 159:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/21\">",
"      Garg G, Thami GP. Psoriasis Herpeticum due to Varicella Zoster Virus: A Kaposi's Varicelliform Eruption in Erythrodermic Psoriasis. Indian J Dermatol 2012; 57:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/22\">",
"      Santmyire-Rosenberger BR, Nigra TP. Psoriasis herpeticum: three cases of Kaposi's varicelliform eruption in psoriasis. J Am Acad Dermatol 2005; 53:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/23\">",
"      Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol 1980; 5:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/24\">",
"      Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol 2010; 11:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/25\">",
"      Suzuki M, Oki T, Sugiyama T, et al. Muscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tract. Urology 2007; 69:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/26\">",
"      Bi MY, Curry JL, Christiano AM, et al. The spectrum of hair loss in patients with mycosis fungoides and S&eacute;zary syndrome. J Am Acad Dermatol 2011; 64:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/27\">",
"      Ram-Wolff C, Martin-Garcia N, Bensussan A, et al. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies. Am J Dermatopathol 2010; 32:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/28\">",
"      Zip C, Murray S, Walsh NM. The specificity of histopathology in erythroderma. J Cutan Pathol 1993; 20:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/29\">",
"      Vasconcellos C, Domingues PP, Aoki V, et al. Erythroderma: analysis of 247 cases. Rev Saude Publica 1995; 29:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/30\">",
"      Nagler AR, Samimi S, Schaffer A, et al. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of S&eacute;zary syndrome. J Am Acad Dermatol 2012; 66:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/31\">",
"      Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/32\">",
"      Viguier M, Pag&egrave;s C, Aubin F, et al. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Br J Dermatol 2012; 167:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/33\">",
"      Khaled A, Sellami A, Fazaa B, et al. Acquired erythroderma in adults: a clinical and prognostic study. J Eur Acad Dermatol Venereol 2010; 24:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/34\">",
"      Boyd AS, Menter A. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989; 21:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/35\">",
"      Kim YH, Bishop K, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the S&eacute;zary syndrome. Arch Dermatol 1995; 131:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13385/abstract/36\">",
"      Kubica AW, Davis MD, Weaver AL, et al. S&eacute;zary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol 2012; 67:1189.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13659 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13385=[""].join("\n");
var outline_f13_4_13385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12240422\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12240271\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12240278\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12240285\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5244727\">",
"      Cutaneous and systemic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3350288\">",
"      Erythroderma of unknown origin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12240306\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12240313\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8845926\">",
"      Onset",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2942806\">",
"      Cutaneous symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2942857\">",
"      Extracutaneous findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5244680\">",
"      LABORATORY ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8113942\">",
"      CLINICAL COURSE AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5244713\">",
"      Evolution of skin findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56307720\">",
"      Hemodynamic and metabolic disturbances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56307727\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12240350\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5244967\">",
"      DETERMINATION OF UNDERLYING CAUSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85504020\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85504067\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10165654\">",
"      Skin biopsy and histopathologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12240357\">",
"      Laboratory and imaging tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12240380\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H579960\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12240401\">",
"      Treatment of underlying conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3350265\">",
"      Management of patients with idiopathic erythroderma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55421654\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H375012\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12240415\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12240422\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13659|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/44/35526\" title=\"picture 1A\">",
"      Pityriasis rubra pilaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/30/11745\" title=\"picture 1B\">",
"      Erythroderma in Sezary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/22/43366\" title=\"picture 2A\">",
"      Keratoderma pityriasis rubra pilaris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/24/3462\" title=\"picture 2B\">",
"      Pityriasis rubra pilaris keratoderma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/32/11783\" title=\"picture 3\">",
"      Keratoderma in S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/7/15474\" title=\"picture 4\">",
"      Nail psoriasis pits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/62/24552\" title=\"picture 5A\">",
"      Pemphigus foliaceous face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/59/12217\" title=\"picture 5B\">",
"      Erythrodermic pemphigus foliaceous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/51/16181\" title=\"picture 6\">",
"      Pityriasis rubra pilaris nails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/9/9375\" title=\"picture 7\">",
"      Diffuse alopecia in SS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/41/13969\" title=\"picture 8\">",
"      Dermatomyositis - upper back",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13659|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/28/31180\" title=\"table 1\">",
"      Causes of erythroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/24/41355\" title=\"table 2\">",
"      Drugs causing erythroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/62/16366\" title=\"table 3\">",
"      Erythroderma pathology features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39809\" title=\"table 4\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22714?source=related_link\">",
"      Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40265?source=related_link\">",
"      Clinical manifestations and diagnosis of herpes simplex virus type 1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/31/9722?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/77?source=related_link\">",
"      Diagnosis of varicella-zoster virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43929?source=related_link\">",
"      Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24360?source=related_link\">",
"      Exanthematous (morbilliform) drug eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/26/44457?source=related_link\">",
"      Management of severe refractory atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/63/18426?source=related_link\">",
"      Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43497?source=related_link\">",
"      Pityriasis rubra pilaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/2/28712?source=related_link\">",
"      Scabies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40042?source=related_link\">",
"      Treatment of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_4_13386="Pneumococcal pneumonia in adults";
var content_f13_4_13386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pneumococcal pneumonia in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13386/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13386/contributors\">",
"     Thomas J Marrie, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13386/contributors\">",
"     Elaine I Tuomanen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13386/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13386/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/4/13386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/4/13386/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/4/13386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the approximately four million cases of pneumonia each year in the United States, the pneumococcus (Streptococcus pneumoniae) is the most common agent leading to hospitalization in all age groups [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/1\">",
"     1",
"    </a>",
"    ]. For many decades, bacteremic pneumococcal pneumonia has accounted for 9 to 18 cases per 100,000 adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A general overview of pneumococcal pneumonia will be presented here. The epidemiology, microbiology, diagnosis, and treatment of community-acquired pneumonia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although S. pneumoniae is the most common cause of community-acquired pneumonia (CAP), many studies have reported isolation of the organism in only 5 to 18 percent of cases. The rate of isolation increases when more invasive methods are used for obtaining specimens, such as transtracheal aspiration, which eliminates contaminating oropharyngeal flora [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/2\">",
"     2",
"    </a>",
"    ]. It is currently believed that many culture-negative cases of CAP are caused by pneumococcus. The following observations support this belief:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sputum culture is negative in about 50 percent of patients with concurrent pneumococcal bacteremia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A discriminant functional analysis, in which cases of unknown etiology were evaluated according to the clinical characteristics of S. pneumoniae, Mycoplasma pneumoniae, or other organisms, predicted that the majority of cases were due to pneumococcus [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A majority of cases of unknown etiology respond to treatment with penicillin [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies using transtracheal aspiration show high yields of S. pneumoniae.",
"     </li>",
"     <li>",
"      S. pneumoniae accounts for 66 percent of bacteremic pneumonias [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There has been a resurgence of outbreaks of pneumococcal pneumonia, particularly in chronic care facilities and involving antibiotic resistant strains. In one report, for example, pneumococcal pneumonia developed in 11 of 84 residents of a nursing home, three of whom died [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/7\">",
"     7",
"    </a>",
"    ]. The strain, which colonized 23 percent of the residents of the facility and some staff members, was resistant to multiple antibiotics including penicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76306199\">",
"    <span class=\"h3\">",
"     Influenza infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza infection greatly predisposes to secondary pneumococcal pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/8\">",
"     8",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of seasonal influenza in adults\", section on 'Secondary bacterial pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Alcohol abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol abuse was associated with an increased risk of infection with S. pneumoniae in a prospective analysis of 1347 patients hospitalized with CAP [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/9\">",
"     9",
"    </a>",
"    ]. The association between S. pneumoniae and alcoholism applied to both current alcoholics (daily alcohol intake &gt;80 g in men or &gt;60 g in women) and former alcohol abusers (&ge; one year of abstinence).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive pneumococcal disease was associated with cigarette smoking (OR 4.1, 95% CI 2.4-7.3) and with passive smoke exposure (OR 2.5, 95% CI 1.2-5.1) in a case-control study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/10\">",
"     10",
"    </a>",
"    ]. A dose-response relationship was demonstrable for number of cigarettes smoked per day, pack years of smoking, and time since quitting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     COPD and asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic obstructive pulmonary disease (COPD) have increased rates of hospitalization due to pneumococcal pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/11\">",
"     11",
"    </a>",
"    ]. There are conflicting data regarding the risk among patients with asthma. In a case-control study, patients with asthma had a twofold increase in risk for invasive pneumococcal disease compared with non-asthmatics [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/12\">",
"     12",
"    </a>",
"    ], although in a separate cohort study, asthmatics did not have increased rates of hospitalization for pneumococcal pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=see_link&amp;anchor=H6#H6\">",
"     \"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia\", section on 'Risk factors for infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Hyposplenism or splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several splenic functions protect the host against infection with encapsulated organisms, including pneumococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/13\">",
"     13",
"    </a>",
"    ]. These functions include the role of the spleen in antibody production, activation of the alternative complement pathway, and phagocytosis of unopsonized particulate matter.",
"   </p>",
"   <p>",
"    Surgical removal of the spleen (for trauma, disease staging, or therapeutic) or functional hyposplenism (sickle cell disease, thalassemia, lymphoproliferative diseases, bone marrow transplantation and total irradiation) increase the risk for overwhelming pneumococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients with disease involving the reticuloendothelial system are at greater risk than those who underwent splenectomy for traumatic injury. All patients who have undergone splenectomy should receive pneumococcal vaccine. If splenectomy is performed as an elective procedure, pneumococcal vaccine should be administered at least two weeks, and preferably one month, prior to the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Immunocompromise",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a 50- to 100-fold increase in invasive pneumococcal disease among persons infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. For HIV-infected patients who were vaccinated with conjugated S. pneumoniae polysaccharide vaccine in childhood, there has been a decrease in invasive pneumococcal disease caused by vaccine serotypes, but an increase in disease due to nonvaccine serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other causes of immunocompromise are also associated with increased risk for pneumococcal disease. For patients with primary immunodeficiency syndromes, risk is greatest for those with B cell defects [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/18\">",
"     18",
"    </a>",
"    ]. Other conditions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple myeloma [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/22-24\">",
"       22-24",
"      </a>",
"      ], and, in particular, bone marrow transplant recipients with chronic graft-versus-host disease [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional risk factors include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Homelessness",
"     </li>",
"     <li>",
"      Incarceration",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Crack cocaine use",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antibiotic resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance of S. pneumoniae to multiple antibiotics is an increasingly important clinical problem. A discussion of pneumococcal drug resistance is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3369?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A report of the emergence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    tolerance in the pneumococcus is a disturbing event, as vancomycin is considered the antibiotic of last resort for this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nasopharyngeal colonization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococci are acquired by aerosol inhalation, leading to colonization of the nasopharynx. Colonization is present in 40 to 50 percent of healthy adults and persists for four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/31\">",
"     31",
"    </a>",
"    ]. Carriage may involve more than one serotype at a time. Disease occurs most frequently upon acquisition of a serotype different from those with which an individual may be colonized [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/32\">",
"     32",
"    </a>",
"    ]. Pneumococcal carriage is more common in smokers than nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colonization with pneumococcus is more common in children than adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] and young children are responsible for the majority of new serotypes introduced into a household [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/36\">",
"     36",
"    </a>",
"    ]. Asymptomatic pneumococcal colonization in children has been implicated as a reservoir for penicillin- or antibiotic-resistant strains [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/37\">",
"     37",
"    </a>",
"    ]. However, some resistant strains do not appear to be easily transmitted to adults as illustrated in a study from a kibbutz in Israel [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/38\">",
"     38",
"    </a>",
"    ]. Serotyping and pulsed-field gel electrophoresis to determine the relatedness of pneumococci did not find that children in day care centers passed their resistant strains to their parents or other adults in the kibbutz.",
"   </p>",
"   <p>",
"    Prolonged courses of antibiotics may increase the likelihood of colonization with antibiotic-resistant S. pneumoniae. As an example, a study evaluated the risk of carriage of penicillin-nonsusceptible pneumococci in children receiving a 5-day course of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    versus a standard 10 day regimen of amoxicillin for the treatment of respiratory tract infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/39\">",
"     39",
"    </a>",
"    ]. The risk of carriage of strains that were not susceptible to either penicillin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    was lower in the group receiving the shorter course of high-dose amoxicillin; the overall risk of carriage of nonsusceptible strains was increased in both groups that received antibiotics compared to baseline.",
"   </p>",
"   <p>",
"    Although children are more frequently colonized than adults, outbreaks of pneumococcal pneumonia in nursing homes have demonstrated high rates of nasopharyngeal carriage among residents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MECHANISMS OF PULMONARY INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal pneumonia is the paradigm of classic lobar bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/40\">",
"     40",
"    </a>",
"    ]. The pneumococcus is acquired in the nasopharynx and is carried asymptomatically in approximately 40 to 50 percent of individuals at any point in time [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/32\">",
"     32",
"    </a>",
"    ]. Invasive disease, defined by the isolation of S. pneumoniae from a normally sterile site (eg, blood, cerebrospinal fluid, but not sputum), most commonly occurs upon acquisition of a new serotype, typically after an incubation period of one to three days.",
"   </p>",
"   <p>",
"    The development of pneumococcal pneumonia becomes more likely when the dose of inhaled or aspirated pneumococci overwhelms the host defense system in the respiratory tract. The relationship between the inoculum dose of S. pneumoniae and pneumonia onset was examined in a rabbit model [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/41\">",
"     41",
"    </a>",
"    ]. Inoculation of S. pneumoniae at a dose of &gt;10(5) organisms was followed by the development of pneumonia in &ge;90 percent of rabbits. In contrast, lower doses caused pneumonia in &lt;20 percent of inoculated rabbits.",
"   </p>",
"   <p>",
"    Pneumococci are presumably aerosolized from the nasopharynx to the alveolus where they enter alveolar type II cells. This process involves bacterial binding to the receptor for platelet activating factor (PAF), a key pulmonary chemokine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/42\">",
"     42",
"    </a>",
"    ]. This attachment occurs through bacterial display of surface localized choline, a chemical constituent shared between the bacteria and the human chemokine PAF. Choline has been found on the surface of many pulmonary pathogens, suggesting a common motif for disease at this body site [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/43\">",
"     43",
"    </a>",
"    ]. The host innate defense element C-reactive protein binds to choline and opsonizes these pathogens if they pass from the lungs into the bloodstream. Thus, choline is useful in attaching to the lung but detrimental to the organism in the bloodstream. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23143?source=see_link&amp;anchor=H3#H3\">",
"     \"Microbiology and pathogenesis of Streptococcus pneumoniae\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Course of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pneumonic lesion progresses as pneumococci multiply in the alveolus and invade the alveolar epithelium. Pneumococci pass from alveolus to alveolus through the pores of Cohn, thereby creating inflammation and consolidation strictly along lobar compartments (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65658 \" href=\"UTD.htm?33/26/34223\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64692 \" href=\"UTD.htm?1/51/1840\">",
"     image 2",
"    </a>",
"    ). The center of the spreading lesion shows more advanced inflammation than the edges.",
"   </p>",
"   <p>",
"    The evolution of the consolidated lung was first described by Laennec in 1838 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Newly involved regions demonstrate engorgement of alveolar capillaries with frothy, serous, blood-tinged fluid in the alveolar spaces. This lesion can be recapitulated by instillation of heat-killed pneumococci into the lung and therefore, may result from the host response to the pneumococcal cell wall [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The engorgement stage rapidly progresses to red hepatization characterized by a dry, granular, dark red lung surface and alveoli filled with copious, clotted inflammatory exudate. A distinctive feature of the exudate is its \"freshness\" in that erythrocytes and leukocytes are intact and a fibrin network extends from one alveolus into the next through the pores of Cohn. Pneumococci are intact and alive. Bronchoalveolar lavage fluid contains high amounts of tumor necrosis factor, interleukin-6 and nitric oxide, reflective of strong recruitment of leukocytes to the infected focus [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/45\">",
"       45",
"      </a>",
"      ]. There is little tissue destruction or necrosis during this process, however, perhaps explaining why the patient and lung architecture may often recover fully from these lesions. Infrequently, infection with S. pneumoniae can lead to a necrotizing pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As red hepatization progresses over two to three days, leukocytes pack into the alveoli, erythrocytes are lysed, and epithelial cells degenerate, leading to grey hepatization. Dying pneumococci release the pore-forming toxin pneumolysin that contributes to this stage.",
"     </li>",
"     <li>",
"      In the presence of antibody, pneumococci are opsonized by leukocytes and begin to be cleared. Consolidation is still prominent when defervescence occurs. An abrupt disappearance of fever, termed \"crisis\", is particularly common in children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Resolution results in a jelly-like consistency to the lung with a slimy, yellowish exudate. A key feature marking this stage is the involvement of mononuclear cells in the exudate. Absorption of the exudate is remarkably efficient with little organization or permanent scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically, the patient with pneumococcal pneumonia becomes ill abruptly with fever, chills, cough and pain in the side, often so severe as to limit respiratory movements. This classical presentation, however, typically occurs in younger patients. With increasing age of the population, older patients more frequently develop pneumococcal pneumonia, and exhibit fewer symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tachypnea and increasing systemic toxicity follow initial symptom onset. The degree of distress is not directly related to the extent of pulmonary pathology, suggesting that hypoxia is not the cause of these symptoms, although hypoxia and cyanosis may develop in severe cases.",
"   </p>",
"   <p>",
"    Presentation may differ for patients with and without bacteremia. In a multicenter study, 56 patients with bacteremic pneumococcal pneumonia (BPP) were compared with 394 patients with community-acquired pneumonia (CAP) and negative blood cultures. The BPP patients were younger (55.6 years versus 63.4 years), had a higher mean oral temperature at presentation, higher pulse rate, and more band forms on CBC (22.1 percent band versus 14.2 percent). The time from onset of symptoms until admission to hospital was shorter for BPP patients, 4.6&plusmn;3.7 days versus 7.0&plusmn;13.9 days [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pneumococcal pneumonia may present atypically, especially in the elderly where confusion or delirium may be an initial manifestation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/49\">",
"     49",
"    </a>",
"    ]. Infrequently, jaundice may occur, leading the clinician to suspect hepatobiliary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic description of the sputum in lobar pneumococcal pneumonia is \"rusty,\" due to mixed blood cells and hemoglobin in the sputum, as described in a 1939 text by Heffron [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Auscultatory findings of rales and bronchial breath sounds are localized to the involved segment or lobe. These findings may disappear at the height of consolidation and reappear on resolution (redux crepitus). Consolidation is associated with physical findings of dullness on percussion, bronchial breath sounds, egophony, and whispered pectoriloquy.",
"   </p>",
"   <p>",
"    In addition to classic lobar pneumonia (alveolar infection leading to consolidation of the greater part or all of one or more lobes, typically with air bronchograms), pneumococci can cause bronchopneumonia (infection of the bronchi with a more segmental pattern and without air bronchograms). The prevalence of these two disease patterns differs by serotype, suggesting that underlying pneumococcal components may contribute to variations in disease progression. Lobar pneumonia is associated with serotypes 1, 2, 3, 5, 7 and 8 and bronchopneumonia is associated with serotypes 3, 7, 8, 10, 18, and 20 in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/40\">",
"     40",
"    </a>",
"    ]. In a multicenter international study of 844 patients from ten countries (the US, South Africa, Sweden, Spain, New Zealand, Taiwan, Argentina, Brazil, Hong Kong, and France), serotypes 14, 4, 6, and 3 were the most common, in decreasing order of prevalence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Spectrum of illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal pneumonia may cause mild disease, but there is a wide range in severity, including patients with overwhelming sepsis in whom the mortality rate may be greater than 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/53\">",
"     53",
"    </a>",
"    ]. However, for those who survive the infection, there is usually complete recovery of normal pulmonary function.",
"   </p>",
"   <p>",
"    A scoring system has been defined to categorize severity of illness in patients with pneumonia, based on demographic factors, comorbidity, and findings from physical examination, laboratory and radiographic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/54\">",
"     54",
"    </a>",
"    ]. Patients in Classes I through III are at low risk for death or complications, with increasing mortality rates for Classes IV and V. Applying this scoring system to a series of 158 patients with pneumococcal pneumonia (including 65 bacteremic patients), 29 percent were Class IV with 2 percent mortality, and 15 percent were Class V with 30 percent mortality in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/55\">",
"     55",
"    </a>",
"    ]. In two other studies of hospitalized populations, slightly over 50 percent of patients were categorized in Classes IV or V [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/26,56\">",
"     26,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential complications of pneumococcal pneumonia include bacteremia with metastatic infection, and pulmonary complications of parapneumonic effusion, empyema, necrotizing pneumonia, and lung abscess. Complications that were prevalent in the preantibiotic era (endocarditis, septic arthritis, peritonitis, pericarditis, and meningitis) are now relatively uncommon.",
"   </p>",
"   <p>",
"    Risk factors for a complicated course include older age, preexisting lung disease, immunodeficiency or AIDS and, importantly, acquisition of a nosocomial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/57\">",
"     57",
"    </a>",
"    ]. The risk of overwhelming pneumococcal sepsis is increased in splenectomized patients, since the spleen is a principal site for clearance of this bacterium (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Hyposplenism or splenectomy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    In addition to complications related to the acute infection, the stress, hypoxemia, and inflammation associated with pneumococcal pneumonia may precipitate acute cardiac events. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Acute cardiac events'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of bacteremic pneumococcal pneumonia was 9.7 per 100,000 person years in a prospective study of adults in Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/26\">",
"     26",
"    </a>",
"    ]. The rate was markedly higher among pregnant women, homeless persons, and those in prison (114, 267, and 52 per 100,000 person years, respectively).",
"   </p>",
"   <p>",
"    Bacteremia with seeding of other organs was seen in 25 percent of cases in the 1960s, but is much less common now, occurring in less than 1 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/26,58\">",
"     26,58",
"    </a>",
"    ]. In a study of 100 veterans with pneumococcal pneumonia, bacteremic patients were more likely to die of their infection during the first week of illness compared to nonbacteremic patients (19 compared to 4 percent in nonbacteremic patients); after the first week, however, mortality rates were approximately the same [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/59\">",
"     59",
"    </a>",
"    ]. Extrapulmonary infections were present in 11 percent of the bacteremic patients (5 with meningitis, 3 with empyema, 3 with septic arthritis and 1 with endocarditis). Alcohol abuse was present in 47 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Pulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusions secondary to pneumococcal pneumonia are common and are usually sterile parapneumonic effusions. Empyema complicates approximately 5 to 12 percent of cases of patients with pneumococcal pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/26,60\">",
"     26,60",
"    </a>",
"    ]. Management of effusions and empyema is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pneumococcal infection of the lung has been reported rarely to result in a lung abscess or necrotizing pneumonia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53664 \" href=\"UTD.htm?27/28/28096\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/61\">",
"     61",
"    </a>",
"    ]. In a study of 351 patients with pneumococcal pneumonia, necrosis was reported in no original chest x-ray readings and in 6 of 136 (4.4 percent) chest computed tomograph (CT) readings [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/62\">",
"     62",
"    </a>",
"    ]. However, upon rereading, 8 of 351 (2.3 percent) chest x-rays and 15 of 136 (11 percent) chest CTs had necrotizing changes. Lung necrosis was detected in 23 of 351 (6.6 percent) of patients overall, suggesting that necrosis is often overlooked on initial lung imaging readings. In some cases, there is polymicrobial infection with S. pneumoniae and anaerobic bacteria (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24729?source=see_link\">",
"     \"Lung abscess\"",
"    </a>",
"    ). It is likely that the latter account for the necrotizing pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Acute cardiac events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Community-acquired pneumonia, particularly pneumococcal pneumonia, has been associated with acute cardiac events that may result from cardiac stress, hypoxemia, and inflammation. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1801?source=see_link&amp;anchor=H14#H14\">",
"     \"Prognosis of community-acquired pneumonia in adults\", section on 'Association with acute cardiac events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history, physical findings, and the finding of an opacity on chest radiograph, usually establish the diagnosis of pneumonia. Although lobar consolidation is suggestive of bacterial pneumonia, radiographs cannot reliably differentiate bacterial from nonbacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Sputum Gram stain and culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is often difficult to determine the microbiologic cause of pneumonia. As an example, an etiologic agent was identified in 51 percent of 154 patients with community-acquired pneumonia (CAP) requiring hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/64\">",
"     64",
"    </a>",
"    ] and in 49 percent of patients with CAP treated on an ambulatory basis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two problems contribute to the difficulty in identifying an organism: 15 to 30 percent of patients are unable to produce a sputum specimen; and approximately 25 percent of patients have received antibiotics prior to producing a specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/2,3,66\">",
"     2,3,66",
"    </a>",
"    ]. In one study, among patients with bacteremic pneumococcal pneumonia who had been treated with antibiotics for over 24 hours before submitting a sputum sample, the Gram stain was positive in one of seven samples, and culture positive in two of seven sputum samples [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/67\">",
"     67",
"    </a>",
"    ]. For patients who had not been previously treated and who were able to produce a sputum sample (n=51), Gram stain suggested pneumococcal infection in 63 percent.",
"   </p>",
"   <p>",
"    For these and other reasons, the utility of sputum Gram stain and culture remains a source of controversy, and most patients with community-acquired pneumonia are treated empirically. Nevertheless, when a proper sputum sample is obtained, a Gram stain may give immediate etiologic information and is useful. The finding of a predominant organism (eg, gram-positive diplococci) may support the etiology of the pneumonia as pneumococcus (",
"    <a class=\"graphic graphic_picture graphicRef75924 \" href=\"UTD.htm?21/0/21507\">",
"     picture 1",
"    </a>",
"    ).&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=see_link\">",
"     \"Diagnostic approach to community-acquired pneumonia in adults\"",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    2007",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    guidelines for the treatment of CAP, recommend blood cultures for patients with CAP requiring admission to the hospital under the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intensive care admission",
"     </li>",
"     <li>",
"      Cavitary infiltrates",
"     </li>",
"     <li>",
"      Leukopenia",
"     </li>",
"     <li>",
"      Active alcohol abuse",
"     </li>",
"     <li>",
"      Chronic severe liver disease",
"     </li>",
"     <li>",
"      Asplenia",
"     </li>",
"     <li>",
"      Positive pneumococcal urine antigen test",
"     </li>",
"     <li>",
"      Pleural effusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the preantibiotic era, about 25 percent of patients with lobar pneumonia had blood cultures positive for S. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/69\">",
"     69",
"    </a>",
"    ]. Currently, 6 to 10 percent of patients requiring hospitalization for treatment of CAP are bacteremic, and 60 percent of these are due to S. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pneumococcal urinary antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for improved speed and accuracy in the diagnosis of pneumonia has led to the development of a urinary assay for pneumococcal cell wall components [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/70\">",
"     70",
"    </a>",
"    ]. The reported sensitivity of the Binax NOW urinary assay ranges from 70 to 90 percent, with a specificity of 80 to 100 percent in adults with pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. The specificity is lower in the setting of nasopharyngeal carriage without infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/71\">",
"     71",
"    </a>",
"    ], and appears to be increased in patients with bacteremia or severe infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/72\">",
"     72",
"    </a>",
"    ]. In a prospective study that included 171 adults hospitalized with CAP caused by S. pneumoniae, the majority of whom did not have S. pneumoniae isolated from blood cultures, the sensitivity of the pneumococcal urinary antigen was 71 percent and the specificity was 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/73\">",
"     73",
"    </a>",
"    ]. Among patients with a definite diagnosis of pneumococcal CAP, the sensitivity of urinary antigen testing was 78 percent compared with 57 percent in those with a probable diagnosis. A definite diagnosis was defined as S. pneumoniae isolated from a blood culture or pleural fluid culture, or detected by PCR from pleural fluid, whereas a probable diagnosis required S. pneumoniae to be the predominant organism in a good quality sputum sample with an accompanying positive Gram stain. Pneumococcal CAP was diagnosed exclusively by the urinary antigen test in 75 cases (44 percent). The results of the urinary antigen test led clinicians to reduce the spectrum of antibiotics in 41 of 474 patients with CAP (9 percent). This study suggests that although the sensitivity of the pneumococcal urinary antigen test is lower in patients who are not bacteremic, the presence of a positive urinary antigen test in a non-bacteremic patient can be helpful for tailoring therapy.",
"   </p>",
"   <p>",
"    The 2007",
"    <span class=\"nowrap\">",
"     IDSA/ATS",
"    </span>",
"    guidelines for the management of CAP, recommend use of the pneumococcal urinary antigen in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intensive care admission",
"     </li>",
"     <li>",
"      Failure of outpatient antibiotic therapy",
"     </li>",
"     <li>",
"      Leukopenia",
"     </li>",
"     <li>",
"      Active alcohol abuse",
"     </li>",
"     <li>",
"      Asplenia",
"     </li>",
"     <li>",
"      Pleural effusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymerase chain reaction (PCR) tests for detecting pneumococcal autolysin or pneumolysin have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/70,74\">",
"     70,74",
"    </a>",
"    ]. However, none of these tests has yet been proven to be sufficiently sensitive or specific to have been adopted for diagnostic use [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with community-acquired pneumonia are treated empirically with a regimen that includes coverage against the pneumococcus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Suspected pneumococcal pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some cases, the clinical picture (rapid onset of fever, chills, and cough with a lobar pneumonia) and Gram stain are strongly suggestive of pneumococcal infection. However, the presence of pneumococcus should be confirmed by a positive blood culture or urinary antigen test prior to narrowing the spectrum of antibiotic coverage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Penicillin-susceptible strains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin-sensitive strains can be treated with beta-lactam antibiotics: penicillin, penicillin derivatives or second-generation cephalosporins (",
"    <a class=\"graphic graphic_table graphicRef73801 graphicRef62200 \" href=\"UTD.htm?38/9/39068\">",
"     table 1A-B",
"    </a>",
"    ); intravenous medication should be given for patients who require hospitalization, are hypotensive, are vomiting, or have evidence of complications.",
"   </p>",
"   <p>",
"    Third-generation cephalosporins offer the convenience of less frequent dosing, but are more expensive than older penicillin and penicillin derivatives. First-generation cephalosporins should not be used to treat pneumococcal pneumonia because of poor penetrance into the CSF, thereby increasing the risk for developing pneumococcal meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Strains with reduced susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal strains with intermediate or full resistance to penicillin are increasing in incidence worldwide (",
"    <a class=\"graphic graphic_table graphicRef63881 \" href=\"UTD.htm?16/13/16605\">",
"     table 2",
"    </a>",
"    ). However, studies have not conclusively shown a worse outcome for patients with pneumococcal pneumonia resistant to beta-lactams but treated with these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. A review of the published medical literature found only a single report of documented microbiologic failure of parenteral penicillin-class antibiotics in the treatment of pneumococcal pneumonia in patients with or without bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The data on increasing the dose of penicillin or using a third generation cephalosporin such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    for nonmeningeal infection are mixed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, most concur with guidelines that patients with pneumococcal pneumonia caused by strains with reduced susceptibility, especially those not highly resistant, can be treated with beta-lactams. We suggest increased doses of penicillin (ie, 4 million units every 4 hours) or another beta-lactam antibiotic for the treatment of possible pneumococcal pneumonia when infection may be due to a strain with reduced susceptibility to penicillin. However, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    has been associated with higher mortality rates in patients with cephalosporin-resistant pneumococcal pneumonia, compared to patients infected with sensitive strains (36.4 versus 5.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/52\">",
"     52",
"    </a>",
"    ], and discordant therapy with cefuroxime is not recommended.",
"   </p>",
"   <p>",
"    S. pneumoniae antibiotic resistance may be associated with increased mortality and morbidity; thus, strategies to control resistance through appropriate antimicrobial use need to be encouraged. In one study, the most important factors influencing death with S. pneumococcal CAP, were older age and underlying disease, rather than resistance to beta-lactam agents [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/81\">",
"     81",
"    </a>",
"    ]. However, when deaths during the first four hospital days were excluded, mortality was significantly associated with infection by an isolate with a penicillin MIC &ge;4.0",
"    <span class=\"nowrap\">",
"     microgram/mL",
"    </span>",
"    or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    MIC &ge; 2.0",
"    <span class=\"nowrap\">",
"     microgram/mL.",
"    </span>",
"    In another study of 192 patients with bacteremic pneumococcal pneumonia, patients with isolates that were not susceptible to penicillin were four times more likely to have a suppurative complication [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis that included 10 studies examined the association between penicillin non-susceptible pneumococcus and short-term mortality in pneumococcal pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/83\">",
"     83",
"    </a>",
"    ]. Although a significant difference in mortality rate was found (19.4 compared to 15.7 percent in the penicillin non-susceptible and the penicillin susceptible groups, respectively), these study results have been questioned. Comorbidities may be higher in patients with non-susceptible organisms, and use of concordant or discordant therapy did not differentially affect survival. An accompanying editorial notes that although earlier studies including a meta-analysis had not shown this association [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/52,84\">",
"     52,84",
"    </a>",
"    ], this meta-analysis provided a rigorous methodology [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with pneumonia and concomitant meningitis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    should be added to initial beta-lactam therapy, pending results of antibiotic sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Bacteremic pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a number of studies cite bacteremia as a risk factor for a poorer outcome or complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/55,59,86\">",
"     55,59,86",
"    </a>",
"    ], in the absence of critical illness, recommendations for choice of therapy for bacteremic versus nonbacteremic pneumococcal pneumonia do not differ.",
"   </p>",
"   <p>",
"    Observational studies suggest that outcomes for sicker patients with bacteremic pneumococcal pneumonia might be improved with combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. This issue was best addressed in a prospective, multicenter, international observational study of 844 patients with pneumococcal bacteremia, caused primarily (but not exclusively) by pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/89\">",
"     89",
"    </a>",
"    ]. The overall 14 day mortality was similar in patients treated with either antibiotic monotherapy or a combination of two active antibiotics. However, among the subset of patients with critical illness requiring intensive care unit admission, combination therapy was associated with a significantly lower 14 day mortality (23 versus 55 percent). A variety of different combination regimens were used. Combination therapy has also been suggested in the setting of pneumonia following influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/91\">",
"     91",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Therapy for critical illness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no clear theoretic rationale for the advantage of combination therapy, we suggest combination therapy for the subset of patients who are critically ill and require intensive care management. Additionally, other supportive measures for this population should be considered. Careful monitoring and glycemic control are indicated for patients requiring intensive care intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=see_link\">",
"     \"Glycemic control and intensive insulin therapy in critical illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with evidence of shock require early goal-directed fluid resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early mortality (less than three days, and especially in the first 24 hours) may occur despite appropriate treatment. While this was observed early in the antibiotic era [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/58\">",
"     58",
"    </a>",
"    ], it remains true today.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence on which to base recommendations regarding the appropriate duration of antibiotic therapy. Therapy is generally continued for five to seven days for uncomplicated disease or until the patient is afebrile for three to five days in more severe cases. It should be noted, however, that some patients with pneumococcal pneumonia have a low-grade fever (&le;38 &ordm;C) for several days, despite clinical improvement.",
"   </p>",
"   <p>",
"    The duration of combination therapy in patients with severe bacteremic pneumococcal disease is also unclear, but usually should not exceed three to five days followed by appropriate monotherapy for the remainder of the course. In patients who are improving on therapy, we suggest switching from combination therapy to monotherapy once susceptibilities are known, which is usually two to three days after cultures are obtained. For patients who remain critically ill in the intensive care unit, we suggest continuing combination therapy until a response to therapy is observed. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Therapy for critical illness'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with bacteremic pneumococcal disease should receive a total of 10 to 14 days of antimicrobial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Eradication of carriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In rare situations, such as outbreak settings, it may be important to eradicate nasopharyngeal carriage. In one study, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (600",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    (400 mg two times daily) for one week controlled an outbreak of a multiresistant strain [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality rate for pneumococcal pneumonia varies by severity at presentation and host, ranging from 16 to 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/53,83,89,93\">",
"     53,83,89,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A prospective, observational study of 638 patients with pneumococcal pneumonia identified the following features of the pneumonia associated with mortality by multivariate analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/93\">",
"     93",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bilateral disease &ndash; hazard ratio (HR) 2.0, 95% CI 1.2-3.2",
"     </li>",
"     <li>",
"      Suspected aspiration &ndash; HR 2.8, 95% CI 1.6-5.0",
"     </li>",
"     <li>",
"      Shock &ndash; HR 5.8, 95% CI 3.4-9.8",
"     </li>",
"     <li>",
"      HIV infection &ndash; HR 2.1, 95% CI 1.1-3.8",
"     </li>",
"     <li>",
"      Renal failure &ndash; HR 1.9, 95% CI 1.1-3.1",
"     </li>",
"     <li>",
"      Pneumonia severity index (PSI) &ndash; HR for class IV versus classes I to III: 2.6, 95% CI 1.3-5.4 and for class V versus I to III: 3.2, 95% CI 1.5-6.9",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was no independent association between initial antimicrobial regimen and mortality (beta-lactam monotherapy versus macrolide monotherapy versus beta-lactam plus macrolide versus fluoroquinolone monotherapy or other combination), except for those with a higher PSI score.",
"   </p>",
"   <p>",
"    Additionally, comorbid conditions are a significant predictor of poor outcome in bacteremic pneumococcal disease. This was illustrated in a multicenter five country study of 460 such patients (82 percent with pneumonia) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/94\">",
"     94",
"    </a>",
"    ]. Among those who died, about half of deaths were attributable to worsening of a preexisting condition.",
"   </p>",
"   <p>",
"    Multivariate analysis identified the following independent predictors of death:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &gt;65 years &ndash; odds ratio (OR) 2.2",
"     </li>",
"     <li>",
"      Residence in a nursing home &ndash; OR 2.8",
"     </li>",
"     <li>",
"      Presence of chronic lung disease &ndash; OR 2.5",
"     </li>",
"     <li>",
"      Need for mechanical ventilation &ndash; OR 4.4",
"     </li>",
"     <li>",
"      High acute physiology and chronic health (APACHE) &ndash; for scores of 9-14, OR 7.6; for scores 15-17, OR 22; for scores &gt;17, OR 41",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H625092237\">",
"    <span class=\"h2\">",
"     Impact of serotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain pneumococcal serotypes are associated with an increased risk of death among patients with bacteremic pneumococcal pneumonia. In a meta-analysis that evaluated serotype-specific outcomes for patients with pneumococcal pneumonia or meningitis in nine studies, significant differences were observed in the risk ratios (RRs) for death among patients infected with different pneumococcal serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/4/13386/abstract/95\">",
"     95",
"    </a>",
"    ]. In patients with bacteremic pneumococcal pneumonia, serotypes 1, 7F, and 8 were associated with reduced RRs for death, whereas serotypes 3, 6A, 6B, 9N, and 19F were associated with increased RRs for death. In contrast, outcomes among patients with pneumococcal meningitis did not differ based upon the serotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"       \"Patient information: Pneumonia in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S. pneumoniae is the most common cause of community-acquired pneumonia (CAP), although the organism is frequently not isolated, but believed to be the cause of many culture-negative cases of CAP. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumococcal pneumonia is the paradigm of classic lobar bacterial pneumonia. Although commonly carried asymptomatically in the nasopharynx, pneumococci cause invasive disease when the host is exposed to large aerosolized inocula of new serotypes. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Mechanisms of pulmonary infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic presentation of pneumococcal pneumonia, with abrupt onset of fever, chills, cough, and side pain, occurs more commonly in the younger patient. Physical examination typically reveals signs of consolidation. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infectious complications involving other organ systems, once prevalent with pneumococcal infection, are now rare with antibiotic use. However, overwhelming infection can still lead to early mortality (often in the first 24 hours), despite use of antibiotics. Pulmonary complications associated with bacteremic illness and comorbidities include empyema, necrotizing pneumonia and lung abscess. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While sputum Gram stain can suggest pneumococcal infection, the diagnosis of pneumococcal pneumonia should be confirmed by blood culture or urinary antigen. Although lobar consolidation is suggestive of bacterial pneumonia, radiographs cannot reliably differentiate bacterial from nonbacterial pneumonia. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients with community-acquired pneumonia are treated empirically with a regimen that includes coverage against the pneumococcus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that patients with documented penicillin-sensitive pneumococci be treated with a beta-lactam antibiotic (",
"      <a class=\"graphic graphic_table graphicRef73801 graphicRef62200 \" href=\"UTD.htm?38/9/39068\">",
"       table 1A-B",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Penicillin-susceptible strains'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with pneumonia due to pneumococci that have intermediate susceptibility to penicillin be treated with higher doses of penicillin (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Strains with reduced susceptibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest treatment with a combination antibiotic therapy (beta-lactam plus either a macrolide or fluoroquinolone) for patients with bacteremic pneumococcal pneumonia who require ICU care (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Bacteremic pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We typically give antibiotic therapy for five to seven days, or until the patient is afebrile for three to five days in more severe cases. Patients with bacteremic pneumococcal disease should receive a total of 10 to 14 days of antimicrobial therapy. (see",
"      <a class=\"local\" href=\"#H30\">",
"       'Duration of therapy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/1\">",
"      Marrie TJ, Durant H, Yates L. Community-acquired pneumonia requiring hospitalization: 5-year prospective study. Rev Infect Dis 1989; 11:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/2\">",
"      Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/3\">",
"      Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994; 18:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/4\">",
"      Barrett-Connor E. The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia. Am Rev Respir Dis 1971; 103:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/5\">",
"      Farr BM, Kaiser DL, Harrison BD, Connolly CK. Prediction of microbial aetiology at admission to hospital for pneumonia from the presenting clinical features. British Thoracic Society Pneumonia Research Subcommittee. Thorax 1989; 44:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/6\">",
"      Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/7\">",
"      Nuorti JP, Butler JC, Crutcher JM, et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N Engl J Med 1998; 338:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/8\">",
"      McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/9\">",
"      de Roux A, Cavalcanti M, Marcos MA, et al. Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. Chest 2006; 129:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/10\">",
"      Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/11\">",
"      Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J Gen Intern Med 2007; 22:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/12\">",
"      Talbot TR, Hartert TV, Mitchel E, et al. Asthma as a risk factor for invasive pneumococcal disease. N Engl J Med 2005; 352:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/13\">",
"      Wara DW. Host defense against Streptococcus pneumoniae: the role of the spleen. Rev Infect Dis 1981; 3:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/14\">",
"      Kobel DE, Friedl A, Cerny T, et al. Pneumococcal vaccine in patients with absent or dysfunctional spleen. Mayo Clin Proc 2000; 75:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/15\">",
"      Schuchat A, Broome CV, Hightower A, et al. Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. JAMA 1991; 265:3275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/16\">",
"      Nuorti JP, Butler JC, Gelling L, et al. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/17\">",
"      Flannery B, Heffernan RT, Harrison LH, et al. Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006; 144:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/18\">",
"      Picard C, Puel A, Bustamante J, et al. Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol 2003; 3:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/19\">",
"      Twomey JJ. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 1973; 132:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/20\">",
"      Costa DB, Shin B, Cooper DL. Pneumococcemia as the presenting feature of multiple myeloma. Am J Hematol 2004; 77:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/21\">",
"      Naveau C, Houssiau FA. Pneumococcal sepsis in patients with systemic lupus erythematosus. Lupus 2005; 14:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/22\">",
"      Linnemann CC Jr, First MR. Risk of pneumococcal infections in renal transplant patients. JAMA 1979; 241:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/23\">",
"      Amber IJ, Gilbert EM, Schiffman G, Jacobson JA. Increased risk of pneumococcal infections in cardiac transplant recipients. Transplantation 1990; 49:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/24\">",
"      de Bruyn G, Whelan TP, Mulligan MS, et al. Invasive pneumococcal infections in adult lung transplant recipients. Am J Transplant 2004; 4:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/25\">",
"      Elias M, Bisharat N, Goldstein LH, et al. Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient. Eur J Clin Microbiol Infect Dis 2004; 23:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/26\">",
"      Shariatzadeh MR, Huang JQ, Tyrrell GJ, et al. Bacteremic pneumococcal pneumonia: a prospective study in Edmonton and neighboring municipalities. Medicine (Baltimore) 2005; 84:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/27\">",
"      Hoge CW, Reichler MR, Dominguez EA, et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med 1994; 331:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/28\">",
"      Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters. Chest 1991; 99:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/29\">",
"      Romney MG, Hull MW, Gustafson R, et al. Large community outbreak of Streptococcus pneumoniae serotype 5 invasive infection in an impoverished, urban population. Clin Infect Dis 2008; 47:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/30\">",
"      McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 2000; 181:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/31\">",
"      Gray BM, Dillon HC Jr. Clinical and epidemiologic studies of pneumococcal infection in children. Pediatr Infect Dis 1986; 5:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/32\">",
"      Austrian R. Some aspects of the pneumococcal carrier state. J Antimicrob Chemother 1986; 18 Suppl A:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/33\">",
"      Greenberg D, Givon-Lavi N, Broides A, et al. The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers. Clin Infect Dis 2006; 42:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/34\">",
"      Regev-Yochay G, Raz M, Dagan R, et al. Nasopharyngeal carriage of Streptococcus pneumoniae by adults and children in community and family settings. Clin Infect Dis 2004; 38:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/35\">",
"      Hill PC, Townend J, Antonio M, et al. Transmission of Streptococcus pneumoniae in rural Gambian villages: a longitudinal study. Clin Infect Dis 2010; 50:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/36\">",
"      Hussain M, Melegaro A, Pebody RG, et al. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 2005; 133:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/37\">",
"      Yagupsky P, Porat N, Fraser D, et al. Acquisition, carriage, and transmission of pneumococci with decreased antibiotic susceptibility in young children attending a day care facility in southern Israel. J Infect Dis 1998; 177:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/38\">",
"      Borer A, Meirson H, Peled N, et al. Antibiotic-resistant pneumococci carried by young children do not appear to disseminate to adult members of a closed community. Clin Infect Dis 2001; 33:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/39\">",
"      Schrag SJ, Pe&ntilde;a C, Fern&aacute;ndez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001; 286:49.",
"     </a>",
"    </li>",
"    <li>",
"     Heffron, R. Pneumonia. Commonwealth Fund, New York, 1939.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/41\">",
"      Yershov AL, Jordan BS, Guymon CH, Dubick MA. Relationship between the inoculum dose of Streptococcus pneumoniae and pneumonia onset in a rabbit model. Eur Respir J 2005; 25:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/42\">",
"      Cundell DR, Gerard NP, Gerard C, et al. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995; 377:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/43\">",
"      Weiser JN, Pan N, McGowan KL, et al. Phosphorylcholine on the lipopolysaccharide of Haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med 1998; 187:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/44\">",
"      Tuomanen E, Rich R, Zak O. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis 1987; 135:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/45\">",
"      Bergeron Y, Ouellet N, Deslauriers AM, et al. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect Immun 1998; 66:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/46\">",
"      Taylor SN, Sanders CV. Unusual manifestations of invasive pneumococcal infection. Am J Med 1999; 107:12S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/47\">",
"      Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/48\">",
"      Marrie TJ, Low DE, De Carolis E, Canadian Community-Acquired Pneumonia Investigators. A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology--results from a Canadian multicentre study. Can Respir J 2003; 10:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/49\">",
"      Janssens JP, Krause KH. Pneumonia in the very old. Lancet Infect Dis 2004; 4:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/50\">",
"      Jaundice due to bacterial infection. Gastroenterology 1979; 77:362.",
"     </a>",
"    </li>",
"    <li>",
"     Heffron, R. Symptoms of lobar pneumonia in Pneumonia with special reference to pneumococcus lobar pneumonia. Harvard University Press, Cambridge, Massachusetts, 1939. p. 501.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/52\">",
"      Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/53\">",
"      Potgieter PD, Hammond JM. The intensive care management, mortality and prognostic indicators in severe community-acquired pneumococcal pneumonia. Intensive Care Med 1996; 22:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/54\">",
"      Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/55\">",
"      Brandenburg JA, Marrie TJ, Coley CM, et al. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med 2000; 15:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/56\">",
"      Ioachimescu OC, Ioachimescu AG, Iannini PB. Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience. Int J Antimicrob Agents 2004; 24:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/57\">",
"      Marfin AA, Sporrer J, Moore PS, Siefkin AD. Risk factors for adverse outcome in persons with pneumococcal pneumonia. Chest 1995; 107:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/58\">",
"      AUSTRIAN R, GOLD J. PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA. Ann Intern Med 1964; 60:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/59\">",
"      Musher DM, Alexandraki I, Graviss EA, et al. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) 2000; 79:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/60\">",
"      Burgos J, Lujan M, Falc&oacute; V, et al. The spectrum of pneumococcal empyema in adults in the early 21st century. Clin Infect Dis 2011; 53:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/61\">",
"      Isaacs RD. Necrotizing pneumonia in bacteraemic pneumococcal infection. Br J Dis Chest 1986; 80:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/62\">",
"      Pande A, Nasir S, Rueda AM, et al. The incidence of necrotizing changes in adults with pneumococcal pneumonia. Clin Infect Dis 2012; 54:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/63\">",
"      Leatherman JW, Iber C, Davies SF. Cavitation in bacteremic pneumococcal pneumonia. Causal role of mixed infection with anaerobic bacteria. Am Rev Respir Dis 1984; 129:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/64\">",
"      Bates JH, Campbell GD, Barron AL, et al. Microbial etiology of acute pneumonia in hospitalized patients. Chest 1992; 101:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/65\">",
"      Marrie TJ, Poulin-Costello M, Beecroft MD, Herman-Gnjidic Z. Etiology of community-acquired pneumonia treated in an ambulatory setting. Respir Med 2005; 99:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/66\">",
"      Garc&iacute;a-V&aacute;zquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004; 164:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/67\">",
"      Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004; 39:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/68\">",
"      Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.",
"     </a>",
"    </li>",
"    <li>",
"     Heffron, R. Pneumonia. In: Chapter 12, Complications: Incidence and treatment. Harvard University Press, Cambridge, Massachusetts, 1979. p. 548.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/70\">",
"      Blaschke AJ. Interpreting assays for the detection of Streptococcus pneumoniae. Clin Infect Dis 2011; 52 Suppl 4:S331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/71\">",
"      Guti&eacute;rrez F, Masi&aacute; M, Rodr&iacute;guez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/72\">",
"      Ros&oacute;n B, Fern&aacute;ndez-Sab&eacute; N, Carratal&agrave; J, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004; 38:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/73\">",
"      Sord&eacute; R, Falc&oacute; V, Lowak M, et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 2011; 171:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/74\">",
"      Butler JC, Bosshardt SC, Phelan M, et al. Classical and latent class analysis evaluation of sputum polymerase chain reaction and urine antigen testing for diagnosis of pneumococcal pneumonia in adults. J Infect Dis 2003; 187:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/75\">",
"      Murdoch DR, Anderson TP, Beynon KA, et al. Evaluation of a PCR assay for detection of Streptococcus pneumoniae in respiratory and nonrespiratory samples from adults with community-acquired pneumonia. J Clin Microbiol 2003; 41:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/76\">",
"      Moellering RC Jr, Swartz MN. Drug therapy: The newer cephalosporins. N Engl J Med 1976; 294:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/77\">",
"      Pallares R, Li&ntilde;ares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/78\">",
"      Deeks SL, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. Pediatrics 1999; 103:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/79\">",
"      Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/80\">",
"      Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? Clin Infect Dis 2006; 42:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/81\">",
"      Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/82\">",
"      Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/83\">",
"      Tleyjeh IM, Tlaygeh HM, Hejal R, et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006; 42:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/84\">",
"      Metlay JP. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infect Dis Clin North Am 2004; 18:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/85\">",
"      File TM Jr, Tan JS, Boex JR. The clinical relevance of penicillin-resistant Streptococcus pneumoniae: a new perspective. Clin Infect Dis 2006; 42:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/86\">",
"      Marrie TJ. Pneumococcal pneumonia: epidemiology and clinical features. Semin Respir Infect 1999; 14:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/87\">",
"      Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/88\">",
"      Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107:34S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/89\">",
"      Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/90\">",
"      Mart&iacute;nez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/91\">",
"      Karlstr&ouml;m A, Boyd KL, English BK, McCullers JA. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009; 199:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/92\">",
"      Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/93\">",
"      Aspa J, Rajas O, Rodriguez de Castro F, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/94\">",
"      Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/4/13386/abstract/95\">",
"      Weinberger DM, Harboe ZB, Sanders EA, et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 2010; 51:692.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7013 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13386=[""].join("\n");
var outline_f13_4_13386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H76306199\">",
"      - Influenza infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Alcohol abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - COPD and asthma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Hyposplenism or splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Immunocompromise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antibiotic resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nasopharyngeal colonization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MECHANISMS OF PULMONARY INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Course of disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Spectrum of illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Acute cardiac events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Sputum Gram stain and culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pneumococcal urinary antigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Future directions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Suspected pneumococcal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Penicillin-susceptible strains",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Strains with reduced susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Bacteremic pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Therapy for critical illness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Eradication of carriage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H625092237\">",
"      Impact of serotype",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7013\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7013|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?33/26/34223\" title=\"diagnostic image 1\">",
"      Pneumococcal pneumonia CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/51/1840\" title=\"diagnostic image 2\">",
"      Pneumonia bulging fissure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/28/28096\" title=\"diagnostic image 3\">",
"      Pneumococcal pneumonia complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7013|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/0/21507\" title=\"picture 1\">",
"      Pneumococcus in sputum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7013|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/31/14843\" title=\"table 1A\">",
"      Doses IV antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/3/43067\" title=\"table 1B\">",
"      Oral antimicrobial doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/13/16605\" title=\"table 2\">",
"      Susceptibility of pneumococci",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18456?source=related_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26026?source=related_link\">",
"      Diagnostic approach to community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/23/28023?source=related_link\">",
"      Glycemic control and intensive insulin therapy in critical illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=related_link\">",
"      Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/9/24729?source=related_link\">",
"      Lung abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23143?source=related_link\">",
"      Microbiology and pathogenesis of Streptococcus pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/48/1801?source=related_link\">",
"      Prognosis of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3369?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19704?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_4_13387="Physiologic progression of lower-extremity rotation";
var content_f13_4_13387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64901&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal physiologic/developmental progression of lower-extremity rotation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Normal rotation at birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hips: Externally rotated 40&deg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tibia: Internally rotated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feet: Internally rotated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Developmental changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Tibial torsion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Birth: Thigh-foot angle 5&deg; lateral (external)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maturity: Thigh-foot angle 15&deg; lateral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Femoral anteversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Birth: 40&deg;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maturity: 8 to 14&deg;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13387=[""].join("\n");
var outline_f13_4_13387=null;
var title_f13_4_13388="Changes 7th ed TNM lung ca";
var content_f13_4_13388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Seventh edition of TNM classification of lung tumors: Changes from sixth edition",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Primary tumor (T):",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1 lesions are divided based upon size into T1a (&le;2 cm) and T1b (&gt;2 cm but &le;3 cm)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2 lesions are divided into T2a (&gt;3 cm but &le;5 cm) and T2b (&gt;5 cm but &le;7 cm)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2 tumors &gt;7 cm are reclassified as T3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4 tumors with separate tumor nodules in the same lobe as the primary tumor are reclassified as T3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Additional nodules in a different lobe of same lung are reclassified as T4 rather than M1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignant pleural or pericardial effusions or pleural nodules are now classified as metastasis (M1a) rather than T4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Regional nodes (N):",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       No changes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Metastasis (M):",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Subdivided into M1a (malignant pleural or pericardial effusion, pleural nodules, nodules in contralateral lung) and M1b (distant metastasis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Stage grouping:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2aN1M0 lesions are classified as IIA, rather than IIB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2bN0M0 lesions are classified as IIA, rather than IB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3 (&gt;7 cm), N0M0 lesions are classified as IIB, rather than IB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3 (&gt;7 cm), N1M0 lesions are classified as IIIA, rather than IIB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3N0M0 (nodules in same lobe) lesions are classified as IIB, rather than IIIB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3N1M0 or T3N2M0 (nodules in same lobe) are classified as IIIA, rather than IIIB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4M0 (ipsilateral lung nodules) lesions are classified as IIIA (if N0 or N1) and IIIB (if N2 or N3), rather than stage IV",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4M0 (direct extension) lesions are classified as IIIA (if N0 or N1), rather than IIIB",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignant pleural effusions (M1a) are classified as IV, rather than IIIB",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Groome, PA, Bolejack, V, Crowley, JJ, et al. J Thorac Oncol 2007; 2:694.",
"     <br>",
"      Goldstraw, P, et al. J Thorac Oncol 2007; 2:706.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13388=[""].join("\n");
var outline_f13_4_13388=null;
var title_f13_4_13389="Occupational exposures";
var content_f13_4_13389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Occupations at high risk for irritant contact dermatitis and common irritants encountered",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Occupation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common irritants encountered",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Agriculture",
"       </td>",
"       <td>",
"        <p>",
"         Oils",
"        </p>",
"        <p>",
"         Solvents",
"        </p>",
"        <p>",
"         Fertilizers and pesticides",
"        </p>",
"        <p>",
"         Cleansers and detergents",
"        </p>",
"        <p>",
"         Plants",
"        </p>",
"        <p>",
"         Animal hair, saliva, secretions",
"        </p>",
"        <p>",
"         Wet work",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Automobile industry",
"       </td>",
"       <td>",
"        <p>",
"         Oils (cutting oils)",
"        </p>",
"        <p>",
"         Solvents and paints",
"        </p>",
"        <p>",
"         Cleansers and detergents",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cement and construction industry",
"       </td>",
"       <td>",
"        <p>",
"         Cement",
"        </p>",
"        <p>",
"         Wood preservatives",
"        </p>",
"        <p>",
"         Oils",
"        </p>",
"        <p>",
"         Acids and alkalis",
"        </p>",
"        <p>",
"         Fiberglass",
"        </p>",
"        <p>",
"         Adhesives and glues",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cleaners and housework",
"       </td>",
"       <td>",
"        <p>",
"         Wet work",
"        </p>",
"        <p>",
"         Cleansers and detergents",
"        </p>",
"        <p>",
"         Abrasives",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Electrical/electronics",
"       </td>",
"       <td>",
"        <p>",
"         Solvents",
"        </p>",
"        <p>",
"         Soldering flux",
"        </p>",
"        <p>",
"         Cleansers and detergents",
"        </p>",
"        <p>",
"         Acids and alkalis",
"        </p>",
"        <p>",
"         Adhesives and glues",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Food industry",
"       </td>",
"       <td>",
"        <p>",
"         Wet work",
"        </p>",
"        <p>",
"         Cleansers and detergents",
"        </p>",
"        <p>",
"         Foods (especially acidic foods and food enzymes)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hairdressing/beautician",
"       </td>",
"       <td>",
"        <p>",
"         Wet work",
"        </p>",
"        <p>",
"         Shampoos",
"        </p>",
"        <p>",
"         Permanent wave solutions",
"        </p>",
"        <p>",
"         Oxidizing agents, bleaching agents",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Healthcare and dental",
"       </td>",
"       <td>",
"        <p>",
"         Cleansers and detergents",
"        </p>",
"        <p>",
"         Wet work",
"        </p>",
"        <p>",
"         Alcohol and other disinfectants",
"        </p>",
"        <p>",
"         Medications",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Painting",
"       </td>",
"       <td>",
"        <p>",
"         Solvents and paints",
"        </p>",
"        <p>",
"         Cleansers and detergents",
"        </p>",
"        <p>",
"         Acids and alkalis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Metal industry",
"       </td>",
"       <td>",
"        <p>",
"         Solvents",
"        </p>",
"        <p>",
"         Cleansers and detergents",
"        </p>",
"        <p>",
"         Paints",
"        </p>",
"        <p>",
"         Glues and adhesives",
"        </p>",
"        <p>",
"         Oils and cutting fluids",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Plastic industry",
"       </td>",
"       <td>",
"        <p>",
"         Plastics",
"        </p>",
"        <p>",
"         Solvents",
"        </p>",
"        <p>",
"         Fiberglass",
"        </p>",
"        <p>",
"         Acids",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Rubber industry",
"       </td>",
"       <td>",
"        <p>",
"         Solvents",
"        </p>",
"        <p>",
"         Cleansers and detergents",
"        </p>",
"        <p>",
"         Frictional/mechanical factor",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Woodwork",
"       </td>",
"       <td>",
"        <p>",
"         Plastics",
"        </p>",
"        <p>",
"         Solvents",
"        </p>",
"        <p>",
"         Wood preservatives",
"        </p>",
"        <p>",
"         Detergents",
"        </p>",
"        <p>",
"         Sawdusts and other",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Chew AL, Maibach HI. Occupational issues of irritant contact dermatitis. Int Arch Occup Environ Health 2003; 76:339, with kind permission from: Springer Science + Business Media B.V. Copyright &copy; 2003.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13389=[""].join("\n");
var outline_f13_4_13389=null;
var title_f13_4_13390="Preventive care by nephrologists";
var content_f13_4_13390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F64678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F64678&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Comparison of preventive care provided by nephrologists and internists",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 282px; background-image: url(data:image/gif;base64,R0lGODlh9QEaAdUAAP////8AAAAzmYCAgICZ/wAzzP+AgH8ZTMDAwEBAQPYAAPeAgPDw8NDQ0ODg4AAAADAwMHcZTKCgoCAgIHBwcLCwsJCQkGBgYFBQUBAQEAAz5fIAAH8ZZsDN//vAwP/AwICMv0BZv79AQL+AgL9NgL+Mv3cZZjsmcruMv7ZNgD8mcruAgLZAQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD1ARoBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5unYIAxIMQgwWAw67xse2Axi9CUIJFhUTwMjU1asJFUIPAAwTQhfZ1uLjotED5wAIzQDo5O7vmRIUEgkU6evt6ef7/P3+/wADChxIsKDBgwgTKlzIsKHDhxAJIoAioKLFixgzwgOQYRqEBg3wWRjSi1+CBBFTqlzJsqXLlzBjAkRJMaNNmxsnTOxWrCOA/49J8m0cukUok5tIL25sAOGkBCESIECwF3QA0atajC5JyhVrFK1ewzoBm4RrUrFjraJd24QsErNI2S5xK1cuXSNwbypBUAyAg75LGlBtQqFBk7+e7tZFq5hIXpxJHkAQ0ljdkwQTmUh4WgSzpcaLvYIW8lhjZF/s1A5IcAEYggoXEhhWt3okOwfEHMTm7BkBhmVCdKOciGDiagwNHEy4YLXCyXCORocmKr00RiUPGExGR6F5s9UMGmRIp5MngAcolSNggOEpZuV/JxSDMJF5agsYADSooN0CggbSOMBZdGqF8YEBCCao4IIMKvjBdJpUZ51F2LEjAToZ7LNNO5hZBv+AZ9vot45vHyIwDGUWMEWZVedEJYFhJfqVgX+RSDeFAQHkqOOOPPa4owEQZiLhhAJUqB06DxRXXGrOFLcOiEJ4aBlm7ZzjITroIEDBBFZ55tcATUFioxQ4+mjmmUAGecmQE1bIDpcf2mYYOgyM5yGUQvg0wEiYqfhhA3UC011qgALg3IfZIMZAiASOUeaZkP6o5poFNkFkRW7WaRV7UuU3wAQJQJDNnRMxWoFUrcUIJgRqRYUBTeecGqphsjrQFAQDNjJmFI9GGmmak1LCpnVX7LrENBfk2omxT/TqK5rBVjJsacVWqsUFUg32CbNOOPusj8BGW6O1W10aLbdNePv/LY/hivvItI+dS24X6q6rY7vu6jpvWeYGiy4T9dobAL75LgJvXvI6KrCZBBecyMFwJaxEBwRUbPHFGGdcMQkLg+vwu/t+XO0SBGhQwMkop6zyygVw0HGPDYtcyL8yF3EXAQVcWtEBL7Nbs8Eh/yzFzTnrzHPP98JxYINMN/2gzDQLzaQSOOsswNFIDwxHwPbGLLHUI1Nd9KVYI+21GVyve/akUTtc0j40iW112T2vzQTFGuetMcdZaw110GAj8fY5cSdRtdF9+21FySw3zrLLfdsdZNs/Ez134pLLjXjkWeCt9+cXdyAL5TVbvnnWmRs+NpF0v5y64SY7LjvKGhAw/zrggTNhOtmYY3E475z7vjqRBdgei3QeLKD88sw337wH/gL+O+u9XzH9hK13/DoS109Y/O1QLLCBAuSXb/755W+wQPQkD29d9gtvb0T3pcEvsPzzu2/d98fjTsQCCliYAtbHNunp7zH265rwLhc86x3wMfyDhXQAKEACqml31GtgFeiHwOo50GoCiOArJhhAgQ2QfZoDHuoWeDqzZYGDEDSeBP03BAqa0IKTMyADV/jBFtbthQ/MiwhdQcIKIsEBxQFMFjLTv/bt0IU9VCEUo3ipIbaiiDcU3EmYSIRdraMIjEIFBrHnwQ0G0SwJVBsQQWhFVmDRXidEQjskUIHfFP/jJMRgB2tcg4DNCKg2lOFGbFqDgAeg5jgwEsUY31dGKsAQLmn8Fv6K8Ei4tFENngMd6ERXhjeuK45H4BAFhHEBAFzgAusZ1KEGkIF5IKA88jkPADAwkgokJ0kNwI9+oBOKRdavkVOoJFci+axJEkGYXLlkGhg3u9nVzgye/BYojcAh4nxHLRk6x4bUQipZXgADFehLiFyUSEXq0IeuY6EUf6jOKsrQDchMijK7EM1nTdNmaunNNbWhJONw80mlgsoFMhDQKG2Jhp855zrTSUUyatCMbHxnG+KJlHlyoZ6+umcX82lNdlDlGUKY0z+bJMvMDCo7+gHGoUbhyw4+NJj/ZxwmMGEa0ThQ9CYWLQpCAWBDOOKQCBKYwATc01FbyYZTEPDUSGO0oaYkABhgooCsgMJShWaQh4uLaVKI6StjDuGmNslpGcCaEbFmAaOR0mhoWpoXrv6qnQ7FalZrCgeyYsSsWEArpNS6GLZCcqZRsKtF3AoprwpBsBbBqxgQWxHFWkGvZ+JrXfyKRsBCgbGEhRZcvSdRNjA2hJ0FA2TNJFm7WDWuU4QoOrW3Rqs5FgyffS0VRuuj0lKDAXwZQgO4GMrTMvKlUsCsZS+rVXmGVg2xPa4XaNsj2x5jNQMIBwUwQIHJVMWJq43fZn8J3OAWt6LKRUNyoblT8aHvvOdT/x88PDSE8cyStxvF7kJZ29DfylW1OpOtF8bbyZ0mz3kAdh703sGcPbkGHyGjrEy7S9wnsrO++wvvGfhLBtKhhTUm8saVCjQ46Mr3qql15HdtklmGtTa/EjYDhcdgYbF4qUMIJkk/Cse9EWekxB6DsEvvK2K6vmHFYmhxWAYFgFi6Fzhy9C13eexdBzNUx3lRAQdI0LQqO+jE7iRv7rhRDwyUEgDTra4SFLzV4TpBuAxucHbvh2XipTgrO3VXbnULX3x+GLUPxi+I86xnPD95rq5981njvOX4pnDPf+7xmhW43R2HWNEo1nKhp0BmpOAYZo1uq5nPbGOMXNpnmRaioP/zSuhJT011TqYvoOer3VBXNs1PAHIYhOywSt/k05KC8l9hzelUt1rXlhx12EwNBVuTeNNMQDOTm7xoNbraLPodWqknbewbI/vO9n00TZstyTZzVtLEfkK1PX3tQ/tZ1atGNLr7/O3+hrvYSnY0n7fNajY/u8y8boKsRTvtQo/7IrhOGrAXvOzAdhrg5TZ3uyvc7y3/e7AJr7Gv7T1wfBdczZF297vTgu0la9vgE2d0xS0dcYkHGtwbn0u8NZ3vjss70ZBW96/T7WaUp/y6Cvf4vJldb5HTPNs753mWNX7zMa981xfvNbeL6W2dw5zeQ2d40VXucpYnXd8Hh3jLq47/9I+D/OREn3pvuf7qqyc76zsr+RGU7XWMR53FDc/dw9O+dVQvvatNf/m6Y17zsIvdzjnX+8z5DvSnC/3cgyd8hG3+9yHM/WpqpyTaIV93u/fc2SMHL+Mbf2qTX77bmT925T0vc4r/fPF+53zn1z75gOfIsGwP+tc/z/R7G3fzjX+86xXHbqfvHeqIN33vSxPtr8RdZh2mMetDjvnhW73tsW595CXvY7hzPvlHLzv0sc580Ife2qNfPtilrnpDW770Ple84IWv/ufL3u19J3/5V0R2gm//7N2v/ffJHf78VT/Ix1cNyRFSSsRv9Wdx93eAJNd/1Hd3b2V7mpd6bBE3/6shf6QXfOkHfIX3e4e3gYmngahngWwREhkAKgmQAV80a9lnf++ndLSHdxAoemaHf+NnfYtRSA+Qgw+QAbxkgIHnfoYHfx7IfiC4fhlYhDGEe2gxD2ige9P3VdLHgMcUhTOogBEognIhDPugLF/ghFJ4WFSYgFYog2L4g6KmhC6mg+iBhQ34gg94ekbYfM7XdS3ogm8HgBAiGUpSTj54fhgoh0hIh0EohL73gR0YgjYYGqzShCuIgHVIg25YWHkHhBw4e3eoghByUC3ChlOYfzAIh5RoiJb4h94HimcogWuRAGqYgn14gUN4hKP4ioAYiNr3iJB4ia1YF7u1h5wIhf+e+IZzWIuDGH2/KIkxGFbC9lgBWA0VQAwDwIdd2IgLWIV+KIulGIwsOIx2GH+JuBgUkIO+8WV4aIbCWInE6IDGuH8I94Vg+H+YOB0ZgC3M0IvtiI6aZYrlKIqEGIfX2H6nSI9hkSSYERsAGXvaeIukqH/4mI3meI4ZB5BeESoTgAEPYBvjWI2FSISxmJGwuJH8qJDYmEzJWAW0dgvikYMQMA0X6YocOYseGYoa+ZKC2JDbaB0nYAIpEGA6KWAcFyT/gYYAYJA0iZDWCJL+mI8xuY95EQHjg15OmV4/hXOhgQGT4QAZUpBhaIvkyJD66JDo55IyaRYRUEI941z0Nx3/DyBdrNgEFZAZDfAqPQh4GPmRnxiS01iGcwmTHamUcDGWWWOWqycXaSkEFLCWSyABV1lkgBJLSTaG4EeNLEmXwGiXt/aEvqgzfok0gFmStoABrfSNFtkEITEotkKYXOh40liZ7CiUXVmTLdmPtMgVmVmWUdmY0wEgKKmSTGArDJAlMRYlM5aaZKiVeTmTrcl99mhix4gRs/kym7mMyAASPwkFssEkGyZjJiGcj4mX4heJ97iQjniQRFkazdkxzwkhJzEFJ5EAQiUBpQlmp3mWxYmUe+makpmO4HmXxDmfskmWzlmbYzcdp6KMQjABi1mA5heZegmWXpmQdUmZwyme/47JnP5pngBKTdB5DKqog4Z5mJzxlthgdBO6jpDZnV8Jm4d4n98JoRlRnkbUFhlqDIW5ntqSi/6XnDmWn6pZoibqoJN5lP35lxcql/PnhTzahidqlLEZnkM5no/holkEoxDCFEkyAaFpo0jqo/gJpEx6nE66oCgalkGqmUOaoHUBARlAUIWJlcW4okuqnxK6lV2alA1qHVDqUz0ZGmlJJR16UdrJf0faiTiKactJotzZo3ZaoS+qOzG6CzOCDcvBpoMKajoaoU06oloXqIJ6KXf6SWWKmhAyAGpYZ/T0p4a6n4j6mkqaomC6qmKaFJ0qTZ8qn6FhAQkATqh4md6pnP+Vup2omqoqyqu9SqFCmqc3CI0rCayt+qBvuqOHeqO7mqPDehGxak+zGphooR052KfLZaqZ+qybmqTM2qyW6qWYWhHVmlHXypmzIAGSAQEPEJ/deq6Up6n1GK2Eqo7f+qvQSiTpmlbr2qi4ACZCsIi5eq/i+qOsapx0ap/LqrALK5aKGqWMulZc8ikoIa86Ra+7B3tZGaf8Oaf16bB9ObF4KqV9pYbbKqn4SqksCqjgGq5a6qbk2qIm66nGyhYdhhrdqKwMO7Jf+rMMWqeqOq4RO6a0mbOqZ6Qxi7AzK6wve6ogq6AlW6woO3/YKrNFabR8SZ9DS7JeG6Zdi7T/qbT/nMe0/Kq1RQuxrwqnlyqnSPGvexWwWEurPhu2rkq0wSqtUbuvU3u3ZGuhZpt73kp39hqUH/u2Ieu25gq3NyG3kUW3dYu2f5ulW8u2YyuyX4ucnHqzsjq4f0e5igu4miu2evuwW8qlceu51gq674Z9HGuZiNumUKu6zpq2avukrKuurhtusOu45dqwQYu3XJu5jCu8wxu4i0p1k1u49dq0szupuaavhgu90du5VluxzRu7q5m4jbu4t1u5lkueuwuwvVt0ovu9pHu8QJu8pZu3p1u1ZHq+N5e+yAu8viq+uYu6NHu0sFq+c0u/KWe/7Yu/MIu7upqwqVuzxDq/V1uk/87bsYXqt6O7vuFbwf06IZBLWpKLtQS8udx7uNerwP3bto8LwJErwBv3wabLuSRcuwwstRg8vrqbvczrwREsu6x5vwYsw+prwTaxwbXVwRAcwtC7wwXcwxT8wxmcqDYsoturxNWLwCP8tHxru8GbxOAbxCjMwSr8biwMvy5sxfk6rUvMw1tss08slUUsxc9LxUgMwkZMxVXsxA6svTg8x/rrtJe7wP7LvnLsxkLcXERcfmFcvGDLlWhMtcSLufErsWtsm3nsxhJMvW+8x3y8tn5swlwcyQE6yWl8wJgcxy08xn1cwsZ7wp6MoXWbtQlMxi6Lxfk7w/srtKXsvqu7yv9Easg53L20e8UxfMZazMjKS7E33Mah7MOL3MSajMqPrMjDDMRqfMfHzMt6TMuZvLdl3LdTjMl1TL66bKZL28uHS8pibMrNDMN/rMrUDMWBwwAXAh1aiKDiTMP8q86pnMWBnMzCvM/E/L/hDKq5YwH+ETfPEA26ucvMrM2xHMzdjM3ZfM/AvM6d3M5snDuW0Q3fEJcCzc8PzcS13MibnM+zDNIhXcwni8cOV0rXCZzZec0mHdG2fM64fMExLdOQbNGSnDsAcmDy+bsefckQbc6InMjvW9ToXMM6/cmBAyAwEhIoctELLdHb7NBCfdPfzNDTa8bo2sVD/MXR4tRE4BP/VMXU0izKQ+29yzzVM43UNV3RSfvAUsOe6wkV2eLO/wzIt0zJspvVVN3QVj3IPHKeURzUlczVV73W9tzWjmzUubzUrFzYeW3Tiv3Kp4zPJI3WWM1Ygr0jhA3Kk63Pe23YfU3UjZ3US+nVhAzWxHbIpw3TlW3Z6TzRnDzNca3S1szXviy9AmfJh43Yna0jn43MoV3Sse3XjD3Sz3zUr02vwZ0jw53bpL3bLbvV3JzY0czWOX3b1TzOsJ3dJ83cyu3YlA3e4f3Y3I3X0l3cmn3cpj3eqJ3czkzecF22cu3dul3Oam3esq3VvQ3cqj3YhYzf063fv1zVVv3b1/3cARDd/wTO3srM38gt0vMd3xSO2cuN3vaN2w9+1hHuz9oNzSAe4uJd4W9t2xve3WdLzke83yO+2BdO25lNrQHu2QO+4t/94v3919Yty+0t4ROO0jh73zie3y1+4IBN0cYN5Jxd48J944Sb46MN4f085VT+0ccd5AAN2Qpd5AV+5Lz9epMo3xhO3yguuEQe5UYOxy5u5R5e5TTt3E4O3VAeuizO5kje4wle2pPH4A7u5VeO3TqO0yLu5iSu13EuyHPe4HUudq4N31Ke6F9Ox00e0HZbdEAd6Aq+5+yo5Yju1nJu6a78usEZ6aA+6d783iYe6lxez2qO6mmd5/993Zse2Iv+5/+vruk63OaSruudXumt3tHE/eZYLuGqXuYWXui9TuwC4OeNPnWPvuqwvtm8fupB7eysbWrRjuym3txrnup9fuvPjr53PsrV7u3TnuXAnt5SDejMXuu1/eODTuglzu2szu47vd7vvuuyLuYTXOzz7unsjO9m3eGHXt7zfuwynuEIb+gwLuSfm+Z23u2Q/u0QLfCivewHX99ozuHuvvFLnvDnXvEWT+1Wg+0S7+jlHuthznu0zucnL+7ZTm0rf9MKj+BKLu8Of94Dn+LqbfAPX+8Ln+xCj/Px/uE7v+PyS/CRDdr7Tt0vPPRE/+noHugo7/G5/vQG3vKGhfEhn/T0ruH/Ha/iWQ/yOq/xPJ/x1u7rIrzuPt/uZR/0VE/ybG+9N5/kR28RV0/2E1/y7j3y0p7uTB7uos6u4rLtUk/xgV/3lE74wX7pHy/3DY/2Sh/jRj/jcL72zL73Px/5af/1lB/2k6/5Zo/0oS/6HL+8nc/TpNrln3/2pP/6ph/7sp/5Vb/5Mp/yQhNm1rX6la/stI/6oB/8wg/7t1/6ep/7WA82R9b6kF/7AA/2d6/nOT/7xy/5qW/Mvi80LQ33v1/0eM/wan/90C/oYO/1Dcz0ri813e/ScIMSAhECsdNMjQM5WSMCECH/9O849g8EAeGQWDQGRAPlktl0MkOawpRatV4L/5zjlot8fsGDKJaMNW0UafWa3U5vWGFmYgCw3/F5/Z7f9/8BAwUHCQsN9RAS7JTyEJoS6MJACCgrLS8xKUsMODs9P0E9R+RIByYzUTM3Q1lbR0vlTlNnNVttQV9hwWRpU1EWgIOFh4mFV3QRDpWXmZudn50z7DCS/RihsbO1t7m7vb/Bw8XHybEpMCggAK/L293f4ePl5+nrxRuq/9jt+fv9/wEGFDjQWh2CBxEmVLiQ4UIE+RpGlDiRYkWLFzFm1LiRY0ePH0GGFDmSZEmTJ1GmVLmSZcuWDB4ekuAA20yFDiS41LkzpYQJAy5MaACAwtBACSA2QwpAEaEEEJ4abf+2j0+ibQkm3JnQlKHPCTm7Lf1T1I5YnmeVZWBgh4EDBhAsJGNgwcJaOxIG0GSa1FE+RxLWOhhgwa3RBmuROniAQCqgpQ2kVVCiF4HgCnYaKKnWwAHdwHrxXgbQ147VzAP8osa8lkFjPpByVoAEgAHeurTxDTjsGYADnAPaDgALAK9e4qhp+nZw2Dbr3Ltv97nGme5o1aMtH09OubRgsIcdPGQM4LRcuMkO0+aNXTha93smRO894QLwrz4RD6gAIZlZAAOowaAOCfijq4EJKpCAAqv22guBB9oTZCkGHiAKgQomWAtCBCC4zIIKOOwPgwrq+6+OCy5AYEEAERBwNEX/PgzxvwDrWIpBPxLAkCnZyIvLAkUQ+AlDCkisYwAIJLAAggX5Y0q/JgVMxEgIlmzARyCFnIDIEqUzKIERLxAQQw2ZvCBJRa6pEIAHmOzvISUgwACAGPlzgL4aEWDgvgzXbPO9PzHDIAMty0pGQTsomEkdAEhsUCvWsprAODPvYHCppdQcJIG40KFNsgmSUbMCOa2jo0GrJsvqUdqyYtARU/nU81Su+kCqvhSb+q1CS5NB1SA1J1uURDsXMfKCO3R9sVBlu1yW1zWLtaPCNKWNVqwGILDrVTwLPZSonIA1CFBAHdi0wWs0a8oq/zKtMFNHmb001EISqO+yA+NqUs1E/95asEQb0USN1nZf7BeBEgkG2LHKHghPEQIleDDeXgOu1kRXkWqKkWsglvjZG/e4RuEGw62WWmhNbFDPoQz+txqk0K2j5HHdk4oCCxoc1Y4LKmBAGuIogBcACIZyQB1Q2eISpqbkRVnTfESed84FNebWVwfUYovo3tRJhEFGtjZ61oV7U1asXZmmOGWUlfD5LgqITTnqaj+mVY+5n5152l8tZmQpDMD6mtu9dAaAZ7bFpZmnCQS8IIG1Bkgg6HodX0RyCGjyb78jL9v8AsKWpOBYLTFA+tLPn77jQACRfuCCdNxa8gIIrK448sgb2LzDgmWnnVHadyeQgtn+MMsqAv8BRNvZihH/73KawkzHSIOQx0D5sauCxM2Jm4cW6+T7xtOCDJQArHcjJW+Q8qZmVvwsfBprwLDGwlPdrjtguh8m48ajLc/00oOdQQTQDuFpjYbqx5bK+IY8zumNXgyoQLu0xn/KkaDqDuOaPRCQguTpFW5WA0IGjqaAEIQIZ272QNV9sIPp6eAewlOZBoJwhtUYoQ0/SEIVgkc8LFugXuQ3Q/JIxYbGcd8RLfIunrxuePdD4hOh6I+k7AQmU4ziFbGYRS1ukYv/yYNNBgHGLo6RjDRTon/IVkY1rpEnDdPPsuYSnThOkC5NmsdcVNMaR0DHLnjZjGZWwxk2DpKQgNj60O6QoicJ4EeRjEQShqzYDrjoLEj60VKRDCcwD4GoSU9JwHAKGUpRikpOSPFWok65yGMJDR4ZEA33EmGnh/yoNLdjCihFmUtC7ksRMDMIE4o1t3m0KANAStuLKlm+lg1Ol81ko5osMLkLkYpnheOZBFaJxnfYhT91w9oEBcdKZ46Ti66DnfpQxLR00iZ0SJuHltKxtOUR5yco6tfsmElOfWqxMvkIYBAxiIf/OTEeMaGhC40Ck4T+UIj7dOhDIRpRiU6UohW16EUxmlGNbpSjHfXoR0EaUpGOlKQlNelJUZpSla6UpS116UthGlOZzpSmNbXpTXGaU28EAQA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A comparison of the results of two surveys suggests that nephrologists provide routine preventive primary care at a rate comparable to that reported by general internists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bender, FH, Holley, JL,. Am J Kidney Dis 1996; 28:67, and Schwartz, JS, Lewis, CE, Clancy, C, et al, Ann Intern Med 1991; 114:46.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13390=[""].join("\n");
var outline_f13_4_13390=null;
var title_f13_4_13391="Results of consecutive unselected HCT";
var content_f13_4_13391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Results of 900 consecutive unselected hemopoietic stem cell transplantations for thalassemia performed in Pesaro since 1982",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Angelucci E, Baronciani D. Allogeneic stem cell transplantation for thalassemia major. Haematologica 2008; 93:1780. Copyright &copy; 2008. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_4_13391=[""].join("\n");
var outline_f13_4_13391=null;
